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ABSTRACT 
Migration Stimulating Factor (MSF) is an oncofoetal protein which is 
constitutively produced by both epithelial and stromal cells during foetal 
development, not expressed by the majority of their normal adult counterparts, but re-
expressed during pathological processes such as cancer and wound healing. Scotland 
has the highest occurrence of oral cancers in the UK; the incidence is still increasing, 
but patient survival remains very poor.  The expression of MSF in oral tumours has 
not been previously reported. 
The aims of this study were:  
• To determine the effects of MSF on the migration of oral tumour cell 
lines and normal stromal cells in culture (chapter 3),  
• To ascertain the possible presence, diagnostic and prognostic value of 
MSF in oral squamous cell carcinoma (OSCC; chapter 4), and salivary 
gland tumours (SGT; chapter 5). 
• To identify the putative MSF receptors in oral tumour cell lines 
(chapter 6).  
For tissue culture studies, the effects of rhMSF (wild type and mutant proteins) 
were examined on human cell lines TYS, HSG, Endo 742 and FSF44. These cells 
were derived from OSCC, SGT, microvascular endothelial cells and skin fibroblasts, 
respectively.  For ex-vivo studies, paraffin embedded archival specimens of OSCC 
and SGT were stained with specific MSF antibodies and the level of staining was 
assessed by consensus of 2-4 independent observers.  The association between MSF 
expression and patient survival was determined by Kaplan-Meier and log-rank tests. 
  Results presented in this thesis indicate that TYS and HSG cells secrete 
bioactive MSF in culture.  rhMSF stimulated the migration of these tumour cells.  The 
use of mutant proteins demonstrated marked differences among the cells examined: 
Five bioactive motifs (4x IGD and 1x HEEGH) were required for MSF bioactivity on 
TYS and HSG cells, whereas only one of these motifs was required for Endo 742 and 
two for FSF44.  MSF+aa and MSF-aa showed the same migration-stimulating 
activity, but differ in their interaction with the MSF-inhibitor Neutrophil Gelatinase-
Asscciated Lipocalin (NGAL).  NGAL was shown to bind to and inhibit MSF+aa, but 
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not MSF-aa.  The bioactivity of MSF+aa and MSF-aa was inhibited by Insulin-like 
Growth Factor Binding Protein-7 (IGFBP7), MSF-function-neutralising antibody and 
antibody to the integrin αvβ3.  This integrin was identified in the cell membrane 
material bound to MSF, suggesting that αvβ3 is a receptor for MSF.  
Analyses of MSF staining in tissue sections indicated that MSF is expressed 
by most OSCC and malignant SGT, being heterogeneously present in both carcinoma 
and stromal cells. In SGT, significantly higher levels of total MSF and MSF-aa were 
detected in malignant than in benign tumours.  In OSCC, high MSF expression in the 
invasive tumour front (ITF) was significantly associated with poor patient survival.  
MSF-aa was more informative than total MSF. 
This study suggests that MSF stimulates tumour cell migration in an autocrine 
and paracrine manner, modulated by the type of MSF isoform expressed and by the 
presence of NGAL and other possible inhibitors.  This provides a rational platform for 
subsequent more extensive investigations of the possible diagnostic and prognostic 
significance of MSF expression in oral tumours.  
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Chapter one: Introduction 
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1.1 Head and Neck Cancer (HNSCC) 
Cancer is one of the main causes of morbidity and mortality, with more than 
7.6 million deaths yearly worldwide (WHO, 2008; Scully, 2005).  Head and neck 
cancer is the fifth most common cancer worldwide, with an estimated annual global 
incidence of 500,000-650,000 cases (Parkin et al., 2001; Parkin et al., 2005; Marur 
and Forastiere, 2008; Jemal et al., 2008). Cancer in the head and neck region includes 
the nasal cavity, sinuses, lip, mouth, salivary glands, throat, and larynx. The most 
common form of malignancy is squamous cell carcinoma, which develops in the 
mucosal linings of the upper respiratory and digestive tracts. This area is further 
divided into sub-sities of which the oral cavity (including lips) and larynx are the most 
common sites of cancer. Salivary gland lesions are relatively rare, representing about 
3-6% of all tumours of head and neck neoplasms of which approximately 80% are 
benign (Speight and Barrett, 2002; Mendenhall et al., 2005). The morphological 
diversity of salivary gland neoplasms complicates the diagnosis and classification of 
these tumours. Despite significant improvements in head and neck cancer treatment, 
long-term patient survival has only moderately improved during the last 20 years 
(Forastiere et al., 2001). Up to 40% of patients with squamous cell carcinoma in the 
head and neck region present with metastatic disease and survival is dependent on the 
disease stage (Lefebvre, 2005). My project has primarily focussed on evaluating the 
diagnostic and prognostic potential of a novel bioactive tumour marker for improving 
the clinical management of patients with OSCC and salivary gland tumours (SGT).  
1.1.1 Oral squamous cell carcinoma (OSCC): 
 
According to the International Classification of Disease (ICD version 10, 
categories:C00-06) oral cancer refers to a sub-group of head and neck cancers that 
develop on lips, tongue, gingival, floor of the mouth, buccal surface and other intra-
oral locations. Oropharynx cancers arise in tonsil, oropharynx and in some 
classification systems, in the base of the tongue and posterior soft palate. Salivary 
gland tumours and tumours of the nasopharynx are excluded from oral and 
oropharyngeal neoplasms. The term oral cancer is synonymous with malignancies 
arising from the lining of the oral cavity in any of the above indicated regions. 
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Squamous cell carcinomas of oral mucosal origin account for more than 80% of all 
malignant presentations at the aforementioned anatomical sites (Shah, 2003). 
Oral cancer is the eighth most frequent cancer in the world among men and the 
14th among women, accounting for nearly 3% of all cancer cases worldwide (IARC, 
2004). While historically the majority of patients have been found to be over the age 
of 40 at the time of detection, it may also occur in those under this age. From a gender 
perspective, although the disease is more frequent in men than in women (1.8:1) the 
higher sex ratio is slowly narrowing. This is most likely due to lifestyle changes, 
primarily an increase in smoking habits among women over the latter part of the last 
century, although firm data on this link are lacking. 
There is a wide geographical variation in the incidence of oral cancer 
(Warnakulasuriya, 2009). It is estimated that more than 750,000 patients worldwide 
suffer from oral cancer (Parkin et al., 2005). There has been a considerable rise in the 
number of oral cancers in many countries (Holmstrup et al., 2006), with 275,000 new 
cases of oral cancer reported in 2002 (Parkin et al., 2005). The areas with highest 
incidence rates are south and south-east Asia (e.g. Pakistan, Sri Lanka, India and 
Taiwan), parts of Western (e.g. France) and Eastern Europe (e.g. Hungary, Slovenia), 
parts of Latin America and the Caribbean (Brazil, Uruguay and Puerto Rico) and 
Pacific regions (e.g. Papua New Guinea and Melanesia). 
In the United Kingdom (UK) oral cancers are less common, accounting for 
1.6% of all new cancer cases (Cancer Research Campaign, 2005), with approximately 
5400 new cases of oral cancer each year and approximately 1800 deaths (Cancer 
Research UK, 2007). Rates in Scotland (13.1 per 100.000 populations) are higher than 
in other parts of the UK,  the incidence is around 670 cases per year with a five year 
survival of 42% for men and 48% for women (Scottish Cancer Intelligence Unit 
Online 2001; Cancer Research UK, 2007). In Iraq, OSCC account for 91.5% of all 
oral cancer whilst the incidence reaches 4.5% of all cancer cases according to Iraqi 
cancer registry (The Iraqi National Cancer Registry INCR, personal communication). 
Several countries and regions have reported sharp increases in the incidence rates e.g. 
Scotland, Germany, France, Central and Eastern Europe due to tobacco use and 
alcohol consumption (Petersen 2005; WHO report, 2004).  
The most common sites of oral cancer are the floor of the mouth, the sides and 
undersurface of the tongue and the back of the throat. The tongue is the most common 
site for intra-oral cancer among European and the US populations, amounting to 40–
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50% of oral cancers (Warnakulasuriya, 2009). It is important to know that the visible 
part of the tongue, the dorsum, is not a site where SCC develops; rather, it develops 
on the side (lateral surfaces) and underside (ventral surface), two areas not visible to 
cursory intra-oral examination. Buccal mucosal cancer is more common among Asian 
populations due to betel quid/tobacco chewing habits. In Sri Lanka, 40% of oral 
cavity cancers are found on the buccal mucosa (Rosenquist et al., 2005). Other 
intraoral sites for mouth cancer include floor of mouth, gingivae and palate. 
Survival rates for oral cancer are still very poor with 15% to 50% 5-year 
survival reported, and these have not improved in the last few decades despite 
advances in therapeutic interventions and our increased understanding of the disease 
(Vokes et al., 1993; Parkin et al., 2005). The essential factor in the lack of 
improvement in prognosis over the years is the fact that a significant proportion of 
OSCC are not diagnosed or treated until they reach an advanced stage. This diagnostic 
delay may be caused by either patients (who may not report unusual oral features) or 
by health care workers (who may not investigate observed lesions thoroughly). It is 
presumed that such delays are longer for asymptomatic lesions (Speight et al. 1992). 
Epidemiological and molecular studies of clinical cases suggest a strong 
association between HNSCC and tobacco use, alcohol consumption, genetic factors 
and infection by human papillomavirus (HPV) (McKaig et al. 1998; Gillison 2004; 
Stadler and Patel et al. 2008; Leemans et al. 2011). 
 
1.1.1.1 Etiology of oral cancer  
The etiology of OSCC is predominantly related to the following factors: 
1.1.1.1.1 Tobacco usage: 
The increased risk of developing OSCC is greater in smokers than in non-
smokers (Johnson et al., 2000). As it might be expected, the risk of cancer 
development increases with the number of cigarettes consumed each day, the amount 
of tobacco previously smoked and the number of years that the habit has been 
pursued. Ten years after cessation of tobacco use, the risk of developing OSCC 
declines (Franceschi et al., 1990). Tobacco contains a number of carcinogens 
(tobacco-specific nitrosamine, polycyclic aromatic hydrocarbons and substances that 
generate free radical oxygen intermediates) which contribute to cancer initiation and 
progression as a consequence of the irreversible genetic damage they inflict (La 
Vecchia et al., 1997). 
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1.1.1.1.2 Alcohol: 
It has been observed that alcohol abuse and OSCC are related. It is considered 
to be an important risk factor for oral cancer development. Cigarettes and alcohol are, 
therefore, associated with the development of most OSCC. It is a common 
observation that heavy alcohol users are also heavy smokers. The synergistic role of 
alcohol and tobacco increase the risk of malignancy significantly (Maier et al., 1990). 
All types of alcohol contribute to the cancer risk in proportion to their alcoholic 
content (Kabat and Wynder 1989). It has been shown that acetaldehyde, the first 
metabolite of ethanol, is carcinogenic. The role of microbes in the production of 
acetaldehyde in the oral cavity has previously been described (Homann et al., 2000; 
Muto et al., 2000; Jokelainen et al., 1996) but one recent study measured the alcohol 
dehydrogenase (ADH) activity of the viridans group of Streptococci and showed that 
Streptococcus salivarius produced high amounts of acetaldehyde. The observation 
supports the concept of a novel mechanism of alcohol in the pathogenesis of oral 
cancer (Kurkivuori et al., 2007). It is believed that possible carcinogenic contaminants 
and congeners may be present in alcoholic beverages and those drinks may enhance 
the penetration of carcinogens across the mucosal barrier (Wight and Ogden, 1998). 
                                                                                                                                                               
1.1.1.1.3 Infective agents:  
25% of cancer deaths in the developing world and 6% in industrialised 
countries are caused by infectious agents (Lopez et al., 2006). Candida albicans and 
some viruses, such as Herpes simplex (HSV), Epstein-Barr virus (EBV) and Human 
Papilloma virus (HPV) have been implicated in development of oral cancer. Several 
studies have suggested that transient viral infection exerts an influence on genomic 
DNA accordingly; the absence of viral particles at the time of presentation does not exclude a 
viral aetiology (Scully, 1992). The genotypes of HPV most commonly found in oral 
carcinoma are 16 and 18. The oncogenic potential of high risk HPV is attributable to 
its ability to insert specific DNA fragments (early genes E5, E6 and E7) into the host 
cellular genome. As a result of this integration, some key functions of tumour 
suppressor factors are abrogated (p21, p53 and pRb pathways, respectively), leading 
to defects in apoptosis, DNA repair mechanisms, cell cycle regulation and, finally, to 
cellular immortalisation (Szentirmay et al., 2005; Ragin et al., 2007). Robinson et al, 
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(2010) found that the diagnosis of ‘HPV related’ oropharyngeal SCC is based on high 
risk HPV DNA detection along with the expression evidence of viral oncogene.  
Serological and electron microscope studies of OSCC have demonstrated the 
presence of these viruses in some cases. While it is debatable that organisms act alone 
to initiate a cancer, they may act along with other agents like alcohol or cigarette 
smoke to cause malignant transformation, viruses act as co-carcinogen. Syrj¨anen 
(2005) found that patients with HPV 16-positive tumours seem to have a better 
overall- and disease-specific survival, as compared with the HPV-negative group. 
 Candida albicans is often associated with speckled leukoplakia; such lesions are 
prone to undergo malignant transformation, because Candida albicans produces 
nitrosamines which are known to be carcinogenic (Krogh et al., 1986).  
1.1.1.1.4 Nutrition:  
The consumption of fruit and vegetables, particularly those rich in carotene, 
vitamin C, and vitamin E has been reported to be associated with a reduced risk of 
oral cancer development, thereby implying that a diet deficient in antioxidants may 
increase the risk of developing oral and pharyngeal carcinoma and for precancer 
(Nagao et al., 2000; Petridou et al., 2002; Chainani-Wu, 2002). 
 
1.1.1.2 Genetic changes associated with oral cancer development: 
Cancer development is a multi-step process involving (i) initiation: the 
occurrence of a genetic lesion resulting in the inappropriately elevated expression of 
an “oncogenes” or the inactivation of a “tumour suppressor gene”’, and (ii) tumour 
progression:  the subsequent accumulation of further such pre-disposing lesions in the 
clonal progeny of the initiated cell (Nigro et al., 1989; Cowan et al., 1992). Tumour 
progression accordingly involves the clonal expansion of these increasingly aberrant 
progeny cells as a result of their acquired relative growth advantage (Nowell, 1976).  
The requirement for the random accumulation of several predisposing genetic lesions 
is consistent with the tendency of oral cancers to develop relatively late in life.  
  Abnormalities in the expression of a wide variety of proto-oncogenes (e.g. ras, 
myc, erbB1 and genes associated with 11q13 amplicon) have been well documented in 
oral cancer (Prime et al., 1997). With regard to tumour suppressor genes, loss of 
heterozygosity studies have indicated that early events in cancer development, (these  
often involving the transitions from normal to dysplasia) are associated with 
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abnormalities on the short arms of chromosomes 17, 9 and 3 (Califano et al., 1996). A 
number of tumour suppressor genes have been implicated in the development of oral 
cancers, including, p53, CDKN2A and Rb gene. For example, p53 inactivation results 
in loss of a G1 checkpoint.  Over-expression of p53 (this taken as an indicator of its 
mutation and is associated with approximately 40% of oral cancers and 80% of OSCC 
(Boyle, 1993; Greenblatt, 1994). Taken together, these findings suggest that knock-
out of normal p53 function is a common/essential step in oral carcinogenesis. Beside 
inactivation of tumour suppressor genes, mutation and dysregulated expression of 
oncogenes may also be involved in the pathogenesis and progression of OSCCs. In 
this regard, mutations in the ras oncogene family result in persistent mitogenic 
signalling, whereas upregulation of c-myc provides an additional proliferative signal 
resulting in dysregulated hyper-proliferation (Field, 1992; Todd et al., 1997). 
Amplification and overexpression of the erb-B oncogenes have also been found to be 
correlated with aggressive tumour growth and poor survival in oral cancer (Brand et 
al., 1995; Werkmeister et al., 1996; Xia et al., 1997). 
  Wang et al., (2006) found that the proteins cyclin D1, Ki-67 and activated 
extracellular signal-regulated Kinase (ERK1/2) expression, were shown to be 
significantly higher in OSCCs than in the normal mucosa, both positive expression of 
the cell proliferation-related index Ki-67 and over-expression of activated ERK1/2 in 
OSCCs were significantly associated with a moderately or poorly differentiated grade. 
Miyazaki et al., (2006) showed that polypeptide growth factors play important roles in 
the processes of cell migration and invasion and they showed that transforming 
growth factor beta (TGF-β) and epidermal growth factor (EGF) differentially affect 
gene expression in primary and metastatic SCC cells, and likely contribute to the 
invasive properties of metastatic cells through regulation of both common and specific 
mediators for each growth factor. 
Although it is believed that up to a third of precancerous lesions may 
eventually evolve into invasive OSCC over a 10 year interval, no reliable 
histopathological parameters have been indentified that predict for the risk of such 
malignant transformation.  There is therefore a pressing need to identify such a 
predictive biomarker (Schepman et al., 1999). 
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1.1.1.3 Clinicopathological aspects: 
Early OSCC may present as a white raised or flat patch, red patch or a mixed 
red and white lesion. The mucosal surface may develop ulceration and with time this 
ulceration becomes an exophitic mass with a fungating or papillary surface. Other 
tumours have an endophytic growth pattern that is characterised by a depressed, 
ulcerated surface with a raised, rolled border (Silverman, 1988), therefore any solitary 
oral lump, ulcer, white or red lesion persisting for more than three weeks (Brandizzi, 
2008) or non-healing socket, numbness, or unexplained loose tooth should be 
regarded as cancer until proven otherwise (Mashberg and Samit, 1995). 
Pain is a common but not a reliable indicator as to whether a particular lesion 
may be malignant; larger, advanced carcinomas will often be painful, but many early 
oral cancers will be totally asymptomatic or may be associated with only minor 
discomfort (Scully and Bagan, 2009). 
 
1.1.1.4 Potential malignant lesions 
  Oral leukoplakia (white lesion), erythroplakia (red lesion) and erythro- 
leukoplakia (mixed red and white lesion) are potentially malignant lesions that can-
not be clinically or pathologically diagnosed as any other conditions (Axell et al., 
1996). In a recent study, 15-20% of non-homogeneous leukoplakia progressed to 
malignant tumours, whereas only 3% of the homogeneous leukoplakia developed 
carcinoma (Holmstrup et al., 2006). Although erythroplakia is much less common 
than leukoplakia, it has been shown to have a higher risk of malignant transformation 
(Reichart and Philipsen, 2005). Currently, clinicians cannot predict if a mild, 
moderate or severe dysplasia will progress to oral cancer based on histopathologial 
morphology alone. However, up to 50% of severely dysplasia lesions progress to 
carcinoma (Speight and Morgan, 1993) although there is no way of predicting which 
severe dysplasia will progress. A recent study revealed that there was significant inter-
observer variation in the grading of oral epithelial dysplasia (Kujan et al., 2007).  
Identifying more accurate predictive markers of subsequent neoplastic transformation 
would greatly assist in the selection of an optimal therapeutic strategy.   
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1.1.1.5 Biomarkers of Head and Neck cancer: 
Advances in the analysis of molecular alterations in cells undergoing 
malignant transformation have increasingly revealed the mechanisms which have lead 
to the occurrence and progression of malignancies. The identification of individual 
molecules that are associated with malignant transformation has led to an ever 
increasing number of molecular markers that have shown to be related to tumour stage 
and grading or may be indicative of prognosis and the clinical course of the disease. 
Many molecular indicators of malignancy have been evaluated in recent years. 
Characterisation of malignant disease by molecular markers is expected to improve 
our understanding of the as yet unpredicable clinical outcome for individual patients, 
as well as identify alternative (non surgical) therapeutic strategies, such as gene 
therapy (Schliephake, 2003). Although several studies have used different types of 
biomarkers regarding head and neck squamous cell carcinoma, none have as yet 
proved to be of sufficient clinical utility. These biomarkers including tyrosine kinase 
receptors: epidermal growth factor receptor (EGFR) and vascular endothelial growth 
factor (VEGF); matrix metalloproteinases (MMPs); p16, p53, Bcl-2, cyclin D1 
(CCND1), and Cox-2, have demonstrated inconsistent and sometimes contradictory 
results (Brinkman & Wong, 2006; Deshpande and Wong, 2008; Molinolo et al., 
2009). 
 Many studies have been divided the tumour markers into different groups 
according to their function;(i) tumour growth development: cell cycle acceleration and 
proliferation, (ii) angiogenesis, (iii) tumour suppression, (iv) tumour invasion and 
metastatic potential including adhesion molecules and matrix degradation. Table 1.1 
shows some of the most important molecular indicators (Schliephake, 2003; Massano 
et al., 2006; Oliveira and Ribeiro-silva, 2011). 
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  Table 1.1: Potential biomarkers in Head and Neck cancer 
Class of marker Oncogene Carcinogenesis Prognosis References 
EGF/EGF-R,  
C-erb1-4 
Or Her-2/neu 
Over expression  
 
Poor  
 
Ibrahim1997; Werkmeister,2000; Wilkman,1998; 
Sakaki,2000;Xie, 1999; 1997;  
Ki-67 
 
Over expression 
 
Less relevant for 
prognosis 
Piattelli,2002; Mishima,1998 
Tumour growth enhancement 
 (cell cycle acceleration, 
proliferation) 
PCNA 
 
Over expression 
 
Less relevant for 
prognosis 
Yue,1997;Schwartz,2000; Sakurai, 2000 
P53 
 
Over expression 
 
Not valid in 
predicting prognosis 
Piattelli,2002; Horta,2007 Tumour suppression & Anti 
tumour defence 
pRb 
 
Lack of 
expression 
poor Nakahara,2000;Pande,1998; 
Koontongkaew,2000  
Angiogenesis VEGF/VEGF-R  
 
Over expression 
 
Questionable  Artese,2001;Carlile,2001; Tae,2000 
Potential tumour invasion & 
metastasis 
MMP9  Over expression Poor  
 
Arenas-Huertero,1999; Kurahara,1999; 
Hong,2000 
Intracellular  Markers Cytokeratins 
8,18,19 
Over expression  Poor  Fillies et al., (2006); Nanda et al, (2011) 
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1.1.2.6 Diagnosis, Prognosis and Management: 
Diagnosis of oral cancer generally relies on the histopathological  assessment 
of haematoxylin and eosin stained paraffin embedded tissue sections 
(Warnakulasuriya, 2001) According to the degree of squamous cell carcinoma 
differentiation, three subtypes are defined: (1) well-differentiated squamous cell 
carcinoma showing more than 75% keratinisation; (2) moderately differentiated 
squamous cell carcinoma with 25-75% keratinisation; and (3) poorly differentiated 
squamous cell carcinoma with less than 25% keratinisation ( Ferlay et al., 2004). The 
majority of cases fall into the moderately differentiated group. The relationship 
between clinical prognosis and histological differentiation is not clear, although a lack 
of differentiation has been associated with more rapid growth and spread. The OSCC 
morphological classification by differentiation degree is used to describe the 
histopathologic specimen (Zarbo and Crissman, 1988).  The signs and symptoms of 
early oral cancers and precancerous lesions are approximately similar and seem to be 
faint. For that reason, if risk factors such as tobacco use or alcohol abuse are present it 
is important for the clinician to show extreme caution in dealing with these cases. 
Studies have shown that areas of tissue which appear clinically altered and were 
identified at the first assessment as “precancerous” have undergone malignant change 
during follow-up (Pindborg et al., 1963, 1968; Gupta et al., 1980; Schepman et al., 
1998). Some of these alterations, particularly red and white patches, are seen to co-
exist at the margins of overt OSCC (Wright and Shear, 1985). From the genetic 
viewpoint, some of the chromosomal, genomic and molecular alterations found in 
invasive OSCC are also detected in these disorders as well (Rosin et al., 2000; Van 
Der Riet, 1994).  OSCC can be preceded by the appearance of disorders (such as red 
or white patches) which have the potential to develop into cancer or enable prediction 
of the development of cancer elsewhere in the oral cavity. As the cancer develops, the 
patient may observe the occurrence of a non-healing ulcer. After a while, symptoms 
may worsen to include bleeding, loosening of teeth, difficulty wearing dentures, 
dysphagia, dysarthria or development of a neck mass (Neville et al., 2002).   
Improvement in the clinical outcome of patients with OSCC depends on the 
early diagnosis and treatment of the cancerous or pre-cancerous lesion (Dolan et al., 
1998; Vernham and Crowther, 1994). Several attempts have found that clinical stage, 
tumour size, pain from face and neck, age and cervical metastasis are strong 
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prognostic indicators;   It should also be noted that there is a good correlation between 
TNM classification, as defined by Union for International Cancer Control (UICC) and 
prognosis (Langdon et al., 1977; Pedersen et al., 1992, Therkildsen et al., 1998). 
As the ultimate control of oral cancer depends on prevention and early 
diagnosis, it is clear that every effort should be made to educate the public about risk 
factors and early features associated with this disease (Horowitz et al., 1996). 
  
1.1.2.7 Treatment  
Treatment of OSCC is inconsistent and depends upon numerous factors 
including the size and location of the primary tumour, lymph node status, presence or 
absence of distant metastases, the ability of the patient to accept treatment and their 
wishes. Surgery and/or radiation therapy remain the principle means for treatment of 
cancers of the lip and oral cavity (Yamamoto et al., 2006). Treatment of oral cancer is 
principally surgical. Resection of the tumour may be the treatment of choice if the 
tumour can be excised with an appropriate margin of normal tissues surrounding the 
tumour (Edwards and Johnson, 1999). Radiotherapy can be delivered with curative 
intent (radical radiotherapy), or to improve local control following surgery (adjuvant 
radiotherapy), or to provide symptomatic relief only (palliative radiotherapy). Ionizing 
radiation may be delivered as an external radiation beam targeting the tumour 
(external beam radiotherapy or by direct implanting radioactive source within the 
tumour (brachytherapy). Radiotherapy is appropriate treatment for some patients 
particularly those with large tumours with bone involvement (Henk and Langdon, 
1985). There is as yet no evidence to suggest the use of chemotherapy alone as a 
curative treatment for oral cancer. Therefore, administration of chemotherapy in 
patients with HNSCC is in combination with locoregional therapy (surgery or 
radiotherapy) (Licitra et al., 2003). Another diagnostic and therapeutic method for 
oral cancer is photodynamic therapy (PDT) which involves administration of 
photosensitizing agents to the target lesion, which is then stimulated, usually by short 
wavelength light.  The photosensitizing agents, along with the light, kill cancer cells. 
These light sensitive chemicals only work after they have been activated or "turned 
on" by certain kinds of light. Regrowth of the tumour was significantly suppressed by 
fractionated PDT, with a 24 hour interval appearing to be the optimal fractionation 
interval (Togashi et al., 2006). The limited depth of penetration of PDT limits its 
usefulness to field change lesions and superficial cancers.   
  
12 
1.1.2 Normal Salivary glands and salivary gland tumours 
1.1.2.1 Normal salivary glands 
The salivary glands are exocrine glands that produce and secrete saliva into 
the oral cavity; saliva is produced at a rate of 600-1500 ml every day and contains 
different types of organic and inorganic substances. It provides a protective barrier for 
the teeth and supporting structures of the oral cavity and assists in mastication and 
swallowing by moistening the oral mucosa as well as dry foods and aids in the 
digestion of food materials. Salivary gland tissue consists of branching ducts that 
contain the principal secretory cells, the acinar cells (Ellis and Auclair, 1996; Mayers 
and Ferris, 2007).The gland is encapsulated by the connective tissues divided into 
lobules internally, and the gland is composed of three mains types of cells; serous, 
mucus and myoepithelial cells (Bhaskar, 1990). 
 
1.1.2.1.1 Histological structure of salivary glands: 
   1.1.2.1.1.1 Cells: 
 All salivary glands are composed of three mains types of cell (Fig.1.1); 
- Serous cells: which are a pyramidal shaped cells resting on a thin basal lamina, have 
a spherical nucleus located in the basal region of the cell, the most characteristic 
features of the serous cell are the accumulation of secretory granules in the apical 
cytoplasm, the cytoplasmic base stains with haematoxylin. While the apical cytoplasm 
stains with eosin. These cells join together to form a spherical mass of cells known as 
the acinus with a small central lumen. The serous cells are where synthesis, storage 
and secretion of proteins occur (Kerr, 1998). 
 
- Mucous cells: which are cuboidal shape cells with a flattened or oval shape nucleus 
located above the basal plasma membrane, the cells are organised into tubules. 
Glycoprotiens are the product of these cells, which are used for moistening and 
lubricating saliva functions. These cells are considered to be poorly stained with 
haematoxylin and eosin (Bhaskar, 1990). 
 
- Myoepithelial cells (basket cells): these cells are located near the secretory and 
intercalated ducts portion, the cell body is small with a flattened nucleus and 
numerous cytoplasmic processes that radiate out to the connective tissue. The function 
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of the myoepithelial cell is their ability to contract to accelerate secretion of saliva  
from the lumina of the secretory units and ducts (Kerr, 1998). 
 
           
 
 Figure 1.1 Histological structure of salivary gland (Oral Anatomy, Histology and Embrylogy, 
Berkovilz et al., 2002) 
 
1.1.2.1.1.2 Ducts: 
The saliva is drained by a series of ducts, the intralobular segments of the 
salivary gland duct system consisting of intercalated and striated ducts, which are also 
known as `secretory' ducts because of their metabolic activity. The intercalated duct 
lies directly in contact with the acinus and is formed by cuboidal cells with an 
irregular layer of myoepithelial cells. Several benign and malignant salivary gland 
tumours are putatively of intercalated duct origin (Chetty, 2000). Normal duct 
epithelium consisted of two layers: inner columnar cells and basal cuboidal or 
squamous cells. A few goblet cells are present amongst the inner cells (Takeda and 
Yamamoto, 1997). An intercalated duct drains into a striated duct, which empties into 
an excretory duct in the direction of the opening of the salivary gland unit (Hanna and 
Suen 1998; Mayers and Ferris, 2007) (Fig. 1.1). Basal (reserve) cells line the outer 
side of excretory ducts. They are relatively isomorphic and have a prominent basal 
cell layer and distinct basement membrane-like structures (Seifert, 1991). 
1.1.2.1.1.3 Connective Tissues:  
The connective tissue of the salivary glands surrounds the gland in a capsule 
and divides the gland into many lobules. It is composed of cells which include; 
fibroblasts, mast cells, macrophages, fat cells, plasma cells, occasional leucocytes and 
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collagen fibres which are embedded in ground substance that consists of proteoglycan 
and glycoprotiens, the blood vessels and nerves supply are also embedded within 
connective tissues (Douglas, 2000). 
 
1.1.2.1.2 Classification of salivary gland: 
Salivary glands have been classified according to their site and location into 
main groups; a) three pairs of major salivary glands consisting of the parotid glands, 
submandibular glands and sublingual glands, which are located outside of the oral 
cavity and have extensive duct systems which deliver saliva to the mouth. b) Minor 
salivary glands which are scattered in the oral mucosa (Seifert and Sobin, 1992; 
Mayers and Ferris, 2007). 
 
1.1.2.1.2.1 Major salivary glands: 
1.1.2.1.2.1.1 Parotid gland; 
            The parotid gland is considered the largest salivary gland, located anterior and 
inferior to the external ear overlying the Ramus of the mandible. It is a bilateral gland 
found in the subcutaneous tissue of the face. The excretory duct of the parotid gland is 
called Stensen’s duct, which opens within the buccal cavity opposite to the upper 
second molar teeth, this opening is marked by a small elevated tissue on the inner 
surface of the cheek called the parotid papilla. The parotid gland receives nerve 
supply from glossopharyngeal nerve (parasympathetic) through the otic ganglion 
(Bhaskar, 1990 & Kerr, 1998). 
Histologically: The Parotid gland is considered a serous gland (100%). There is 
extensive connective tissue septa that divides the glands into lobules, the intercalated 
duct is long and has a small diameter and lumen and there are numerous striated ducts 
that are lined by columnar cells. Numerous fat cells are also present in the parotid 
gland which increases in number with age (Bhaskar, 1990; Kerr, 1998). During 
embryonic development the parotid is seeded with lymphoid cells that develop into 
several lymph nodes within and around the parenchymal tissue. The lymph nodes are 
often located in the superficial lobe of the gland. Lymph vessels pass to 
retromandibular, superficial and deep cervical lymph nodes, which have to be 
considered when treatment is planned (McKean et al, 1985). 
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1.1.2.1.2.1.2 Submandibular gland: 
          A pair of salivary glands is located in the submandibular triangle behind and 
below the free border of mylohyoid muscle beneath the floor of the mouth. The 
excretory duct of the submandibular gland called (Wharton’s ducts) which opens into 
the oral cavity at sublingual (caruncles) which is a small papilla on either sides of the 
lingual frenum on the floor of the mouth near the sublingual gland duct. Secretion by 
the submandibular gland and other salivary glands is regulated directly by the 
parasympathetic and indirectly by the sympathetic nervous system. The 
parasympathetic innervations of the submandibular and sublingual glands input from 
the facial nerve through the submandibular ganglion, whilst the sympathetic through 
preganglionic nerves in thoracic segment T1-T3 (Ten Cate, 1998). 
Histologically: These glands are enclosed in a well-defined capsule of connective 
tissue, separating the gland into lobules, which contain the secretory units. They are 
classified as branching tubuloacinar glands as they contain both serous and mucous 
secretory cells and the mucous terminal ends are capped by demilunes of serous cells. 
Although the serous cells are most predominant, the mucous cells are more active, so 
the main product of the glands is viscous saliva (Ten Cate, 1998; Douglas, 2000). 
There are no lymph nodes, lymphoid nodules nor large peripheral nerves within the 
gland. The lymph vessels drain to pre-vascular and pre-glandular sub-mandibular 
lymph nodes. The lymph vessels run straight through to sub-gastric lymph nodes from 
the dorsal side of sub-mandibular gland (Mayers and Ferris 2007). 
 
1.1.2.1.2.1.3 Sublingual gland: 
          A pair of salivary glands is located between the floor of the mouth and the 
mylohyoid muscle anterior to the submandibular gland, the main excretory duct that 
opens near the submandibular ducts called Bartholin’s duct, 5% of saliva is produced 
by the sublingual glands (Bhaskar, 1990). 
Histologically: Sublingual glands are enclosed by a poorly defined capsule of 
connective tissue, but the connective tissue septa are clearly present within the gland. 
It is a mixed gland consisting of mucous cells which are most predominant and serous 
demilunes and very rare pure serous acini are present. In the sublingual glands, both 
the intercalated ducts and the striated ducts are relatively short. Lymphoid tissue and 
large peripheral nerves are not present in the sublingual gland. The lymph vessels lead 
to submandibular or to deep jugular lymph nodes (Mayers and Ferris 2007). 
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1.1.2.1.2.2 Minor salivary glands: 
           These glands are located beneath the epithelium in almost all parts of the oral 
cavity where there are about 400 to 500 minor salivary glands located in oral mucosa. 
More than 50% of minor salivary glands are present in the palate and the others are 
present in the lips, floor of mouth, tongue, and buccal mucosa. 
Their ductal system is simpler and the secretory units of these glands secrete 
saliva which is mostly mucous product directly through short ducts into the mouth, 
except the Van Ebner’s glands (Douglas, 2000). 
Histologically: Minor salivary glands are not encapsulated but are separated from one 
another by connective tissue beneath the mucous membrane. They are considered to 
be mixed glands consisting of mucous and serous acini, predominantly mucous, 
contributing about 5% of total saliva secretion (Bhaskar, 1990; Kerr, 1998; Spiro and 
Spiro 2001). 
 
1.1.2.2 Saliva: 
         Saliva is a complex fluid present normally in the mouth which is secreted and 
produced by various salivary glands, it represents about 1/5 of the total plasma 
volume, and the total volume of saliva secreted daily is between 0.5-1.5 L. The 
contribution of each type of gland to saliva secretion depends considerably upon the 
stimulation of various intensities (Herrera et al, 1988; Fox, 1989). 
Saliva contains 99% water and the remaining 1% consisting of: 
-  Inorganic substances which include; 
   Calcium, phosphate, hydrogen carbonate, sodium, potassium, chloride, fluoride, 
thiocyanate, magnesium, lead. 
-  Organic substances include; 
    Protein (glycoprotein, mucins), proline rich protein, amylase, lysozyme, lactoferrin, 
lipase, peroxidase, immunoglobulin (SIgA), histatin, statherin . 
 -  Serum constituents; albumin, blood clotting factors, blood groups, amino acids, 
urea, steroid hormones, ammonia, and sugar. 
   - Growth factor [GF]: Epidermal growth factor [EGF],  Nerve growth factor [NGF],  
Transforming growth factor alpha [TGF-α] and beta [TGF-β], Basic fibroblast growth 
factor [bFGF], Vascular endothelial growth factor [VEGF], Insulin growth factor 
[IGF-I] and [IGF-II]. 
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Functions of saliva: 
The main functions of saliva shown in Table 1.2:  
Table 1.2: The Major functions of saliva 
Adapted from FDI Working Group 10 (1992); Fox (1989); Herrera et al., (1988). 
 
 
 
 
 
Functions 
 
Salivary components 
(1) Protective functions:  
1-Lubrication Mucins,   proline-rich   glycoproteins,    water 
2-Antimicrobial Amylase 
 
 
 
 
Complement, defensins, lysozyme, lactoferrin,    
lactoperoxidase , mucins, cystatins, histatins, 
proline-rich glycoproteins, secretory IgA, 
secretory leukocyte protease inhibitor, statherin, 
thrombospondin 
3-Growth factors 
 
 
 
Epidermal growth factor (EGF), transforming growth 
factor-  alpha               
(TGF-α), transforming growth factor-beta (TGF-β), 
fibroblast 
growth factor (FGF), insulin-like growth factor (IGF-I & 
IGF-II), 
nerve growth factor (NGF) 
4-Mucosal integrity Mucins, electrolytes, water 
5-Lavage/cleansing Water 
6-Buffering Bicarbonate, phosphate ions, proteins 
7-Remineralization 
 
  Calcium, phosphate, statherin, anionic proline-rich 
proteins 
(2) Food- and speech-related functions: 
1-Food preparation  Water, mucins 
2-Digestion  Amylases, lipase, ribonuclease, proteases, water, mucins 
3-Taste Water, gustin 
4-Speech  Water, mucins 
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1.1.2.3 Salivary gland tumours 
Salivary gland cancers are an uncommon disease of the upper aerodigestive 
tract. These tumours represent about 3% to 6% of all tumours of head and neck 
neoplasms. Neoplasms of the salivary gland are a heterogeneous and important group 
of tumours of Oral and Maxillofacial pathology.  Salivary gland tumours may be 
categorised into benign neoplasms, tumour like lesions, and malignant, they arise 
from either the major salivary glands (i.e. parotid gland, submandibular gland, and 
sublingual gland) or in one of the 600-1000 minor salivary glands which are 
distributed throughout the sub-mucosa of the upper aerodigestive tract. Salivary gland 
neoplasms present a most diverse group of tumours. They originate from the cells of 
neuroectoderm or neural crest which have the potential to differentiation into a wide 
variety of cell types (Shrestha et al., 1994; Mackie et al., 1988). The etiology, 
prognostic factors and risk factors are poorly defined. Considering variation in 
histological characteristics, clinical behaviour, pathogenesis and the diversity of 
anatomic sites, these tumours represent a challenge for head and neck surgeons and 
pathologists (Cawson, 1978; Ward and Levire, 1998). 
Salivary gland neoplasms vary morphologically not only among individual 
tumours but there is also heterogeneity within the one and the same tumour mass in an 
individual patient (Eveson, 1992). The difficulty and controversy in the diagnosis and 
management of salivary gland neoplasms requires a clear understanding of 
histogenetic concepts for salivary gland tumours, the histomorphology of certain 
tumours, and their classification in order to overcome this challenge. It is also difficult 
to differentiate benign from malignant tumours and furthermore the decision as to the 
best method of treatment depends upon reliable information about survival rates. 
Prognosis and survival statistics following treatment of salivary malignant tumours 
have been very difficult to interpret because these are rare tumours with a diverse 
histology. Besides, the clinical course of salivary gland tumours is generally insidious 
and a long-term follow-up is required to determine the outcome (Licitra et al., 2003). 
 
1.1.2.3.1 Classification: 
  Different classification of salivary glands tumours have appeared based on 
their cytological, architectural, and biological characteristics and recently the 
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classification has taken into consideration the behaviour and the prognosis of these 
tumours.   
The first well recognised histological classification of salivary gland cancer 
(SGC) was published in 1953 (Foote and Frazel 1953). The World Health 
Organisation (WHO) published a classification in 1991 (Seifert, 1991) which has been 
updated several times, and the most recent version from 2005 (Table 1.3), where 24 
salivary gland carcinoma (SGCs) of epithelial origin are included (Barnes et al., 
2005). Currently, 24 (SGCs) entities have been described and some are also grouped 
by degree of malignancy. Carcinoma ex pleomorphic adenoma is classified into three 
types based on the degree of invasion into the capsule. The low-grade cribriform 
cystadenocarcinoma was originally described as a low-grade salivary duct carcinoma 
but has been renamed to avoid confusion with salivary duct carcinoma (Barnes et al., 
2005). The secondary tumours of the salivary glands consist usually of metastases 
from primary squamous cell carcinomas or from melanomas of the skin of the head 
and neck region. 
Benign epithelial tumours: 
 
- pleomorphic adenoma 
- myoepithelioma 
- Basal cell adenoma 
- Wartin’s tumour 
- Oncocytoma 
- Canalicular adenoma 
- Sebaceous adenoma 
- Lymphadenoma, sebaceous and non-sebaceous 
- Ductal papillomas 
- Cyctadenoma 
 
Soft tissue tumours 
 
- Haemangioma 
 
Lymphoma 
- Hodgkin’s lymphoma 
- Diffuse large B-cell lymphoma 
- Extra-nodal marginal B-cell lymphoma (MALT lymphoma) 
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Table 1.3: WHO histological classifications of malignant salivary gland tumours 
of epithelial origin, 1991 (Seifert, 1991) and 2005 (Barnes et al., 2005).  
Seifert 1991 Barnes 2005 
Acinic cell carcinoma Acinic cell carcinoma 
Mucoepidermoid carcinoma Mucoepidermoid carcinoma 
Adenoid cystic carcinoma Adenoid cystic carcinoma 
Polymorphous low-grade 
adenocarcinoma (terminal duct 
adenocarcinoma) 
Polymorphous low-grade adenocarcinoma 
Epithelial-myoepithelial carcinoma Epithelial-myoepithelial carcinoma 
 
 
*Clear cell carcinoma, not otherwise 
specified 
Basal cell adenocarcinoma Basal cell adenocarcinoma 
Sebaceous carcinoma Sebaceous carcinoma 
 *Sebaceous lymphadenocarcinoma 
Papillary cystadaenocarcinoma *Cystadenocarcinoma 
*Low-grade cribriform cystadenocarcinoma 
Mucinous adenocarcinoma Mucinous adenocarcinoma 
Oncocytic carcinoma Oncocytic carcinoma 
Salivary duct carcinoma Salivary duct carcinoma 
Adenocarcinoma *Adenocarcinoma, not otherwise specified 
(NOS) 
Malignant myoepithelioma 
(Myoepithelial carcinoma) 
Myoepithelial carcinoma 
Carcinoma in pleomorphic adenoma 
(Malignant mixed tumour) 
Carcinoma ex pleomorphic adenoma 
 *Carcinosarcoma 
 *Metastasising pleomorphic adenoma 
Squamous cell carcinoma Squamous cell carcinoma 
Small cell carcinoma Small cell carcinoma 
 *Large cell carcinoma 
 *Lymphoepithelial carcinoma 
 Sialoblastoma 
Undifferentiated carcinoma  
Other carcinoma  
* New entities in 2005, Malignant tumours highlighted in bold have been used in this study 
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1.1.2.3.2 Epidemiology  
Salivary gland tumours are uncommon and represent about 3% to 6% of all 
tumours of head and neck neoplasms and affect about 1 to 3 per 100,000 people. 
Salivary gland tumours occur most commonly in the sixth decade of life, benign 
tumours develop in women more than men above the age of 45, while the malignant 
tumours have an equal sex distribution after 60 years of age (Ellis & Auclair, 1996). 
Most of the benign tumours arise in the parotid salivary gland, while 80% of minor 
salivary glands are found to be malignant (Spiro, 1986; Eveson and Cawson, 1985; 
Joseph et al., 2003; Barnes et al., 2005) (Table 1.4). 
The incidence of malignant salivary gland neoplasms varies significantly in 
different parts of the world. The Surveillance, Epidemiology and End Results (SEER) 
and American Cancer Society registries record salivary gland cancers according to the 
anatomical site of origin, e.g., oral cavity and pharynx, rather than within a single, 
organ-specific salivary gland entity (Witt, 2005).  The latest incidence figure from the 
USA is 1.2/100 000 (2000-2004) (SEER, 2010). Very high incidence rates have been 
reported in Greenland (Albeck et al., 1992) and among the Canadian Arctic Inuits, 
13.5/100 000 person. The high risk of SGC persists after migration to a low incidence 
area, which indicates that genetic or environmental factors gained early in life are 
etiologically important (Boysen et al., 2008). 
 
Table 1.4: The percentage of tumours according to the salivary gland types  
  Salivary gland benign tumour malignant tumour 
Parotid gland 70- 85% 15 – 34% 
Submandibular 8 – 15% 30-55% 
Sublingual 1 % 80-90% 
Minor salivary 1% 40-85% 
 
1.1.2.3.3 Etiology: 
Ionising radiation and certain occupational exposures are associated with an 
increased incidence of salivary gland cancer. Serum or tissue markers associated with 
a risk for neoplastic transformation have not been reported. 
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1.1.2.3.3.1 Radiation  
The role of the etiological factors for the development of salivary gland cancer 
is not well understood, but exposure to ionizing radiation from various sources is 
clearly associated with these tumours (Takeichi et al., 1983, Little 2001). Several 
studies have not found any association between the uses of mobile phones and 
salivary gland tumours. (Johansen et al.,  2001; Auvinen et al., 2002; Elwood 2003, 
Hardell et al., 2004; Kundi et al., 2004). 
1.1.2.3.3.2 Occupation, lifestyle and nutrition: 
Salivary gland cancer risk increases with certain occupations, for example 
some types of woodworking, plumbing, asbestos mining, rubber manufacturing, 
among hairdressers and in personnel employed in beauty shops, but the clinical 
significance has by no means been established (Swanson and Belle, 1982; Horn-Ross 
et al., 1997). Muscat and Wynder (1998) found that tobacco use and alcohol 
consumption are unrelated to salivary gland cancers in a case/control study. 
 
1.1.2.3.3.3 Hormones: 
Endogenous hormone receptors, such as estrogen, progesterone and androgen, 
have been recognised in normal and neoplastic salivary glands, but no clear etiologic 
nor prognostic pattern has appeared (Jeannon et al., 1999; Dori et al., 2000; Nasser et 
al., 2003). 
 
1.1.2.3.3.4 Viruses 
Several viruses have been associated in the pathogenesis of salivary gland 
cancer. There is a strong relationship between Epstein-Barr virus (EBV) infection and 
lymphoepithelioma-like carcinomas; this association appears to be in the region of 
limited to Eskimo and Asian populations (Iezzoni et al., 1995). EBV has also been 
detected in undifferentiated salivary gland carcinomas (Hamilton-Dutoit et al., 1991; 
Gallo et al., 1994). This implies that a specific EBV strain may have a special 
oncogenic potential in Greenland and Asia than in other parts of the world (Tsai et al., 
1996). In contrast, Atula et al., (1998) did not identify EBV, human herpesvirus 8, 
human papilloma virus (HPV) nor cytomegalovirus presence in salivary gland cancer 
(Iezzoni et al., 1995). 
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1.1.2.3.4 Histology and clinical features of salivary gland tumours 
1.1.2.3.4.1 Pleomorphic adenoma (PA): 
          Is the commonest type of the benign salivary gland tumours and mostly affects 
parotid gland 85% whereas the submandibular and minor salivary glands account for 
8% and 7%, respectively. Intraorally, the majority of those tumours are located in the 
palate. It is considered a mixed tumour and it is called pleomorphic because it is 
composed of both epithelial and connective tissue components, it arises from 
intercalated duct cells and myoepthelial cells, (Stennert et al., 2001). 
Clinical aspects: 
       Older female patients, more than males, 40-50 years of age are more likely to be 
affected. Pleomorphic tumours appear as a single irregular nodular mass with a well 
defined border, slow growth and are asymptomatic. The tumour is almost mobile 
except when found in the palate, and because it has a thin and delicate capsule have 
the ability to grow to large proportions and may project into the surrounding parotid 
tissue. Pleomorphic adenoma may change into a malignant tumour when associated 
with long duration of the tumour, recurrent, radiotherapy, increasing age of patient 
and tumour size, in this case the recurrent lesion appears as a multiple nodules and are 
less mobile than the original tumour (Joseph et al., 2003). 
Histological aspect: 
       Pleomorphic adenoma in the major salivary glands can be partially capsulated or 
unencapsulated whereas in minor salivary is unencapsulated. Histologically it has a 
variable structural appearance, there is a wide variety of epithelial structure ranging 
from duct like structures, sheet, strands of polygonal shape, spindle or stellate cells 
with a bland nuclear and small or absent nucleoli in a variable stroma either myxoid, 
mucoid, cartilaginous or hyaline. Myoepithelial cells are the major components of 
pleomorphic adenoma which may have two morphologic types either plasmacytoid 
cells which often tend to aggregate or spindle cells which tend to be arranged in 
parallel pattern. Squamous metaplasia and keratin forming cells may be also present 
(Joseph et al., 2003; Stennert et al., 2001). 
1.1.2.3.4.2 Angioleiomyoma (Ang): 
Angioleiomyoma is a benign mesenchymal tumour derived from the vascular 
smooth muscle cells, composed of convoluted thick-walled vessels and smooth 
muscle fascicles (Weiss et al., 2001). Although it typically involves the superficial 
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soft tissues of the head and neck (Brooks et al., 2002), this tumour is rarely found in 
the salivary gland. The aetiopathogenesis of Angioleiomyoma in the major salivary 
gland is unclear. Its predilection for the parotid gland may be attributed to the absence 
of a well-defined capsule and the presence of thick-walled vascular structures. It is 
well-known that the parotid gland is in close contact or embraces branches of the 
external carotid arteries and the internal jugular vein (Ellis & Auclair, 1996).  
 
1.1.2.3.4.3 Mucoepidermoid Carcinoma (MC): 
         Mucoepidermoid Carcinoma is the most frequent malignant tumour of salivary 
glands representing approximately 30% of all major and minor salivary gland 
neoplasms in general (Myers and Ferris, 2007). There is a 3:2 female predilection 
(Barnes et al., 2005). It arises within the parotid and minor salivary gland in about 2/3 
and 1/3 cases respectively and the palate is the common site when the tumour arises 
within oral cavity. Although it is considered the most common salivary gland 
malignancy in children, elderly people especially women are also affected in the 5th 
decade of life, (Brandwein et al., 2001). According to the multicellular theory, 
mucoepidermoid tumours develop in the excretory duct cells while the reserve cell 
theory proposes that the origin is in the reserve cell of the excretory duct (Hanna and 
Suen, 1998). Prognosis is influenced by the degree of malignancy, tumour grade, 
stage and the gender and age of the patient (Pires et al., 2004; Mendenhall et al., 
2005). 
Clinical Aspect: 
        Mucoepidermoid carcinoma is divided into low and high-grade malignancy, the 
clinical features of low grade malignancy are a slowly growing swelling that does not 
exceed 5cm in size, is fixed, asymptomatic, but with high grade histology tumour the 
symptoms include local pain, tenderness, trismus, dysphagia, facial paralysis and 
intraorally the tumours are bluish-red and fluctuant and may metastasizes to the 
bones, lungs, brain and subcutaneous tissues (Brandwein et al., 2001). 
 
Histological aspect: 
        Mucoepidermoid carcinoma is characterised by containing well defined cellular 
elements in different proportions; i.e.  Epidermoid cells which are arranged in sheets 
or nests and mucous secreting cells which are always arranged in a glandular pattern 
and intermediate cells (Joseph et al., 2003). 
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 Mucin and glycogen free clear cells can also be seen. Cysts are found in different 
sizes, they are filled with mucus, so rupture of these cysts lead to inflammatory 
reaction in response to mucus liberation. Histologically the cell types are classified 
according to the Armed Forces Institute of Pathology (AFIP) criteria proposed by 
Goode et al., (1998); Licitra et al., (2003) and Brandwein et al., (2001) into: 
- High grade tumours which are composed of squamous (epidermoid) epithelial and 
intermediate cells and is poorly differentiated (Total point score >7). 
- Low grade tumours which are made up from mucous secreting and epidermoid cells 
and is well differentiated (Total point score 0-4). 
- Intermediate grade in which the tumour histologically falls in-between the other two 
grades (Total point score 5-6). 
Prognosis: 
     Prognosis of mucoepidermoid carcinoma is dependent upon different factors 
including the site, grade, clinical stages and the surgery accuracy. The survival rates 
of low and intermediate grade mucoepidermoid carcinoma for 5 years and 10 years 
are 70% and 96% respectively, whilst for high grade drops to 45% for 5 years and 
25% for 10 years (Brandwein et al., 2001) (Table 1.5). 
 
1.1.2.3.4.4 Adenoid cystic carcinoma (ACC): 
       A malignant epithelial neoplasm of ductal and myoepithelial cells represents 20% 
of all salivary glands malignancies (Myers and Ferris, 2007). About 75% arise in the 
minor and 25% in major salivary glands (Spiro et al., 1974; Shah and Pate, 2003). 
Submandiular gland and minor salivary glands are the most common malignancy sites 
(Matsuba, et al., 1984).  ACC can be also seen in other tissues sites include the 
lacrimal gland, skin, trachea, breast, and the oesophagus (Fordice et al., 1999). 
According to the reserve cell theory, adenoid cystic carcinoma originates from the 
reserve cell of the intercalated duct (Dardick and Burford-Mason, 1993). ACC 
appears most frequently in the 6th decade of life with no sex predilection. The clinical 
behaviour of adenoid cystic carcinoma is characterised by slowly growing, 
recurrences, their clinical course is long with late metastasis (Matsuba, et al., 1984).  
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Clinical aspect: 
       The signs and symptoms of the tumour depend mostly on the site of the origin, 
the classic presentation is a painless, slowly growing mass, mucosal ulceration in 
minor glands of palate and tongue, but advanced tumour Mendenhall et al., 2005 
causing local pain, fixation to the underlying structures, and facial nerve palsy is 
found in case of parotid gland involvement (Conley & Dingman, 1974; Fordice, et al., 
1999). 
 Histological Aspect: 
Adenoid cystic carcinoma has a highly distinctive histological pattern 
composed of rounded groups of uniform, small, darkly staining cells with uniform 
round nuclei around many clear spaces containing hyaline and mucoid material which 
gives the classic Swiss cheese appearance (Szanto et al., 1984). 
Perzin et al., (1978) describe the histological pattern of adenoid cystic 
carcinoma and give three types; the cribriform (cells are arranged in abundant 
hyalinised eosinophilic stroma as delicate anastomosis cords), the solid (cystic 
glandular pattern), and the tubular types. Because three histological types can appear 
in a single specimen and to overcome the problem of polymorphism, a pathologic 
grading system has been initiated to describe the three pathological grades; (Szanto et 
al., 1984; Fordice, et al., 1999) 
Grade one:  tubular and cribriform only without any solid component. (Best survival). 
Grade two:  mostly cribriform and less than 30% solid component. 
Grade three: solid type predominantly (poor prognosis).  
 Prognosis: 
       The survival rate of the adenoid cystic carcinoma is 89% at 5 years, 67% at 10 
years, and 40% at 15 years (Fordice et al., 1999). The 5-year survival of patients with 
distant metastases is 20 % (Bradley, 2004). The local recurrence rate ranges from 16% 
to 85% in several series. Chen et al., (2008) studied 46 patients with ACC of whom 
12 (26%) had a late recurrence after a 5-year follow-up. The 5-, 10- and 15-year 
survival rates are disappointing, about 75%, 40% and 8–25% respectively (Spiro et 
al., 1974, Szanto et al.,. 1984, Hamper et al., 1990, Kokemueller et al., 2004). The 
tumour shows frequent recurrences and the distance metastasis is late. Negative 
factors influence prognosis including tumour size greater than 4 cm, presence of more 
than 30% of solid type within the tumour which may associate with poor prognosis 
(Table 1.5). 
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1.1.2.3.4.5 Adenocarcinoma (AC): 
         Adenocarcinoma represents “any malignancy arising from salivary duct 
epithelium or within salivary glands of epithelial origin” (Regezi and Sciubba, 1999). 
It accounts for 5-10% of all salivary gland tumours and 16.8% of all salivary gland 
malignancies, 90% arise in the parotid gland and the remainder (10%) are in the 
palate, submandibular gland, buccal mucosa, and minor salivary glands. The term 
Adenocarcinoma is less commonly used as a specific diagnostic entity, because most 
classification systems have broken down this complex group of neoplasms into 
separate entities. After recognition of polymorphous low grade adenocarcinoma, 
salivary duct carcinoma, epimyoepithelial carcinoma the small remaining group of 
salivary carcinomas with no specific designation may be categorized as 
Adenocarcinomas (Matsuba et al., 1988; Regezi and Sciubba, 1999).  
Clinical Aspect: 
         The clinical characteristics of adenocarcinoma are that they enlarge slowly, are 
solitary, painless masses (2-8 cm) which are fixed to the underlying structures, when 
they arise in the palate there are visible ulcerative and hemorrhagic areas (Spiro et al., 
1989; Matsuba et al., 1988). 
Histological Aspect: 
       Adenocarcinoma is an aggressive, high grade malignancy. The neoplastic cells 
exhibit different morphology including cuboidal, columnar, epithelioid, polygonal, 
and plasmacytoid, there may also be clear or oncocytic cells. Architectural diversity is 
represented by various degrees of differentiation consisting of sheet, nests, islands 
glandular or ductal pattern (Ellis & Auclair, 1996). 
 Prognosis: 
      Several factors indicate the prognosis of adenocarcinoma including histological 
types, perinural and vascular invasion, recurrence, and metastasis. The tumours of the 
oral cavity have more favourable prognosis than tumours of the parotid and 
submandibular glands and solid histologic type and perineural invasion seem to be 
independent clinicopathological factors involved with shorter survival. Patients with 
low grade tumours have a better prognosis than high grade, due to less cervical lymph 
node involvement and distance metastases (Ellis & Auclair, 1996) (Table 1.5). 
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Table 1.5: Malignant salivary gland incidence and survival age according the tha 
age and origin  
Type of tumour 
 
Incidence 
 
Average 
age 
Origin 
 
Survival rate (prognosis) 
Mucoepidermiod 
 
 
 
35% 
 
 
 
47 
 
 
 
Excretory 
duct 
 
 
Low& intermediate: 
[70-90% (5-10 ys)] 
high Grade: 
 [45-25% (5-10 ys)]           
Adeniodcyctic 
   Carcinoma 
 
40% 
 
 
50 
 
 
Intercalate 
duct 
 
89% 5 years 
67% 10 years 
40% 15 years 
Adenocarcinoma 
 
 
10% 
 
 
58 
 
 
Intercalate 
duct 
 
good prognosis for oral  
cavity tumours and poor for 
others. 
Basal cell 
adenocarcinoma 
1% 60 basaloid 
epithelial 
cells 
good prognosis 
 Sebaceous 
carcinoma 
>1% 55 ectopic 
sebaceous 
cells 
62%  5 years 
 
1.1.2.3.4.6 Basal cell adenocarcinoma (BcAC): 
Basal cell adenocarcinoma is avery rare tumour of the major salivary gland 
and is believed to be the malignant counterpart of basal cell adenoma. It appears 
microscopically similar to the basal adenoma, except that it exhibits an infiltration 
growth pattern and has the ability to metastasise. These tumours are composed of nest, 
cord and solid zones of basaloid cells. Two cytological types of cells are frequently 
seen, small compact cells and larger polygonal cells. The former may frequently be 
seen surrounding the latter, often in a palisades fashion. The feature that distinguishes 
this tumour from the basal cell adenoma is the observation of small nests of neoplasm 
in adjacent normal structures. Infiltration of the nerve is also seen. Local recurrence 
and distant metastasis seem to be a distinct potential for basal cell adenoma. This 
tumour is generally regarded as a low-grade malignancy. With adequate surgical 
treatment, patients should have a favourable outcome. Most tumours are 
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asymptomatic but may be associated with pain, tenderness and swelling (Joseph et al., 
2003). 
Macroscopy: 
Basal cell adenocarcinomas most frequently occur in the superficial (lateral) 
lobe of the parotid gland. The cut surface has a variable colouration of grey, tan-
white, or brownish. The texture is homogeneous although some tumours are focally 
cystic. They are unencapsulated, but some tumours appear well-circumscribed, while 
others are obviously infiltrative. 
Histopathology 
Basaloid epithelial cells, which vary from small, dark cells to larger, paler 
stained cells, form histomorphologic patterns that are described as solid and 
membranous. 
 
1.1.2.3.4.7 Sebaceous carcinoma (SC) 
Sebaceous carcinoma is a rare malignant tumour mainly involved in the ocular 
adnexae, skin and salivary glands. Sebaceous tumours of the salivary glands are 
classified into five categories: sebaceous adenoma, sebaceous lymphadenoma, 
sebaceous adenocarcinoma, sebaceous lymphadenocarcinoma and sebaceous 
differentiation in other tumours (Ahn and Park, 2006). Approximately 37 cases of 
salivary gland sebaceous carcinoma had been described; most cases involving the 
parotid gland and a few appear in the submandibular gland (Ahn & Park 2006; 
Altemani et al., 2008). Because of its rarity, clinicopathological characteristics and the 
histogenesis are not fully understood particularly at skin sites (Gnepp, 2005). The 
parotid is the most common extraorbital site accounting for 30% of all cases (Gnepp, 
2005). The neoplastic tissue probably originates from ectopic sebaceous cells, and in 
fact these normal cells are more frequently found in the parotid than in the 
submandibular and sublingual glands. The tumour may arise from ectopic sebaceous 
cells that are displaced in the parotid gland during embryologic development. Like 
Fordyce granules that develop mainly after puberty, sebaceous cells in the major 
salivary glands are more common in adults. Takata et al., (1989) also suggested that 
the presence of sebaceous, ductal and mucous cells indicates the origin of SC from 
pluripotential duct cells. Therefore it is reasonable to suggest that SC, particularly in 
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children, arises from undifferentiated cells from ductal structures, rather than from 
ectopic sebaceous cells.  
Clinically: the symptoms vary from any indolent, slow-growing, painless and 
asymptomatic mass, to a painful rapidly progressing swelling accompanied by facial 
paralysis (MacFarlane et al., 1975). If the sebaceous tumour is associated with 
lymphatic structures, it will be named lymphadenoma or lymphadenocarcinoma. 
 
1.1.2.3.5 Immunohistochemistry for Salivary tumour diagnosis 
         Salivary gland tumours have complex cytopathological features, so the cytologic 
criteria of the salivary gland neoplasms are not obvious. The diversity of salivary 
gland neoplasm morphology from one tumour to other and even within the same 
tumour makes the recognition of many of these tumours impossible by microscopy 
alone. Immunohistochemistry (IHC) is a globally available tool that complements 
histopathological analysis by detecting gene expression at the protein level (Oliveiro 
and Ribeiro-Silva, 2011). The technique of immunohistochemistry has supplanted a 
specific diagnostic problem through its general role in salivary gland tumours 
especially in problematic cases and because the histological appearance does not 
always correlate with biological behaviour, immunohistochemical staining might give 
a new measure for understanding and predicting the behaviour of a tumour. 
Immunohistochemistry uses antibodies to determine the expression of cellular 
proteins in tissue specimens. The site of this expression is associated with cell 
structures or cell functions. For analysis of cell differentiation, a variety of new 
immunohistochemical markers for different cell types have been introduced during 
the recent years. An appropriate combination of them aids diagnostics and differential 
diagnostics of diverse histological entities (Agra et al., 2008). There are three main 
types of epithelial cells of the salivary glands which can be distinguished by tumour 
markers: acinic cells, ductal cells and myoepithelial cells (deAraujo et al., 2000). 
Cells can be identified by characteristic markers found on their surface in order to 
distinguish between benign and malignant tumours and within the different types of 
salivary gland tumours. Holst et al. (1999) and Gnepp and el-Mofty, (1997) suggested 
that the expression of the product of the C-kit proto-oncongene (CD117) 
(transmembrane tyrosine kinase receptor) and glial fibrillary acidic protein (GFAP) 
may help in distinguishing some salivary gland tumours which are share 
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morphological features, for example, glial fibrillary acidic protein (GFAP) is detected 
immunohistochemically in a considerable percentage of pleomorphic adenoma 
(Curran et al., 2001) whilst in polymorphous low-grade adenocarcinoma and adenoid 
cystic carcinoma expression is low, so this positive result suggests it might be a quite 
helpful marker. Detection of protein expressed by the c-kit proto-oncogene (CD117) 
which is negative in normal salivary gland cells (Jeng et al., 2000) and positive in the 
glandular cells of various types of salivary gland tumours, can be considered as a 
useful marker for diagnosis of adenoid cystic carcinoma rather than for polymorphous 
low-grade adenocarcinoma (Holst et al., 1999; Jeng et al., 2000). Functional markers 
have been associated with survival; e.g. expression of Ki-67 is a well-known 
prognostic marker in salivary gland cancer (Ben-Izhak et al., 2008). 
Recently immunohistochemistry can be used to differentiate between luminal 
(acinar and ductal cells) and abluminal cells (myoepithelial and basal cells) which can 
help in understanding the complexity of salivary gland tumours and aids in diagnosis 
(Cheuk and Chun, 2007).  
 
1.1.2.3.6 Biomarkers used in the diagnosis and prognosis of salivary tumours: 
1.1.2.3.6.1 Biomarkers in Saliva  
      The use of saliva as a diagnostic medium has increased in the last 10 years in US, 
in preference to peripheral blood, due to several advantages e.g. ease of collection, 
storage and most molecules that are present in the blood and urine are also identified 
in salivary secretions. Many studies demonstrated that these salivary markers are 
reliable and might also be used in post-operative follow up of the patients (Zelles et 
al., 1995). 
         The diagnostic and prognostic factors of the salivary gland tumours are 
dependent on many variables. Numerous studies have concentrated mainly on 
cytokeratin, actin, S100, vimentin and carcino-embryonic antigen, but none of these 
markers has proved reliably specific to be used in a diagnostic context. Other attempts 
have been made by several authors to identify significant diagnostic factors, these 
studies have taken into consideration clinicopathological features, location of 
tumours, type and duration of the symptoms, perineural and vascular invasions, 
histological subtype and age of the patient. Several studies have shown that clinical, 
histological, and some immunohistochemical markers for prognosis of salivary gland 
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tumours such as  p53, p63, Maspion, (Edwards et al., 2004; Baily et al., 2006), cell 
proliferation (ki-67, PCNA ), NM 23 protein, Mucin (MUC1, MUC4, MUC5AC, 
MUC5B), CA 125, c-erbB-2, bcl-2 have been associated with patient survival and 
tumour metastasis (Alos et al., 2005; Do Nascimento et al., 2006). 
        Speight and Barrett, (2002) found that clinical stage, particularly tumour size, is 
a critical factor in determining the outcome of salivary gland tumours, and is possibly 
more important than histological grade for prognosis because large malignancies tend 
to have a poor prognosis despite of grade and even high-grade tumours may do well 
when they are small. The 4 cm rule has proved to be a useful clinical guide to 
behaviour and outcome (Renehan et al., 1999; McGurk, 2001). 
        The salivary gland and their secretion of saliva is considered to be the natural 
reservoir of growth factors (GF) and many other regulatory peptides like epidermal 
growth factor (EGF), several studies recently showed that transforming growth factor 
alpha (TGF-α ) and beta (TGF-β), fibroblast growth factor(FGF), insulin, insulin like 
growth factor(IGF-I, IGF- II) and vascular endothelial growth factor (VEGF) were 
identified in the salivary gland which synthesised and secreted them into saliva, so the 
level of these factors in saliva will reflect the amount present in the salivary gland. 
Vallejo et al., (1984) and Fekete et al., (1993) have suggested that the salivary gland 
is a source of growth factors in saliva derived from serum through movement of 
serum macromolecules via the salivary glands. Purushotham et al., (1995) found that 
synthesis of growth factors is primarily performed by ductal cells of salivary glands. 
         The existence of these factors in the salivary gland raises many questions about 
the effect of these factors on the salivary gland cells and how these factors could be 
used as diagnostic or prognostic markers. 
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Table 1.6: Potential biomarkers in salivary gland tumours   
Class of marker oncogene SGT 
 
Significance/Association Refernces 
EGF(R) SDC, ACC & MC 
 
over expression associated with 
poor prognosis  
Press et al., 1994; Etges et al., 
2003;Dodd and Slevin, 2006 
Growth factor and 
their receptor 
VEGF(R) ACC, histological grading of 
mucoepidermoid carcinoma 
 
Neck node metastasis, worse 
survival, and poor local control 
of the disease. 
Lim et al., 2003; Lequerica-
Fernández et al., (2007) 
Ki-67 MEC, ACC, CXPA, acinic cell 
carcinoma 
 
Prognostic marker, poor 
survival. Questionable  
Luukkaa et al., (2006); Dodd and 
Slevin, 2006 
Cell proliferation 
markers 
PCNA 
 
ACC, CXPA, MEC, PA prognostic  & diagnostic value,  Trendell et al., (1997); Young, 
(1994) 
P53 SGC, MEC Limited value asprognostic 
marker mutations 
Lim et al., 2003; Alves et al., 2004 Cell cycle tumour 
suppressor genes 
Maspin ACC, MEC, CXPA prognostic value Schwarz et al., (2007); De Lima 
Navarro, (2004) 
MC, mucoepidermoid carcinoma; ACC, adenoid cystic carcinoma; SDC, salivary duct carcinoma; CXPA, carcinoma ex pleomorphic 
 adenoma; SCC, squamous cell carcinoma; PA Pleomorphic adenoma. 
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1.1.2.3.6.2 Biomarkers in tissue/tumours (Histological section) 
 
In order to facilitate appropriate prognosis and estimating a preferable 
treatment modality many attempts have been made by several authors in order to 
perform comparative analysis of biological, pathological, and clinical characteristics 
of salivary gland tumours. Multiples prognostic biomarkers have been studied by 
many authors including kallikrein 6, ki-67, proliferating cell nuclear antigen (PCNA), 
c-erbB2, P53, osteopontin, bcl-2, E-cadherin and DNA content in order to determine 
whether there was a correlation between the expression of these proteins and patients 
outcome. Furthermore, the oral mucosa is considered to be the site of mechanical and 
chemical trauma from mastication, ingestion of hard food and pathological processes, 
so the maintenance of mucosal surfaces from the external environment exposure and 
repair process of the oral soft tissue wound requires the presence of growth factors for 
proper rates of healing. Tumour markers that can be recognised in saliva may be 
potentially useful for screening for malignant diseases. Salivary diagnosis may be part 
of a comprehensive diagnostic sheet that will supply improved sensitivity and 
specificity in the finding of malignant diseases and will aid in monitoring the 
effectiveness of treatment. Additional studies are certainly required to find out which 
salivary markers can be used for these diagnostic purposes, and to determine their 
diagnostic value in comparison with other, more established, diagnostic tests. Table 
1.6 provides basic information regarding a number of cytokines relevant to salivary 
gland tumours. 
1.1.2.3.7 Diagnostic aspects 
A salivary gland neoplasm must be considered in any patient who presents 
with a painless, slowly growing swelling at the site of the parotid, submandibular or 
sublingual glands. Especially at the early stage, malignant and benign tumours are 
clinically indistinguishable. The overall detection rate for a malignant parotid gland 
tumour based on clinical findings is approximately 30% (Wong, 2001). The mass may 
have been present for years in the case of a benign tumour or a low-grade salivary 
gland cancer. It is remarkable that adenoid cystic carcinoma usually present as a slow-
growing mass. Inflammatory disease may be associated with pain and intermittent 
swelling. Obstruction in the parotid gland is much less frequent than in the 
submandibular gland; thus, a painful mass in the parotid gland may be a sign of
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malignant disease (Spiro and Spiro, 2001). Although both benign and malignant 
tumours may present with pain, this is not common (Witt, 2004). Findings indicating 
malignancy are rapid enlargement, palpable cervical lymph nodes, paresis of all or 
part of the facial nerve, presence of associated lymphadenopathy and fixation of the 
tumour to the overlying skin or deep structures (Spiro and Spiro, 2001; Wong, 2001 
and Shah and Patel, 2003). Salivary gland cancer often spreads by infiltrating into the 
surrounding structures as nerves, bone, muscles and skin. Parotid gland cancer may 
infiltrate the facial nerve and invade perineurally to the base of the skull. Regional 
lymph node involvement is an important route for metastasis in most histological 
types of tumours. 
1.1.2.3.8 Clinical examination 
The problem regarding salivary gland malignancies is the difficulty in 
assessing the malignancy clinically. Locoregional staging of malignant tumours is 
based on clinical examination in combination with imaging. For lesions in the 
superficial parotid and the submandibular gland, Fine needle aspiration cytology 
(FNAC) and sonography are a suitable combination for initial assessment (Lee et al., 
2008). Contrast enhanced computer tomography (CT) or/and magnetic resonance 
imaging (MRI) of the primary site and the neck and carried out in selected cases 
(Okahara et al., 2003). The objective of imaging studies is to identify accurately the 
location and extent of the tumour and to recognize whether the lesion is intraglandular 
or has extraglandular extension (Shah and Patel, 2003). Computed tomography of the 
chest should be performed to exclude the possibility of distant metastases, if needed 
(Bradley, 2001). The possibility of distant metastases is associated with tumour grade 
and is most common in patients with adenoid cystic carcinoma, high-grade 
mucoepidermoid carcinoma, salivary duct carcinoma and tumours of the 
submandibular gland, posterior part of the tongue and the pharynx (Bradley, 2001). In 
general, FNAC is taken preoperatively of all salivary gland tumours (Atula et al., 
1995; 1996; Al-Khafaji et al., 1998; Filopoulos et al., 1998 and Chhieng et al., 2000). 
Surgical biopsy should not be performed on any of the major salivary gland 
neoplasms, in order to avoid the risk of facial paresis and tumour spread. Further 
imaging studies are performed postoperatively depending on the tumour type. If a 
diagnosis of a malignant tumour is made from the surgical specimen in addition to the 
histological diagnosis, the TNM classification is the only significant prognostic factor 
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of salivary gland cancer. The TNM classification system is based on tumour size 
(local extension of the tumour), metastasis to regional lymph nodes and distant 
metastases. The most recent changes to the TNM classification relate to a revision of 
the definition of T3 (Sobin and Wittekind, 2002) and the division of T4-tumours 
which have been divided into T4a (moderately advanced local disease) and T4b (very 
advanced local disease), leading to the stratification of Stage IV into Stage IVA 
(moderately advanced local/regional disease), Stage IVB (very advanced 
local/regional disease) and Stage IVC (distant metastatic disease) (Edge, 2010). 
Tumours arising in the minor salivary glands are classified according to the criteria 
for other carcinomas by anatomic site of origin (Sobin and Wittekind, 2002). 
 
1.1.2.3.9 Treatment: 
The treatment of salivary glands tumours depends upon numerous factors 
including whether it is benign or malignant, site of origin, the size, the location, and 
the extent of the tumours, in order to avoid multiple risk factors that may occurs from 
incorrect choice of the treatment, for example; extension of the tumour via defective 
capsule and inadequate initial removal may causes recurrence of the tumour, nerves 
damage may happened in perineural invasion or during surgical resection of tumours. 
The main purpose of the treatment of salivary gland carcinoma (SGC) is disease 
control and preservation of nerve, vascular and muscle function and secretion of 
saliva. Despite thorough preoperative assessments, very often the diagnosis of 
malignancy is not known prior to surgery. 
Generally the treatment of choice for salivary glands tumours are either 
medicine likes steroids (Haemangioma) or surgical removal of most benign tumours 
(Ward & Levier, 1998). Surgery is the main treatment for SGC. Due to anatomical 
limits of each site, the feasible margins vary to a large extent. Eisele and Kleinberg, 
(2004) recommend adjuvant radiation therapy for patients at high risk; Radiation 
therapy affects the function of the salivary glands. Buus et al., (2006) reported that 
half of the parotid gland function was lost when the radiation dose is 30 Gy. At doses 
below 25 or 30 Gy, recovery is substantial and the function returns to pre-treatment 
levels within two years after radiotherapy (Li et al., 2007).  
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1.2 Migration stimulating Factor  
  
Schor et al, (1980-1988) first identified Migration-stimulating factor (MSF); 
in studies comparing the behavior of different cell types in the collagen gel migration 
assay (Schor, 1980; Schor et al., 1985a; 1988a).  They reported that (i) foetal 
fibroblasts migrated into a 3-dimensional collagen matrix to a significantly greater 
extent than did their normal adult counterparts, (ii) this behavioural difference 
resulted from the production of a soluble “migration stimulating factor” (MSF) by the 
foetal, but not adult cells, and (iii) tumour-derived and skin fibroblasts obtained from 
patients with various types of cancer resembled foetal cells with respect to their 
elevated migration and production of MSF (Durning et al., 1984; Schor et al., 1985b, 
1988b; Haggie et al., 1987).  Normal adult fibroblasts did not produce MSF or an 
inhibitor of MSF; the migration of these cells was however stimulated by conditioned 
media from foetal and cancer patient fibroblasts, thereby providing a sensitive 
bioassay for the subsequent purification of MSF.  MSF was eventually cloned and, 
most unexpectedly, shown to be a genetically truncated isoform of fibronectin (Schor 
and Schor, 2001; Schor et al., 2003).   
Fibronectin is a ubiquitously distributed macromolecule, present as an 
insoluble constituent of the extracellular matrix (ECM) and as a soluble component of 
serum (Hynes, 1990). Both forms consist of two similar, but not necessarily identical, 
polypeptide chains (with individual molecular masses in the region of 260 kDa) 
covalently linked by disulphide bonds at their respective C-termini. Each protein 
chain consists of a tandem array of “functional domains” defined on the basis of their 
binding proclivities for other matrix molecule and integrin receptors on the cell 
surface (Fig1.2). Starting at the N-terminus, these include: the Fib1/Hep 1- binding 
domain (exhibiting affinity for fibrin and heparin ), the Gel –binding domain ( affinity 
for collagen/gelatin), the cell binding domain (affinity for certain cell surface integrins 
such as α5b1), the Hep 2- binding (affinity  for Heparin) and the C-terminal Fib2 – 
binding domain (affinity for fibrin). Each of these functional domains consists of 
different combinations of three “structural homology modules” designated types I, II 
and III. This modular structure is reflected by a corresponding modularity in the 
fibronectin gene, in which types I and II modules are each coded by a single exon, 
whilst the majority of type III modules are coded by two exons (designated “a” and 
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“b”). There are approximately 20 previously described full length fibronectin 
isoforms, all having molecular masses in the region of 260 kDa. These are generated 
by alternative splicing of the primary fibronectin gene transcript involving the 
retention or deletion of two particular type III exons (EDA and EDB), as well as a 
more complex splicing repertoire within the down-stream IIICS region (Hynes, 1990) 
(Fig 1.2). 
Fibronectin is a multifunctional molecule interacting with the cell surface, as 
well as various other macromolecular constituents of the extracellular matrix. A 
number of studies involving both limited proteolytic digestion and electron 
microscopy have revealed that each polypeptide chain consists of a linear array of 
discrete protease-resistant globular domains joined together by short stretches of 
extended protease-sensitive linking sequences. Functional analysis of these protease 
resistant domains indicates that they each express characteristic and discrete affinities. 
For example, digestion of fibronectin with thermolysin yields at least five peptides 
referred to as Hep-1/Fib-1 (29kDa), gel (43kDa), Cell (110kDa), Hep-2 (30kDa) and 
Fib-2(20kDa) in accordance with their respective affinities for heparin (Hep), 
fibrin(Fib), gelatin (Gel) and the cell surface (cell) (Zardi et al., 1985) 
In vitro, fibronectin is synthesised by a variety of cultured cells where it is often 
incorporated into the extracellular matrix. In vivo, fibronectin has a ubiquitous 
distribution, it is a prominent component of plasma, other fluids and connective tissue 
matrices. 
Fibronectin receptors have been shown to include a multiplicity of integrin 
dimers. Integrin family members currently known to interact with fibronectin include: 
α3β1, α4β1, α5β1, α8β1, αvβ3, αIIbβ3, αvβ1, αvβ5, αvβ6 and α4β7 (Yamada et al., 1996). 
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Figure 1.2: The structure of fibronectin and MSF and the sequence of MSF and its component 
parts.   Functional domains of fibronectin; Hep1/Fib1, Gel-BD, Cell-BD, Hep2 and Fib2 with 
each domain consisting; 3 structural modules type I, II and III.  The structure of MSF is also 
shown indicating similarity of Hep1/Fib1 and Gel-BD with a unique 10 amino acid sequence 
(Schor and Schor, 2001; Ellis et al., 2010) 
 
1.2.1 Modular Structure of MSF and FnI-type: 
Migration-stimulating factor (MSF) is a soluble genetically truncated isoform 
of fibronectin and a potent oncofoetal regulatory molecule. MSF message is 
transcribed from the fibronectin gene by an unusual “failure” of normal alternative 
splicing involving read-through of the intron 12 separating exons III-1a and III-1b, 
and subsequent premature transcript cleavage (Schor et al., 2003).  The retained 
intronic sequence contains a 30 bp in-frame coding sequence (immediately contiguous 
with exon III-1a), followed by several in-frame stop codons and a cleavage/poly-
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adenylation signal.  The resultant MSF protein is consequently a truncated isoform of 
fibronectin, identical to its 70 kDa N-terminus, up to and including the amino acid 
sequence coded by exon III-1a, and ends in a unique, intron-derived, 10 amino acid 
sequence not present in any previously identified “full-length” fibronectin isoform 
(Fig 1.2).  As is the case with many cytokines and stress response molecules, MSF 
message exhibits an extremely short half-life as a consequence of an AU rich 
instability element in its 3'-UTR (Schor et al., 2003; Bakheet et al., 2001; Chen et al 
1994).  
The MSF originally cloned by Schor et al., 2003 was essentially identical to 
the N- terminus of fibronectin consisting of 9 type I modules, two type II modules 
including heparin/fibrin (Hep1/Fib1) and gelatin (Gel-BD) binding domains of 
fibronectin and half of the first fibronectin type III module, with the exception of an 
MSF-unique C-terminal 10 amino acid sequence (Fig 1.2).  
The MSF N-terminal fragment is made up of 1–5FnI; the C- terminal region 
contains 6FnI, 1FnII, 2FnII, 7FnI, 8FnI, 9FnI and part of 1FnIII.  The structure of 
each Fn I module consists of two beta sheets formed by five β-strands and with a 
hydrophobic core. Two disulfide bonds help in maintaining the structure of Fn I and 
the anti-parallel β-sheets are stabilised by three amino acids forming a short loop.  
Four out of nine of the MSF FnI modules contain IGD (Isoleucine-Glycine-Aspartate) 
amino acid motifs referred to as 3FnI, 5FnI, 7FnI and 9FnI. In vitro mutagenesis data 
indicate that motogenic effect of MSF on fibroblasts is mediated by two IGD amino 
acid motifs located in MSF modules 7FnI and 9FnI. Significantly, neither of these 
potent MSF bioactivities is expressed by full-length fibronectin; the mechanism 
responsible for this crypticity is not known, but is likely to result from steric 
hindrance blocking the accessibility of the two IGD motifs. On the other hand these 
studies have been shown also that mutations of IGD to DGI in 7FnI and 9FnI 
eliminates the motogenic activity of MSF on fibroblasts (Schor et al., 2003).  
Two isoforms of MSF have been cloned. These differ by a 15 amino acid 
deletion (FYSCTTEGRQDGHLW) in the first type II fibronectin structural module 
and are referred to as MSF+aa (AJ535086-NCBI/PubMed) and MSF-aa (AJ276395-
NCBI/PubMed).  The term MSF will be used to denote both isoforms. Both isoforms 
contain the same MSF-specific 10 amino sequence and IGD functional domains. Both 
isoforms display the same spectrum of potent bioactivities and these are effectively 
inhibited by PEPQ function-neutralising antibodies.  MSF+aa and MSF-aa differ in 
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terms of their inhibition by NGAL (neutrophil gelatinase-associated lipocalin) which 
is present in serum and certain tumours (Jones et al., 2007):  MSF+aa is inhibited and 
MSF-aa is not.  
1.2.2 MSF Bioactivity. 
Recombinant MSF exhibits a broad spectrum of bioactivities, including the 
(i) stimulation of fibroblast, epithelial and endothelial cell migration, (ii) Up-
regulation of Hyaluronic acid (HA) synthesis by target fibroblasts, (iii) Angiogenesis, 
(iv) Proteolysis (Schor and Schor; 2001; Schor et al., 1989, 2003; Houard et al,. 
2005).  These activities are unusually potent, commonly being manifest in vitro and in 
vivo at femtomolar concentrations (Fig 1.3).  In vitro mutagenesis studies (Schor et 
al., 2003; Millard et al., 2007) indicate that MSF stimulation of fibroblast migration is 
mediated by two of its constituent IGD tri-peptide motifs located in structural 
modules 7FnI and 9FnI (Fig 1.2).  The IGD motif is a highly conserved feature of 
fibronectin type I modules (Hynes, 1990), although no biological functionality had 
previously been ascribed to it.  Significantly, synthetic tri- and tetra-peptides 
containing the IGD motif mimic all MSF bioactivities (Schor et al., 1999; Schor et al., 
2003; Ellis et al., 2010a).  Initial data indicate that cellular response to MSF/IGD 
requires maintenance of integrin αvβ3 functionality and is mediated, at least in part, 
by the PI-3 kinase signal transduction pathway (Schor et al., 1999; Ellis et al., 2010b).   
 Full-length fibronectin isoforms do not express any of MSF’s potent 
bioactivities, presumably as a consequence of steric hindrance of their constitutive 
bioactive motifs.  The functional “unmasking” of these in MSF is accordingly 
postulated to result from appropriate alterations in its tertiary structure (higher order 
folding) resulting from truncation. Analogously, proteolytically-generated fragments 
of fibronectin display a host of “neo-activities” not expressed by the parental 
molecule (Fukai et al., 1995), including the stimulation of monocyte migration (Clark 
et al., 1988), the inhibition of cell proliferation (Muir and Manthorpe, 1992), the 
induction of protease gene expression by adherent synovial fibroblasts (Werb et al., 
1989), adipocyte differentiation (Fukai et al., 1993) and an RGDS-independent 
mediation of cell migration (Fukai et al., 1991).  The two active IGD motifs in MSF 
(in I-7 and I-9) reside in the gelatin–binding domain (GBD), and as predicted, GBD 
generated by proteolytic cleavage of fibronectin, mimics all MSF bioactivities (Schor 
et al., 1996, 2003).  Interestingly, the proteolytically-generated cell-binding fragment 
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of fibronectin (containing the RGD motif) inhibits the motogenic activity of MSF, 
Gel-BD and IGD synthetic peptide (Schor et al., 1999; unpublished observations).   
 Another bioactive motif has been identified in MSF.  The putative zinc-
binding motif (HEEGH), located in module I-8, is required for fibronectin-proteinase 
activity (Houard et al., 2005).  These workers further demonstrated that this motif is 
required to promote the migration of a breast tumour cell line (MCF-7).  Mutagenesis 
of the two histidine residues to phenylalanine (FEEGF) abolished both the proteinase 
and motogenic activities of MSF. 
 Available evidence suggests that the motogenic response of target fibroblasts 
to MSF is mediated by its stimulation of HA synthesis: i.e. (i) exogenously provided 
HA stimulates the migration of adult-derived fibroblasts, and (ii) the motogenic 
response of adult fibroblasts to MSF is abrogated by co-incubation with Streptococcal 
hyaluronidase (Schor et al., 1989).  MSF is not unique in this regard, as other, but not 
all, motogenic cytokines also up-regulate HA synthesis which similarly appears to 
mediate cytokine-stimulated migration (Schor, 1994; Ellis et al., 1992, 1997, 2007).  
As predicted, foetal fibroblasts produce significantly more HA (Chen et al., 1989) and 
migrate to a greater extent compared to adult cells; hyaluronidase and MSF function-
neutralising antibody reduces the elevated migration of foetal cells down to that of 
their adult counterparts.  In contrast, endothelial cells, in vitro, do not synthesise HA 
(Winterbourne et al., 1983; Amanuma and Mitsui, 1991) either in the presence or 
absence of MSF (unpublished observations); the stimulation of endothelial cell 
migration and adoption of a sprouting cell phenotype by MSF in vitro must 
accordingly be mediated by an HA-independent mechanism.  The situation in vivo is 
clearly more complex.  In view of the well-documented effect of HA and HA 
fragments on angiogenesis, it is likely that the pro-angiogenic activity of MSF in 
animal model systems may also be indirectly mediated by its effect on HA synthesis 
by other cell populations (e.g. fibroblasts, carcinoma cells) within a multi-component 
tissue environment (unpublished data).   
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 Figure 1.3: The expression of MSF bioactivity.   
MSF secreted by three different cell line (producer cells) carcinoma cells, fibroblast cells and 
endothelial cells. The secreted MSF performs different bioactivities in the target cells in vitro 
and in vivo, including cell migration, HA synthesis, matrix remodelling and angiogenesis 
(adapted from Schor et al., 2001). 
1.2.3 MSF Expression 
MSF exhibits an “oncofoetal” pattern of expression as defined by its 
(i) constitutive production by keratinocytes, fibroblasts and endothelial cells in foetal 
skin, (ii) reduced or undetectable expression in skin and other tissues in healthy 
adults, and (iii) re-expression by both carcinoma and stromal cells in the majority of 
common human tumours, including those of the breast, lung, colon, prostate (Schor et 
al., 2003; unpublished observations).  As is the case with other oncofoetal regulatory 
molecules, including full-length fibronectin isoforms containing the EDA and/or EDB 
type III modules (ffrench-Constant et al., 1989). 
Expression of MSF protein by adult skin fibroblasts is regulated by an unusual 
post-transcriptional mechanism involving the initial generation of a 5.9 kb MSF pre-
message by read-through of the majority of the intron separating exons III-1a and III-
1b of the fibronectin gene (Kay et al., 2005). This precursor remains sequestered 
within the nucleus where it exhibits a short half-life.  In response to an inter-
dependent array of regulatory signals, the intron-derived 3’-UTR of the precursor 
mRNA is cleaved to produce the shorter 2.1 kb mature MSF message, which is then 
exported to the cytoplasm for translation (Kay et al., 2005).  This post-transcriptional 
control mechanism, coupled with the afore-mentioned message instability allows the 
cell to respond rapidly to micro-environmental cues, thereby controlling the temporal 
and spatial expression of MSF bioactivities.  In contrast to this post-transcriptional 
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mechanism, epithelial and endothelial cells appear to constitutively express MSF 
protein and regulate the manifestation of its potent bioactivities by the variable co-
expression of selective inhibitors.   
In addition to its local expression by tumour cells and tumour-associated 
stromal cells, patients with cancer may also exhibit an aberrant systemic expression of 
MSF (Picardo et al., 1991).  For example, MSF is inappropriately expressed by skin 
fibroblasts obtained from distant uninvolved sites in patients with cancer; these 
aberrant “foetal-like” cells further differ from their normal adult counterparts in terms 
of their migratory phenotype and elevated expression of HA. Schor et al., (1994) 
reported that the tumour-free, histologically normal, tissue margin adjacent to resected 
breast carcinomas commonly contain MSF-expressing intra-lobular fibroblasts (Schor 
et al., 1994; unpublished observations).  The presence of such a functionally disturbed 
peri-tumour field may carry as yet unrecognised prognostic significance, as well as 
provide useful insight into the factors (systemic and local) which contribute to cancer 
pathogenesis. 
MSF bioactivity has also been detected systemically in the serum of 
approximately 90% of patients with breast cancer, as compared to only 10% of age- 
and sex-matched healthy controls (Picardo et al., 1991; additional unpublished data).  
This systemic expression of MSF does not appear to be a measure of tumour burden 
(as is the case with other oncofetal tumour markers), as it may persist for decades 
after resection of the primary tumour in patients with no evidence of recurrent disease.  
The presence of bioactive MSF in the serum of cancer patients stands in marked 
contrast to results obtained in a corresponding study in patients recovering from post-
surgical trauma; in these individuals, MSF bioactivity was not present in serum, in 
spite of being clearly detected locally in wound fluid (Picardo et al., 1992).   
 MSF is present in wound fluid implicating a functional role in wound healing 
(Picardo et al., 1992). MSF stimulated migration of high density adult fibroblasts in 
the 3D collagen gel assay (Schor et al., 1988, 1993). MSF exerts a direct stimulatory 
effect upon the synthesis of high weight hyaluronic acid (HA) and it is the 
accumulation of this HA in the matrix which is responsible for the observed increase 
in migrating activity (Schor et al., 1989). The influx of fibroblasts into the wound site 
and the transient elevation in HA level in granulation tissue are both consistent with a 
suggested role in wound repair. TGF-β1 is a potent antagonist of MSF, blocking its 
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stimulation of fibroblast migration and HA synthesis (Ellis et al., 1992), and might 
thereby regulate MSF activity in the wound. 
  
1.2.4 Inhibitors of MSF activity 
 
1.2.4.1 Neutrophil gelatinase-asscciated lipocalin (NGAL): 
NGAL (Lipocalin-2), belongs to a family of low molecular weight proteins, is 
an inhibitor of MSF motogenic activity. NGAL is a 25kDa protein which was first 
identified in neutrophils, hence its name NGAL. Jones et al., (2007) studied the 
bioactivity of MSF in keratinocytes. They compared the migration activity of tumour 
derived fibroblasts and the paired forearm skin fibroblasts of cancer patients with the 
keratinocytes cell line (HaCat) in collagen migration assay. They found that the 
conditioned medium of early passage keratinocyte or a keratinocyte cell line (HaCat) 
did not show any migration stimulating activity. This result led to the hypothesis that 
even though keratinocytes secrete MSF, the co-secretion of a functional inhibitor 
masks its bioactivity, whilst the tumour derived and the paired forearm skin 
fibroblasts exhibit an effective bioactivity. So a putative inhibitor (MSFI) can regulate 
the bioactivity of endogenous MSF and its play an important role in the inhibition of 
MSF induced migration activity. Fractionated keratinocyte conditioned medium by 
size-exclusion chromatography revealed the presence of bioactive MSF and inhibitor 
of MSF (MSFI) with size of 70kDa and 25kDa respectively. This inhibitor of MSF 
activity was isolated and identified as NGAL (Lipocalin-2).  Expression of MSF and 
NGAL was confirmed in keratinocyte cells by immunostaining studies (Jones et al., 
2007). Experiments in the collagen gel assay also reported that NGAL dose not affect 
the viability or proliferation of the target cells.  
NGAL is a multi-functional protein, performing a wide range of mechanisms. 
NGAL can bind ferric siderophores which enables it to perform a wide range of 
functions including iron transport, controlling iron-responsive genes and also to act as 
bacteriostatic agent. NGAL is vital during mesenchymal-epithelial transition and also 
in Ras-transformed mesenchymal tumour cells. Even though the iron-chelator 
Dimethyl sulphoxide (DFOM) is capable of reversing iron dependant NGAL activity, 
it does not affect its inhibitory affect on MSF, suggesting iron is not involved in this 
process (Jones et al., 2007).  
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1.2.4.2 Endothelial MSF-Inhibitor (eMSFI) 
         Endothelial cells produce a wide range of cytokines, extracellular components 
and cell surface molecules. Different cytokines produced by endothelial cells include 
interleukin 1, 6, and 8, platelet derived growth facor (PDGF), Endothelin, basic 
fibroblast growth factor (bFGF), insulin like growth factor and TGF-β1. Molecules 
secreted by endothelial cells include prostacyclin, nitric oxide, platelet activating 
factor and plasminogen activator inhibitors-1 etc. Many of the soluble factors and 
extracellular matrix components synthesised by endothelial cells can control fibroblast 
migration and matrix biosynthesis in processes such as angiogenesis and wound 
healing i.e. TGF-β1 and PDGF. Endothelial cells in vitro show two reversible 
phenotypes namely cobblestone and sprouting (Schor and Schor, 2010). These cells in 
culture form a cobblestone monolayer on the surface of two dimensional (2D) 
substrata, whereas the same cells show elongated sprouting morphology when 
embedded within three dimensional (3D) collagen gels (Sutton et al., 1991). 
Conditioned media (CM) collected from cobblestone endothelial cells inhibits MSF 
stimulated cell migration, whereas CM collected form sprouting endothelial cells 
shows normal MSF like activity (Schor and Schor, 2010). The above observations 
indicate the presence of an inhibitor of MSF activity (eMSFI) in cobblestone CM 
which has been identified as Insulin-like growth factor binding protein-7 (IGFBP7) 
by (Dr Sarah Jones/ Cell and Molecular Biology Unit/ Dental School). She purified 
IGFBP7 from Endo 742 CM by diethylaminoethyl cellulose (DEAE) chromatography 
(Jones et al., unpublished data) and gel elution (unpublished data). Insulin-like growth 
factor binding protein-7 (IGFBP7), also known as mac25 or IGFBP-related protein-1 
(IGFBP-rP1) is a secreted protein belonging to the IGFBP family. The major function 
of the protein is the regulation of availability of Insulin like growth factor (IGFs) in 
tissue as well as in modulating IGF binding to its receptors (Oh et al., 1996; Pollak, 
2008). Oh et al., (1996) shown that IGFBP-7 has a wider distribution in normal tissue 
and has lower expression in several cancer cells (breast, prostate, colon and lung) 
indicating that IGFBP-7 may function as a growth-suppressing factor, as well as an 
IGF-binding protein.  
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1.2.4.3 Transforming Growth Factor-β1 
 
Transforming growth factor type β1 (TGF-β1) is a homodimeric polypeptide 
of molecular weight 25kDa that belongs to a large family of multifunctional secreted 
homologous proteins. This family of polypeptides includes the TGF-β 1-5 and a 
number of other similar proteins.  
TGF-β1 participates in a number of cellular mechanisms and is a potent 
regulator of cell growth, differentiation, degradation of matrix proteins such as 
collagen and fibronectin, hematopoiesis, mammary gland development, bone 
metabolism, skin formation, angiogenesis, inflammation and repair, chemotoxins, and 
fibroblast proliferation (Robert et al., 1990). TGF-β actions and mechanism vary from 
cell to cell according to different parameters including type of target cell and the 
conditioned media. TGF-β has a pleiotropic effect and may have a stimulatory or 
inhibitory effect on cell migration, proliferation, protein synthesis and differentiation. 
Levy et al., 2006 data support TGF-β’s role as an important component in the 
initiation and progression of cancer. TGF-β has a dual role in tumourigenesis; 
In the initial stages TGF-β acts as a tumour suppressor and inhibits growth of 
epithelial cells, endothelial cells and early cancer cells. Whereas later on, TGF-β 
accelerates the malignant process enhancing survival, progression and metastasis of 
the tumour in an established tumour by promoting angiogenesis and escape from 
immune surveillance (Rangnathan et al., 2007). These observations indicate that the 
normal epithelial cells behave differently than cancer cells in response to TGF-β. 
Tumour cells and normal cells show different gene expression in response to TGF-β. 
For example tumour cells show increase in the production of proteases and down-
regulation of the inhibitors of proteases in response to TGF-β, whereas this is not 
observed with normal cells. The mechanism responsible for this differential response 
of various cell types is not clear. 
The cytokine TGF-β1 acts as a potent inhibitor of fibroblast cell migration and 
HA synthesis. HA synthesis stimulation by TGF-β1 is largely based on the anatomic 
site, for example, TGF-β1 can promote HA synthesis in foetal lung fibroblasts but not 
in foetal skin cells (Ellis et al., 1995). Ellis et al., (1992) studied the antagonistic 
effect of TGF-β1 on MSF, the study revealed that TGF-β1 blocks the migration of 
sub-confluent adult fibroblasts and high molecular weight HA synthesis. TGF-β1 is a 
potent inhibitor of MSF-stimulated cell migration.  
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1.3 Aims of the study 
In this thesis I studied the possible role of migration stimulating factor (MSF) 
on the progression of oral tumour, focussing on oral squamous cell carcinoma 
(OSCC) and salivary gland tumours (SGT). The overall objectives of this study were: 
 
1- To ascertain the possible presence, diagnostic and prognostic value of MSF in 
OSCC and SGT. 
2- To determine the effects of MSF on the migration of oral tumour cell lines and 
normal stromal cells.  
3- To identify the putative MSF receptors. 
 
The specific studies carried out towards these objectives included:  
1. To ascertain the possible presence, diagnostic significance and role of both 
MSF isoforms in SGT. Immunohistochemical was used to compare the 
expression pattern of MSF in histologically normal salivary gland tissue, 
benign and malignant SGT. 
2. To determine the diagnostic and prognostic value of MSF expression in 
OSCC. 
3. Determine the effect of MSF on different types of cells (TYS, HSG, Endo 742 
and FSF44) in terms of migration.  
4. Determine the specific amino acid motifs of MSF (IGD and/or HEEGH or 
both) that are responsible for its bioactivity.  
5. Determine the modulation of MSF bioactivity by antibodies (PEPQ, TYN and 
anti-αvB3 Ab) and other proteins (NGAL and IGFBP-7). 
6. Determine the expression of MSF by oral tumour cell lines.  
7. To verify the receptors responsible for the motogenic activity of MSF.  
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2. Chapter two: Materials and Methods 
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2.1 Bacterial rhMSF WT Preparation 
 
The following recombinant proteins have been purified for use in this study: 
- rhMSF+aaWT; rhMSF-aaWT; rhMSF+aaDGI 3, 5 and rhNGAL. The purification 
method was identical for all recombinant proteins and rhMSF is given as an example. 
 
2.1.1 Expression of recombinant MSF in Bacteria 
 
Background: 
            The gene encoding MSF was cloned into the expression vector pRSET. When 
the recombinant protein was expressed using this plasmid, it had two N-terminal tags; 
a poly-histidine tag (his6) to aid subsequent purification and the Xpress tag, which is 
recognised by a commercially available antibody (Invitrogen, Paisley, UK). 
 
Materials: 
Plasmid pRSET (Invitrogen, Paisley, and UK); L-broth medium; 50µg/ml 
carbenicillin; Isopropyl-β-D-galactopyranoside (IPTG) and competent DE3 plysS 
cells. 
Table 2.1: Protein and its plasmid encode 
Protein name 
 
Plasmid name 
rhMSF+aa WT pRSET MSF+aa 
rhMSF-aa WT pBEN0404 MSF-aa 
rhMSF+aa DGI 3,5  pRSET MSFDGI 3,5 
 rhNGAL  pRSET LCN2 
 
Methodology: 
The plasmid pRSET containing the MSF gene (Table 2.1) was transformed 
into competent DE3 plysS cells. The cells were plated on LB-agar containing 50µg/ml 
carbenicillin and then incubated at 37°C overnight. 
A single bacterial colony from the plate was then used to inoculate 10ml of L-broth 
containing 1% (w/v) glucose and 50µg/ml carbenicillin. This culture was then grown 
at 37°C overnight, in an orbital shaker (≈275rpm). The overnight culture was then 
used to inoculate 2 x 100ml cultures of L-broth containing 1% (w/v) glucose and 
50µg/ml carbenicillin. These cultures were grown in the same conditions, to an optical 
density at 600nm (O.D. 600nm) of between 0.4 and 0.6. Transcription and translation 
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i.e. protein synthesis was then induced by addition of IPTG to a final concentration of 
1mM. Induction was then allowed to continue at 37°C for 3-5 hours in the orbital 
shaker (incubator). The bacteria were then pelleted by centrifugation at 3000rpm for 
10 minutes at 4°C. The supernatant was then removed and collected for sterilisation 
and the bacterial pellets were then stored at -20°C. 
 
2.1.2 Extraction of recombinant protein from bacterial cell pellets 
Materials Required: 
Bacterial pellets (Bacterial cell pellets collected after induction and expression of 
rhMSF);  BugBuster (Invitrogen);  Benzonase (Invitrogen);  1M  Dithiotrietol (DTT);  
500mM CAPS pH 11;  20mM Tris-HCl pH 8.5;  30% (w/v) N-lauryl sarcosine and  
10mg/ml lysozyme. 
 
 
Methodology: 
The recombinant protein is present as insoluble inclusion bodies when expressed in 
bacteria. 
 
Each bacterial pellet, collected from 50ml culture was resuspended in 2.5ml of 
BugBuster with the addition of 1µl/ml benzonase. The pellet was thoroughly 
resuspended by vortexing and then the tubes were shaken vigorously for 20 minutes. 
The bacterial cell lysate was pooled and split into 5ml aliquots and centrifuged at 
20,000rpm for 15 minutes (Hereaus). The supernatant containing the soluble bacterial 
proteins was then collected and frozen at -20ºC. Lysozyme was then diluted 50x with 
BugBuster and 5ml added to each insoluble protein pellet. The pellet was then 
thoroughly resuspended and incubated at room temperature for 20 minutes, with 
gentle agitation, then 30ml of 1/10 dilution BugBuster was added to each tube spun at 
20,000 rpm for 20 minutes, the supernatant was then removed completely and 
discarded each pellet was then resuspended and washed for a second time. Each pellet 
was then dissolved in 2.5ml of 500mM CAPS pH 11. 0.5% (w/v) n-laurylsarcosine, 
10mM DTT for up to 1 hour at room temperature then spun at 20,000 rpm for 10 
minutes. The solubilised protein was then dialysed (Pierce dialysis cassette 3.5kDa 
cutoff) using 2 litres of 20mM Tris-HCl pH 8.5 0.1mM DTT (4 hours at 4ºC) the 
buffer was then replaced and dialysis continued overnight, finally the protein was 
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dialysed for four hours at 4ºC in 2 litres 20mM Tris-HCl pH 8.5. The protein (rhMSF) 
was then purified on a HiTrap (Pharmacia) Chelating column, charged with nickel.  
 
2.1.3 Bacterial rhMSF Purification 
 
Materials: 
Washing buffer: 20mM sodium phosphate (NaH2PO4) and 0.5M sodium chloride 
(NaCl).  
Elution buffer: washing buffer + 0.5M imidazole.  Both buffers were adjusted to pH 
7.6 – 8.0 using NaOH. 
 
Overview: 
After the final dialysis step, the recombinant MSF was purified from the 
protein extract by affinity chromatography. The affinity column (HiTrap) was charged 
with nickel sulphate and the rhMSF had been engineered to have an N-terminal tag 
containing 6 histidine residues which can bind to nickel. The dialysed extract was 
pumped onto the column, which was then washed to remove unbound material and 
the rhMSF eluted by an increasing gradient of imidazole which competes with the 
rhMSF to bind to the column. 
 
2.1.3.1 Charging the HiTrap Chelating Column (1ml) With Nickel 
The Hi-Trap column was washed with 5ml of distilled water (to wash away 
the 20% ethanol storage solution). Then 500µl of 0.1M Nickel Chloride was then 
applied. The HiTrap column was then washed with 10ml of distilled water 
 
2.1.3.2 Affinity Purification of rhMSF  
 
Materials: 
Affinity column charged with 0.1M Nickel chloride. 
Column Used: Hi-Trap chelating 1ml (GE Healthcare) 
 
Reagents used: 
Binding buffer: 20mM sodium phosphate, 0.5M sodium chloride, pH 7.6 – pH 8.0. 
Eluted buffer: as binding buffer + 500mM imidazole. 
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Methodology: 
The nickel charged column was equilibrated with 10 column volumes (cv) of 
binding buffer at a flow rate of 1ml/minute. The dialysed crude extract containing 
rhMSF was spun at 13,000 rpm for 5 minutes. The sample was then applied to the 
column at a slower flow rate of 0.3ml/minute. Fractions were then collected during 
sample application and column washing. The column was then washed again 
(1ml/minute) with binding buffer to remove any unbound proteins. The rhMSF was 
then eluted from the column by running a 0-500mM imidazole gradient through the 
column over 15cv. The rhMSF usually eluted at around 250mM imidazole. 1ml 
fractions were collected during the gradient phase. The presence of rMSF was 
confirmed by SDS PAGE or Western blotting, where the protein runs at a molecular 
weight of ~77kDa under reducing conditions. 
 
2.1.4 Endotoxin treatment 
Endotoxin also called lipopolysaccharides (LPS) is a natural component of the 
cell wall of most gram- negative bacterial. Bacterial expression systems are widely 
used to produce different types of proteins and therefore these samples may be 
contaminated with endotoxin. In order to remove endotoxin from recombinant protein 
preparations different processes have been developed, these include two-phase 
extractions, ultrafiltration, hydrophobic interaction chromatography, ion exchange 
chromatography. 
 
2.1.4.1 Two-phase extraction: 
Triton X-114 (Sigma) was added to the protein solution to a final 
concentration of 1% (v/v) in a sterile microcentrifuge tube (pyrogen free). The 
mixture was incubated at 4°C for 45-60 minutes with end over end mixing to ensure a 
homogenous solution. The sample was then transferred to a 37°C water bath and 
incubated for 15-60 minutes until the solution appeared cloudy. The mixture was then 
centrifuged for 10 minutes at 13000 rpm at 37°C. The upper layer containing the 
protein (endotoxin-free) was carefully removed from the tubes and pooled in a sterile 
tube in order to test with LAL kinetic chromogenic assay to determine endotoxin units 
per millilitre (EU/ml).  
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2.1.4.2 The Limulus Amebocyte Lysate (LAL) assay: 
 
Endotoxin levels were measured by LAL assay. The reagent preparation and 
experimental protocol used was that supplied with the kit. Different dilutions of the 
protein and buffer samples were prepared using the LAL reagent water as the diluent. 
Positive controls containing endotoxin standards and negative control containing the 
LAL reagent water were run at the same time. After incubation and in the presence of 
endotoxin, gelation occurs. The test is positive if a gel has formed and remains intact 
in the bottom of the tube after inversion, whilst in the absence of endotoxin, gelation 
does not occur, the test is considered negative. After removed of the endotoxin from 
the purified proteins, all the proteins purified in this study were dialysed against PBS 
except rhNGAL which was dialysed using 20mM sodium phosphate, 500mM sodium 
chloride, pH 7.6 – pH 8.0.    
 
2.2 Identification of protein  
 
2.2.1. SDS-PAGE (Sodium Dodecyl Sulphate PolyAcrylamide Gel 
Electrophoresis) 
 
Materials: 
1M Tris HCl pH 8.7 and pH 6.9 (Sigma); 30% Acrylamide/Bis-solution 37.5:1 (2.6% 
c) (Bio-Rad);  10 % (w/v) SDS( Melford);  APS ammonium persulphate (Bio-Rad);  
TEMED(Sigma);  Laemmli loading buffer (Bio-Rad Laboratories Ltd,. Hemel 
Hempstead, Hertfordshire UK); Magic Markers (Invitrogen Ltd, Paisley UK) 
Molecular weight markers (Bio-Rad, Glycine (Sigma); TGS buffer: Glycine 1.92M; 
SDS 1 % (w/v); Tris 250mM, 2-mercaptoethanol; Gel CodeBlue (Pierce). 
 
Methodology: 
The purified protein quality was analysed using SDS-PAGE which separates 
proteins according to their molecular weight under an electrical current. The pH 
difference was established by the resolving and stacking gel. SDS PAGE was carried 
out according to the method of Laemmli (1970). Typically 10% separating gels with 
4.5% stacking gels were run, under reducing conditions. Samples were made up in an 
equal volume of Laemmli loading buffer containing 5% (v/v) 2-mercaptoethanol and 
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heated for 5-10 minutes at 95˚C prior to loading onto the gel. Precision protein plus 
molecular weight markers were also loaded. Magic Markers (Invitrogen Ltd, Paisley 
UK) were loaded for molecular weight estimation, on gels that were to be 
subsequently Western blotted. Electrophoresis buffer was 1 x TGS (Tris Glycine SDS, 
Bio-Rad). The gel was then run at 150-180v until the dye front reached the end of the 
gel. Lanes containing molecular weight markers and samples for sequencing were 
washed 3 x 5 minutes in distilled water and then stained in Gel Code Blue (Perbio).  
 
2.2.2 Western blots: 
Western blotting is a frequently used method to detect specific proteins in a 
complex mixture of samples like body fluids or cells. In this technique SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) is used to separate the protein by 
size, and then the protein bands are transferred from the gel onto a membrane such as 
nitrocellulose or PVDF using an electric current.  The technique is dependant on the 
use of a specific antibody directed against a required protein after blocking the non-
specific binding sites on the blot by using blocking buffer. After washing unbound 
primary antibody the secondary antibody is added which can only recognise this 
protein primary antibody and is conjugated with the enzyme horse radish peroxidase 
(HRP) for visualisation. The conjunction of enzyme (HRP) with a chemilumienscent 
substrate can be visualised to determine the location of the antibody. 
Materials:  
- Transfer Buffer: 5.82g Tris; 2.93g Glycine; 3.75ml 10% (w/v) SDS; 200ml    
   Methanol made up to1litre with dH2O. 
-  TBST: 24.2g Tris; 80g Sodium chloride; 5ml Tween; 14ml Hydrochloric acid     
   pH 7.6; 1litre dH2O. 
-  Blocking Buffer; 100ml 1X Tris-buffered saline Tween TBST (PH 7.6); 1g dried     
   milk powder. 
-  TBS: TBST without Tween 20 
-  Bio Rad Extra thick blotting paper. 
 
-  Nitrocellulose membrane (0.2 µm; Bio-Rad) 
-  Bio-Rad’s Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell 
-  Super signal West Dura (Pierce) (Enhanced Chemiluminescence substrate) 
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Antibodies: 
Primary antibodies: 
-  Rabbit polyclonal identification antibody RpVSI (Stock Conc 20µg/ml, 2005),     
   2µg/ml in 1% (w/v) BSA-PBS-T. (Working concentration) 
 
-  Goat Anti- human integrin αV lCD 51 antibody,R&D Systems cat no. AF1219 
   (Stock Conc 200µg/ml), 200ng/ml in 1% (w/v) Milk TBST. 
 
-  Anti- human integrin β3 (CD61) Mouse Monoclonal antibody,R&D Systems cat no.  
   MAB2266, (Stock Conc 500µg/ml), 2µg/ml in 1% (w/v) Milk TBST 
Secondary antibody: 
- DAKO rabbit anti-goat HRP was used at a 1:10,000 diluted in 1% (w/v) Milk TBST.  
- DAKO rabbit anti-mouse HRP was used at a 1:10,000 diluted in 1% (w/v) Milk 
TBST. 
- DAKO Goat anti- rabbit HRP was used at a 1:10,000 diluted in 1% (w/v) Milk 
TBST. 
 
 
Methodology: 
The purified protein quality was analysed using SDS-PAGE which separates 
proteins according to their molecular weight under an electrical current. The pH 
difference was established by the resolving and stacking gel. A 10 % acrylamide 
resolving gel was used for the rhMSF (as example of purified protein had been used in 
this study). The wells were created in the stacking gel which stacks the proteins, 
which then passes through the resolving gel where the separation of the protein takes 
place. The samples and markers were prepared in Laemmli loading buffer containing 
2-mercaptoethanol and were heated for 5 minutes at 95 ºC to denature the proteins for 
effective separation. When the gel kit was ready it was suspended in the gel tank in 
TGS buffer  the gel was allowed to run by providing 180V, 150 W and 20mA until 
the dye front reached the bottom of the gel. The gel was stained with GelCode blue 
solution; until desired stain was obtained and destained with water. 
The bands thus obtained were analysed for quality analysis where the marker 
provides the identification of protein molecular weight. The protein gels that obtained 
from the SDS-PAGE were used for semi-dry Western blotting. The gels were trimmed 
to size and then rinsed in the transfer buffer. The Western blot was prepared by 
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placing pieces of BioRad extra thick paper soaked in transfer buffer onto the anode, 
followed by nitrocellulose membrane, gel and again another piece of soaked BioRad 
extra thick paper on top. The proteins were blotted onto the membrane at 15V for 42 
minutes. The proteins were blocked by using 1 % (w/v) dry milk in TBST (Tris buffer 
saline containing 0.05% Tween-20). The membrane was then probed overnight with 
primary antibody, excess unbound primary antibody was then removed by washing 
with TBST. The membrane was then probed with the HRP-labelled secondary 
antibody in TBST for 60 minutes. After removing the excess secondary antibody by 
washing with TBST, the secondary antibody was localised by reaction with Pierce 
Supersignal for 1-5 minutes. Chemiluminescence was visualised and documented 
using the GeneGnome (Syngene). 
 
2.2.3 Dot Blots.  
Samples of rhMSF +aa and Fn were concentrated by series dilutions of 
100ng/ml, 200, 400, 800ng/ml and 500ng/ml, 1 µg/ml, 2µg/ml, 4µg/ml for both 
samples respectively. For dot blots, nitrocellulose sheets were cut to an appropriate 
size, marked into 1cm squares, spotted with the test protein solutions and allowed to 
air dry. The blots were then blocked with TBST plus 1% (w/v) Marvel dried milk 
powder for 20 minutes at room temperature. Blots were then incubated with the 
appropriate antibody overnight, rinsed three times with TBST  Tween 20, incubated 
with HRP conjugated secondary antibody for 2 hours, washed three times in TBST at 
room temperature, and finally washed for 5 minutes with TBS. Visualisation was 
achieved by enhanced chemiluminescence using SuperSignal (Pierce) and the 
GeneGnome (Syngene). 
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2.2.4 ELISA (enzyme-linked immuno-sorbent assay) 
 
This method makes used of an enzyme that reacts with a colourless substrate 
to produce a coloured product. The enzyme is covalently linked to a specific antibody 
that recognises a target antigen. ELISA is a simple and highly sensitive method of 
analysis that allows for simultaneous and rapid quantification of a large number of 
samples.  
2.2.4.1 Materials 
 
ELISA plates Colorimetric assay: 96-well plates (polystyrene, treated surface, flat 
bottom), [Corning-Costar, cat. no. 07-200-38 (9018).] 
Standard proteins and other routinely tested antigens 
- Recombinant human MSF (rhMSF) and (rhMSF-aa) prepared in house, of 
known concentration, was used as a standard protein for quantification of MSF 
concentration in analysed samples.  
- Human cellular Fn [Upstate, cat. no. 08-102]. A 45kDa proteolytic fragment of 
the human plasma Fn containing a gel-binding domain (GBD) [SIGMA, cat. 
no. F0162] 
Buffers: 
- Washing buffers:  
1x PBS - prepared from tablets (Phosphate buffered saline. SIGMA, cat. no. P-4417) 
according to manufacturer instructions, filtered. 
1x PBST-1x PBS with final conc 0.05% Tween 20 (10% Tween Surfact-Amps 20. 
Pierce, cat. No. 28320), filtered. 
- Coating buffer: Commercial Carbonate-Bicarbonate buffer (Pierce, cat. no. 28382) 
- Blocking buffers: 1% (w/v) bovine serum albumin (BSA), ELISA grade (98% 
purity) (SIGMA, cat. No. A7030) in PBST. 
 
Antibodies: 
Primary antibodies 
- RpVSI, 2µg/ml in 1% BSA-PBS-T. 
- Anti-cell binding domain of Fibronectin antibody (CHEMICON, cat. no. MAB1937) 
- TYN 1.1 (batch 3) –Mouse monoclonal antibody to MSF- aa, purified on protein L.       
prepared in house. 
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- PEPQ 1.2: (mouse monoclonal anti-IGD), Stock concentration 61.4 µg/ml, Batch 
no.2, prepared in house. 
- Anti-human NGAL (goat polyclonal AF1757), (R&D systems) 
- Recombinant αvβ3 (R&D Systems Cat. # 3050-AV-050) (Lot # OMM0409081) 
 
Secondary antibodies 
- Goat anti-rabbit conjugated with horse radish peroxidase (GAR-HRP), (DAKO or 
Pierce) 
- Rabbit anti-mouse conjugated with horse radish peroxidase (RAM-HRP), (DAKO) 
- Rabbit anti-goat conjugated with horse radish peroxidase (RAG-HRP), (DAKO) 
 
Substrate for HRP: TMB [TMB+ Substrate Chromogen, DAKO, cat. no. S1599] 
 
ELISA plate reader: ELISA plate reader (MRX Dynex) was used to measure 
resultant optical density of the colorimetric assay. The reader was run under computer 
control with software supplemented by the manufacturer (REVELATION, version 
3.2). The program for MSF quantification was created in the Revelation software as 
an endpoint measurement with following parameters:  
- Dual wavelength mode (filters 450/570nm). 
-Template (96-well plate) setting – position of blanks, standards and test samples - 
was defined manually before each measurement.  
- Blanking was performed automatically by subtracting the averaged blank values in a 
given plate from all standards and test sample values. 
 
2.2.4.2 Methodology 
 
2.2.4.2.1 Indirect ELISA:  
Polystyrene 96-well microplates (Costar) were coated overnight with rhMSF-
aa, rhMSF +aa, cellular fibronectin (cFN) and fibronectin gel binding domain (GBD) 
diluted in carbonate buffer pH 9.6. After washing with PBS, non-specific binding sites 
were blocked by incubation with 200µl/well 1% (w/v) BSA in PBST (BSA-PBST) for 
1 hour at room temperature with gentle agitation. After further washing, 100µl/well 
TYN 1.1, RpVSI antibodies were added diluted to 1µg/ml and 10µg/ml respectively 
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in BSA-PBST and the plate was then incubated for 1 hour at ambient temperature. 
Antibody binding was detected by incubating the plate for 1 hour at ambient 
temperature with 100µl/well of HRP -conjugated rabbit anti-mouse secondary 
antibody diluted 1:1000 in BSA-PBST, followed by further washing and incubation 
with tetramethylbenzidine (TMB), (Code S1599 from DAKO UK Ltd., Ely, 
Cambridgeshire UK), for 10 minutes with gentle orbital shaking. The reaction was 
stopped by adding 50µl/well 2M H2SO4, and the OD at 450 nm was measured using a 
plate reader (MRX DYNEX Technologies Limited, Worthing. West Sussex UK). 
2.2.4.2.2 Sandwich ELISA: 
Polystyrene 96-well microplates (Costar, Insight Biotechnology Limited, 
Wembley, UK) were coated overnight at room temperature with 1µg/ml of MAB 
PEPQ 1.2 as the capture antibody, 100µl/well diluted in coated buffer. After washing 
with PBS, non-specific binding sites were blocked by incubation with 200µl/well 1% 
(w/v) BSA in PBST (BSA-PBST) for 1 hour at room temperature with gentle 
agitation. The plate was then washed with PBS, twice with PBST and again with PBS. 
Recombinant MSF was plated 100µ/well and incubated for 1 hour at room 
temperature.  After washing with PBS, twice with PBST and again with PBS, 
100µl/well RpVSI diluted to 10µg/ml in 1% (w/v) BSA-PBST was added and then the 
plate was incubated for 1 hour at ambient temperature. Followed washing as described 
above, goat anti-rabbit (Pierce) HRP conjugate was then added to each well at a 
dilution of 1:1000 and incubated for one hour at room temperature, followed by the 
washing procedure, tetramethylbenzidine (TMB), (Code S1599 from DAKO UK Ltd., 
Ely, Cambridgeshire UK), was added 50µl/well and left for 10 minutes with gentle 
orbital shaking. The reaction was stopped by adding 50µl/well 2M H2SO4, and the OD 
at 450 nm was measured using a plate reader (MRX DYNEX Technologies Limited, 
Worthing. West Sussex, UK). 
 
2.2.5 Electro-Chemiluminescenes detection (Meso Scal Discovery Technology 
MSD) 
 
Another ELISA technique was used in this study that was more sensitive than 
the basic one and required less volume of sample this was called MSD 
electrochemiluminescence. 
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The MSD electrochemiluminescence detection used SULFO-TAGTM labels 
that emit light upon electrochemical stimulation initiate at electrode surfaces of 
MULTI-ARRAY and MULTI-SPOT microplates. In Electro-Chemiluminescence a 
reaction cascade transfers electrical energy from the plate surface to a light-emitting 
antibody / transition metal complex. 
The Sector Imager 6000 uses an ultra-low noise charge-coupled device (CCD) camera 
with custom-designed telecentric lenses for rapid detection in all MULTI-ARRAY® 
or MULTI-SPOT® plates.  
Materials: 
- MSD has combined MULTI-ARRAY ® microplate: 96 multispot plate using 
direct immobilised on uncoated standard surface. 
- MSD® Read Buffers T 4x 
 
Antibodies: 
Identification Antibody 
- Rabbit polyclonal identification antibody RpVSI, prepared in house (stock Conc 
20µg/ml, 2005), 2µg/ml in 1% (w/v) BSA-PBS-T. 
 
- Anti- human integrin αVβ3 antibody Mouse MAB3050 (R&D Systems lot # 
VUK02). Stock Conc of 500µg/ml. 
- Anti- human integrin αVlCD 51 antibody Goat AF 1219 (Stock Conc 200µg/ml), 
2µg/ml in 1% BSA-PBS-T 
 
- Anti-human integrin β3 CD61 Mouse Monoclonal Antibody (Stock Conc 
500µg/ml), 2µg/ml in 1% BSA-PBST 
- Anti- human lipocalin/ NGAL Goat Polyclonal AF1757 (Stock Conc 200µg/ml). 
2µg/ml in 1% (w/v) BSA PBST. 
 
- IGFBP7 antibody (R&D Systems Polyclonal Goat IgG.Catalog # AF1334. lot # 
C0108051). Stock Conc of 100µg/ml, 1µg/ml in 1% (w/v) BSA-PBST. 
 
- TYN 1.2 Mouse monoclonal antibody to MSF aa-, purified on protein L. prepared in 
house (Stock Conc 100µg/ml). 
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Anti-Species Antibody:  
- MSD Sulph-Tag Goat -anti- Mouse ab (Cat. No. R32AC-1), (Stock Conc 500µg/ml). 
2µg/ml 1% (w/v) BSA- PBST. 
- MSD Sulph-Tag Goat -anti- Rabbit ab (Cat. No. R32AB-5), (Stock Conc 500µg/ml). 
2µg/ml in 1% (w/v) BSA- PBST. 
- MSD Sulph-Tag Donkey -anti-Goat ab (Cat. No. R32AG-5), (Stock Conc 
500µg/ml). 2µg/ml in 1% (w/v) BSA- PBST. 
  
Methodology: 
Indirect MSD ELISA:  
Samples were plated 25µl/well and incubated overnight at 4°C (tapping the 
plate after addition to allow the liquid to coat the bottom of the well).  Wells were 
then washed once with PBS and twice with PBST (0.05% Tween), then 150µl/well of 
blocking buffer 1 % (w/v) BSA- PBST was added and incubated for 1hour with 
shaking. After washing with 150µl PBST per well, 25µl of detection antibody was 
added and the plate was then incubated for two hours at room temperature with 
shaking. Followed washing as described above, 25µl of anti-species antibody 
(2µg/ml) was added and incubated with shaking for 1 hour at ambient temperature, 
followed by the washing procedure. 150µl 2X Read buffer was then added to the 
wells before reading (1 part 4x Read Buffer: 1 part distilled water) and then the plate 
was read by the Sector Imager 6000 reader.  
 
Sandwich MSD ELISA: 
 
96-well plates were coated overnight at 4ºC with the capture antibody, 30µl 
per well diluted in PBS. The plate was then washed (3x) with PBST, 150µl per well. 
The plate was then blocked under constant orbital shaking for 1 hour at room 
temperature with 5% (w/v) BSA PBS (150µl per well). The plate was then washed 
with PBST (3x), 150µl per well and samples were added 25µl per well with constant 
orbital shaking for two hours at room temperature. After washing as described above, 
25µl per well of detection antibody in 1 % (w/v) BSA PBST was added with constant 
shaking for 2 hours at room temperature. The plate was then washed as above, and 
incubated with Anti-Species Antibody: MSD Sulph-Tag in 1% (w/v) BSA PBST.  
25µl per well, with orbital shaking for 2 hours at room temperature followed by the 
washing procedure. 150µl 2X Read buffer was then added to the wells before reading 
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(1 part 4X Read Buffer: 1 part distilled water) and then the plate was read by the 
Sector Imager 6000 reader.  
 
2.3 Affinity purification 
 
2.3.1 Purification of IgG from Mouse Monoclonal Antibodies  
Monoclonal antibodies were purified from large volumes of hybridoma 
supernatant using Hitrap Protein G columns.  
 
Materials: 
-  Dialysis buffer: 20mM Sodium phosphate pH 7.0. 
-  Binding buffer: 20mM Sodium phosphate pH 7.0. 
-  Elution buffer:  0.1M Glycine pH 2.7  
-  Antibody storage: 50µl1M Tris-HCl  pH 8.0 added to the eluted sample per ml 
-  20% (v/v) Ethanol in distilled water (1 litre) for column storage and BioCAD 
Methods 
Conditioned media (CM) was dialysed using Pierce Snakeskin dialysis tubing 
against 20mM Tris HCl pH 7.0 2 x 4 litres overnight at 4°C, the buffer was changed 
after the first hour. Then sample was spun at 12.000rpm for 10 minutes to remove 
particulates before chromatography. The HiTrap protein G column was then 
equilibrated with binding buffer. The sample was then pumped on slowly to facilitate 
maximum binding and the column was then washed with binding buffer to remove 
any unbound material. The buffer was then changed to elution buffer and the low pH 
caused antibody elution. The low pH was not suitable for antibody storage so the pH 
was raised by addition of 1M Tris-HCl pH 8.0 (50µl/ml) to the test tubes either before 
the experiment or immediately after the antibody elutes. The concentration of 
antibody was estimated by absorbance at 280nm on the spectrophotometer. The 
protein concentration of the antibody was determined by the following equation: 
Conc. mg/ml = OD 280nm x 10 x dil. Factor 
                                               14 
The purified antibody was aliquotted and stored at -20°C. The column was 
then re-equilibrated with binding buffer and then washed with 20% ethanol for 
storage. 
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2.3.2 Purification of IgG from Rabbit Polyclonal Antibodies  
 
Immunised rabbit serum was heat inactivated and the IgG was purified using HiTrap 
Protein A columns 
 
 
Materials: 
 
-  Dialysis buffer: 20mM Sodium phosphate pH 7.0. 
-  Binding buffer: 20mM Sodium phosphate pH 7.0. 
-  Elution buffer:  0.1M Glycine pH 2.7  
-  Antibody storage: 50µl1M Tris-HCl pH 8.0 added to the eluted sample per ml  
-  20% (v/v) Ethanol in distilled water (1 litre) for column storage and BioCAD 
Methods: 
After thawing, the serum was heat inactivated by heating to 56ºC for 30 
minutes. The serum was then dialysed using a Pierce cassette (3.5kDa cut off) against 
20mM Tris HCl pH 7.0 2 x 4 litres overnight at 4°C, the buffer was changed after the 
first hour. The sample was then spun at 12.000rpm for 10 minutes to remove 
particulates before chromatography. The Protein A column was then equilibrated with 
binding buffer. The antibody was then purified following the previously described 
method on page (63). 
 
2.3.3 Affinity column preparation   
Several affinity columns were prepared for use in this study using different 
proteins and antibodies as mentioned below: 
2.3.3.1 Materials 
 
A- Reactigel resin (Pierce CDI- Agarose) 
B- Buffer: 
Coupling buffer: 100mM borate made up to a pH 10. 
Blocking buffer: 50mM Tris HCl pH 10  
Wash buffer:  phosphate buffered saline (PBS).   
 
 
 
 
  
65 
C- Proteins used in this study for affinity column preparation: 
1- 10µg of procaryotic recombinant MSF WT (rhMSF WT +aa) was dialysed against 
50mM sodium phosphate (NaH2PO4) + 150 mM NaCl pH 8.0.using Pierce dialysis 
cassettes (cut-off 3.5kDa), overnight. The sample was then coupled to the activated 
resin then continued overnight at 4°C with mixing. 
2- 10µg of procaryotic recombinant rhMSF WT -aa was dialysed against 50mM 
sodium phosphate (NaH2PO4) + 150 mM NaCl pH 8.0. Using Pierce dialysed 
cassettes (cut-off 3.5kDa), overnight. The sample was then coupled to the activated 
resin then continued overnight at 4°C with shaking. 
3- 10µg/2ml of Bovine Serum albumin (BSA) coupled to the activated resin then 
continued overnight at 4°C with shaking. 
 
D-Antibodies used in this study for affinity column preparation: 
1- Rabbit polyclonal identification antibodies (RpVSI) that recognise the MSF-unique 
sequence, RpVSI affinity column (0.5ml): affinity resin used; 1µg/ml RpVSI. 
Prepared in house  
2- TYN 1.2. Mouse monoclonal antibody to MSF-aa, purified on protein L. prepared 
in house, 10µg/ml (Working concentration). 
 
E- Washing buffer: 20mMTris – HCl pH 7.4 
F- Blocking buffer:  50mM Tris buffer pH 10 
G- Eluting buffer: 0.1 M Glycine pH 2.7, and 20mM Tris – HCL + NaCl 2M pH 7.4. 
 
2.3.3.2 Methods:  
Preparation of the RpVSI column is described here as an example, other columns 
were prepared by the same method. 
 
2.3.3.2.1 RpVSI chromatography affinity column preparation: 
The bottle of resin (Reactigel, Pierce) was equilibrated to room temperature 
before opening to ensure moisture did not condense on the product, decreasing its 
activity level for later use. 1ml of Reactigel resin (pierce CDI – Agarose) was used. It 
was then washed with ice cold water to remove acetone. The agarose was then 
suspended in a solution of the ligand e.g. MSF specific rabbit polyclonal antibody 
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(RpVSI) at 1µg/ml. The mixture was then transferred to a plastic bijoux bottle, sealed 
with parafilm and then placed in a 50ml tube and allowed to couple overnight at room 
temperature on rotator drive mixer. The resin was allowed to settle and unbound 
ligand was then removed. The uncoupled sites were blocked by resuspending the resin 
in 50mM TrisHCl buffer pH10 for several hours (3-4 hours) at room temperature. 
Finally the coupled agarose was washed with 3ml of PBS containing 0.05% (w/v) 
sodium azide and stored, sealed with parafilm at 4°C. 
 
2.4.2.2.2 RpVSI affinity purification  
Sample preparation: 5ml of TYS conditioned medium (CM) was dialysed using Pierce 
dialysis cassettes (cut-off 3.5kDa) against 20mM Tris HCl 7.4. 2 x 4 litres overnight 
at 4°C, the buffer was changed after the first hour.  
The RpVSI column resin was then equilibrated with the Tris buffer, for 2 
hours at 4ºC with mixing. The test proteins were then added to the resin; the tubes 
were then sealed with parafilm and mixed overnight at 4°C. The resin was then 
allowed to settle or was spun at 1,000 rpm for 1 minute and the unbound, soluble 
material removed. The resin was then washed for 1 hour at 4°C with the Tris buffer, 
allowed to settle and the wash buffer removed. The resin was then washed again with 
4 x 1ml of Tris buffer, the resin was pelleted between each wash by a 1 minute spin at 
1,000rpm. The resin was then eluted with 5 x 1ml of 0.1 M Glycine pH 2.7 the eluted 
material was pipetted into tube containing 50 µl 1 M Tris-HCl pH 8.7. The column 
was re-eluted with an increasing salt gradient formed by mixing 20mm Tris HCl pH 
7.4 with 20mm Tris HCl pH 7. The affinity resin was washed until the pH was neutral 
and then stored in PBS containing 0.05% (w/v) sodium azide at 4°C. Eluted fractions 
were tested for MSF bioactivity in the transmembrane migration (Boyden chamber) 
assay.  
The same method was used to prepare the other affinity columns with different 
ligands which have been used in this study. 
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2.4 Immunohisochemistry Study 
 
2.4.1 Detection of MSF by immunohistochemistry (IHC) 
  Immunohistochemistry is the localisation of antigens in tissue sections by the 
use of labelled antibody as specific reagents through antigen-antibody interactions 
that are visualised by a marker such as a fluorescent dye, enzyme, radioactive element 
or colloidal gold. Immunohistochemistry for MSF was carried out using a protocol 
developed by Cell and Molecular Biology (Dr Ana Schor), Dental School, Dundee 
University.   
 
2.4.1.1 Materials  
 
2.4.1.1.1 Slide staining: 
         - Xylene – BDH AnalaR; VWR International, Leics., Cat. no. 102936H (2.5l). 
 
         - Ethanol – BDH AnalaR; VWR International, Cat. no. 101077Y (2.5l). 
 
        - PBS – PBS tablets; Sigma-Aldrich, Dorset, Cat. no. P-4417. 
 
        - Tween 20 – Sigma-Aldrich, Cat.no. P1379.  
 
-           Hydrogen Peroxide 30% v/v; Cat.no: 103665H (1l ). VWR Ltd, Leicestershire.Uk  
 
        - ImmunoPen – DakoCytomation Pen; DakoCytomation Ltd., Cambs, Cat.no. S2002. 
 
        - Normal Goat Serum – Vector Labs. Peterborough, Cat. no. S1000. 
 
        - Avidin/Biotin Blocking Kit – Vector Labs, Peterborough, Cat. no. SP-2001. 
 
        - Normal mouse IgG (as negative control). DAKO, X0931 (100mg/L).  
 
        - ABC Kit – Vectastain ABC kit, Standard Elite. Vector Labs., Cat no PK6100. 
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        - DAB – (3, 3-diamino benzidine) Sigma-Aldrich, Cat no. D-5637.   
                     10% v/v or w/v solution made up in PBS heated to approx 50ºC.  Aliquoted into 800µl 
                     aliquots in Cryotubes.(NUNC, Cat. No. 363401), quick-frozen at -80ºC for 1 hour then  
                     stored at -20ºC. 
 
        - Haematoxylin – Haemalum, Mayer. Triangle Biomedical Sciences (TBS), Lancashire,  
                     Cat.no. PS50/c.  
 
        - Blueing agent – Thermo Shandon, Cheshire, Cat. no. 6769001. 
 
        - DPX – BDH; VWR International, Cat. no.360292F (100ml).  
 
2.4.1.1.2 Antibodies and Negative Controls: 
 
The following antibodies and controls were used: 
 
Primary antibodies: 
- Mouse monoclonal antibody HYB7.1 batch 1. 40µg/ml. (Hybridoma antibody to 
total    MSFWT) (stock prepared in house, 0.243mg/ml). 
 
- TYN 1.2 (batch 3) 40µg/ml. Mouse monoclonal antibody to MSF aa-, purified on 
protein L. prepared in house (Stock conc. 221µg/ml). 
 
- Normal mouse IgG (nMIgG); negative control Cat no: X093101, Lot no: 0033117, 
(Dako, Ely, Cambridgeshire, UK). Stock Conc 100µg/ml, (40µg/ml in 20% (v/v) 
NGS) 
 
 
Secondary antibodies: 
- Biotinylated goat anti-mouse IgG. Code BA-9200, lot.T0206. Stock Conc1.5 mg/ml, 
(Vector Labs Ltd, Peterborough, UK). (1:5 diluted in 20% (v/v) N.G.S). 
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2.4.1.2 Methods 
 
2.4.1.2.1 Immunohistochemistry: 
 
- The sections were dewaxed in xylene for 5 minutes. 
- The sections were then rehydrated through 100% -95% - 70% v/v ethanol for 2 
minutes, in each solution. 
- The sections were incubated with 3% hydrogen peroxide (H2O2) in PBS for 20 minutes 
to inhibit endogeneous peroxidise activity.  The slides were then rinsed twice in 
PBS, 5 minutes per rinse. 
- The sections were then outlined with Immuno pen. 
- The sections were incubated in 20% v/v normal goat serum (NGS) diluted in 
PBS for 30 minutes. 
- Sections were then rinsed with PBS using a wash bottle.  
- The slides were then rinsed twice in PBS, 5 minutes per rinse. 
- The sections were then incubated in avidin block from the avidin-biotin 
blocking kit for 15 minutes. 
-  Sections were then rinsed with PBS using a wash bottle, and then rinsed twice 
in PBS, 5 minutes per rinse. 
- Sections were then incubated in biotin block for 15 minutes. 
- The biotin solution was then gently removed from each section.. 
- The sections were then incubated overnight at 4ºC in the primary antibody, 
monoclonal 7.1b1 40µg/ml, diluted in 20% v/v NGS in PBS. 
 
The slides were then equilibrated at room temperature for 1 hour. 
- The primary antibody was then removed from the sections by rinsing gently 
with PBS using a wash bottle. 
- Rinsed the sections in PBS-T (PBS + 0.05% v/v Tween 20) for 5 minutes twice. 
- Then rinsed the sections in PBS for 5 minutes. 
- Incubated the sections in secondary antibody biotinylated anti-Mouse IgG at 
6µl/ml in 20% v/v NGS in PBS for 40 minute. 
- Prepared Vectastain (ABC) complex during incubation at 12µl, 2 drops from 
reagent A (Avidin) and 2 drops from reagent B (Biotinylated) per 5 ml PBS for 
30 minutes at 37ºC. 
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- The sections were then rinsed gently with PBS from a wash bottle. 
- The sections were then rinsed twice in PBS-T (PBS + 0.05% v/v Tween 20) for 
5 minutes. 
- The sections were then rinsed in PBS for 5 minutes. 
- The sections then incubated in ABC complex for 30 minute. 
- The sections were rinsed gently with PBS from a wash bottle.  
- The sections were then rinsed twice in PBST (PBS + 0.05% v/v Tween 20) for 
5 minutes. 
- The sections were then rinsed in PBS for 5 minutes. 
- The slides were immersed in DAB (diaminobenzidin) made up of 400 ml PBS, 
800 µl DAB, 400 µl of H2O2 for 10 minutes, with agitation. 
- The sections were then washed in running tap water. 
- The sections were then counter-stained with Mayer’s Haematoxyline for 30 
seconds. 
- The slides were rinsed in running tap water until the water ran clear. 
- The sections were incubated in blueing agent for I minute then running in tap 
water. 
- Sections were then dehydrated through 95% (v/v), 100% v/v ethanol for 1 
minute in each, then in 100% v/v ethanol for 2 minutes. 
- The slides were soaked in xylene for 5 minutes, then cover slip with mounting 
DPX. 
 
2.4.1.2.2 Quantification and Assessment of MSF expression in salivary gland 
Tumour and OSCC tissue sections.   
 Duplicate sections of each specimen were stained and assessed by 2-4 
independent observers. The final results were obtained by consensus.  MSF staining 
was first evaluated at x100 magnification, scanning the whole section.  The overall 
distribution of staining was recorded (e.g. homogeneous/heterogeneous, tumour cell- 
and/or stromal cell-associated, etc) and the following semi-quantitative parameters 
were then evaluated by comparison to pre-selected calibration slides:  
MSF overall grade (0-3): Specimens were initially graded as negative (grade 0), 
weak (grade 1), moderate (grade 2), or strong (grade 3) positive.  At least 10% of the 
whole area stained was chosen as the cut-off point between grade 0 and grade 1.  
Although such overall grade evaluation includes epithelial and stromal compartments, 
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it reflects mainly the former, as higher magnification is required to assess the stroma.  
The epithelial and stromal compartments were then evaluated individually. The final 
results were obtained by consensus. 
MSF % of area stained (0-100): MSF expression in epithelial and invasive tumour 
front (ITF) for OSCC was defined by four indices. The percentage of total area 
stained (1-100%) was estimated, and the intensity of the staining was graded from 0 
(negative) to 3 (strong) by comparison to calibration slides.  The highest (hot spot) 
intensity (present in at least 10% of the epithelium) was also recorded.  Final score (0-
300) was derived by multiplying the % area stained by the intensity of the staining.  
Heterogeneous staining was common and this is reflected in the final score; for 
example, 50% area stained with intensity 2 and 20% area with intensity between 2 and 
3 (2.5) gives a final score of 150.   
Stromal MSF expression was classified, using higher magnification, as either 
positive or negative for three constituent stromal cell types: fibroblasts, microvascular 
and inflammatory cells.   
MSF expression in NSG. The staining of the various cell types comprising the 
epithelial compartment of histologically normal salivary glands (NSG) adjacent to 
tumours was similarly classified as either positive or negative.  
MSF expression in Hp. The staining of epithelial hyperplasia was similarly classified 
as MSF overall grade (0-3) for both basal and suprabasal cell layers. 
The protein MSF is visualised as a brown colour due to the use of 3, 
3’diaminobenzidine (DAB solution). 
 
2.4.2 Immunocytochemistry (ICC) of Cultured Cell Lines: 
Cell lines used for immunocytochemical staining were prepared by two methods: 
- Plated onto a plastic surface, namely chamber slides and 24 well plates (Nunclon). 
- Plated within and/or on a 3D collage type I matrix (cell pellets). 
Cells were plated onto the plastic surface at densities of 5-9 x 104cells/cm2 and 
incubated for 1-3 days under standard conditions, until reaching approximately 70-
90% confluence in 1-3 days, as convenient for the staining. The medium was then 
removed, cells were washed twice with PBS or Hanks and then fixed with 2% (v/v) 
formalin in PBS for 30 minutes at room temperature followed by permeabilisation 
with 100% (v/v) methanol for 10 minutes at -20°C (methanol stored at -20°C). 
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After washing twice with PBS, endogenous peroxidase activity was blocked by 
immersion in 3% (v/v) hydrogen peroxide in PBS for 20 minutes and non-specific 
binding was blocked by incubating in 20% (v/v) normal serum in PBS (same species 
as secondary antibody) for 30 minutes. 
Sections (or wells) were ringed using an immuno pen (Dako, Demark) to 
minimise the volume of reagent required. To reduce non-specific background, 
sections were pre-treated with an Avidin/Biotin blocking step (Avidin/Biotin 
Blocking kit, Vector Labs, Peterborough, UK). Following optimisation, the 
appropriate dilution of primary antibody was made using 20% (v/v) normal goat 
serum in PBS and incubated overnight in a humidified chamber at 4°C, followed by 1 
hour at room temperature. Controls were incubated with normal serum IgG from the 
same species as the primary antibody was raised in. Secondary antibody incubation 
was for 1 hour at room temperature in a humidified chamber, the appropriate dilution 
was made in 20% (v/v) normal goat serum PBS. Staining was visualised using the 
avidin-biotin enzyme complex (Vectastain ABC Kit, standard Elite Vector Labs, 
Peterborough, UK).and incubation with DAB (3’3’- diaminobenzidine), a substrate 
for the enzyme (Sigma, Dorset,UK) Slides were counterstained with haematoxylin 
and Blueing agent before being cover slipped with mounting medium (Aqueous 
mount Sigma, Dorset, UK) for plastic and DPX. 
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2.5 Tissue Culture:  
2.5.1 Materials: 
2.5.1.1 Chemicals and reagents: 
- Eagles Minimum essential Medium (MEM), lot no. M0275. 
- L-glutamine, Lot no.G-7513 was purchased from Sigma-aldrich, UK.  
- Donor Calf Serum (DCS), batch no. 0, lot no. APD21173 was from Thermo-Fisher 
Perbio, Hyclone, UK. 
- Hank’s solutions free of calcium and magnesium, (Lot no.H-4641), Sigma- Aldrich, 
UK) 
- NaHCO3 Lot no. 301515V, Merck. BDH, Germany.  
- Trypsin solution was prepared from trypsin (lot no. T4549), Ethylene glycol 
tetraacetic acid (EGTA) (lot no. E-4378) and PBS tablet (lot no. P-4417). Sigma- 
Aldrich, Uk. 
- Freeze mix was prepared by 15% (v/v) heat treated DCS and Dimethyl  Sulfoxide 
(D-5879, Sigma- Aldrich, UK). 
- Tissue culture plastic ware was purchased from SLS (Nottingham, UK).  
- Haematoxyline was from Mayer’s; distributed by Bios-Europe Lancs, UK, Cat no 
PS50C.  
 
2.5.1.2 Cells:  
The human salivary tumour cell line (HSG) and oral tumour cell line (TYS)  
which was derived from an oral squamous cell carcinoma of the floor of the mouth 
and were both a gift from Professor Mitsunobu Sato (Department of Maxillofacial 
Surgery, School of Dentistry, University of Tokushima School of Dentistry, Japan) 
(Shirasuna et al., 1981). The human endothelial cell line (Endo 742) was a gift from 
MJ O’Hare Ludwig cancer Research Institute, London (O'Hare et al,. 2001). Human 
foreskin fibroblast (FSF44) cultures were established in our laboratory from health 
male donors and cultured as previously described (Schor, 1980). 
  Cells were maintained in cell culture using Eagle’s Minimum Essential 
Medium (MEM) growth medium supplemented with 15% (v/v) Donor Calf Serum 
(DCS) and 1% (v/v) Glutamine, as previously described (Motegi et al,. 2008). Sub-
culturing, cryopreservation and resuscitation of the frozen cell lines was performed as 
described below. 
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2.5.1.3 Collagen cell pellets. 
 
Materials: 
10x MEM (Gibco/Sigma), 7.5% NaHCO3, Collagen 2.2mg/ml, Cells to be used 
(HSG, TYS), HBSS, Normal growth medium for cells to be used and trypsin (EGTA).  
 
Method: 
For each 2ml collagen cell pellet 2x 90mm dish of cells (1 dish for in gel and 1 
dish on gel) were used (2 x 106 cell/dish).  
For in gel: The normal growth medium was aspirated from the cells (1 dish). 
The cells were then washed twice with 3mls of HBSS (Hanks Balanced Salt Solution) 
and this was then aspirated from the dish. Then 2ml of 0.05% (w/v) trypsin in 
EGTA/PBS was added to the dish and the dish was then placed onto the hot-plate. 
After 5 minutes (or when the cells had rounded and floated up from the dish) the 
effect of the trypsin was reversed with normal growth medium. The floating cells 
were then pipetted into a universal and the cells pelleted in a centrifuge at 900rpm for 
5 minutes. The medium was then aspirated and the cell pellet resuspended in 100µl of 
growth medium. 
After the cells were resuspended, a 2ml collagen gel was prepared (200µl of 10x 
MEM, 100µl of 7.5% Na HCO3, 1.7ml of 2.2mg/ml collagen), this was then added to 
the cells and allowed to set in the universal. After 30 minutes 10ml of normal growth 
medium was added to the collagen gel and the universal placed into the incubator for 
3-4 days (the lid was loosened to allow gas exchange).  
For on gel: On day 3-4 a further dish of cells was trypsinised (as above). After 
the cells were pelleted they were resuspended in 5mls of medium. The medium from 
the collagen pellet was removed and replaced with the 5mls of cell suspension. This 
was placed in the incubator and after 30 minutes a further 5mls of growth medium 
was added. After a further 24 hours the collagen gel was washed and fixed overnight 
at 4ºC with 10% (v/v) formalin buffered saline. The fixed pellets were sent to the 
pathology department, Ninewells hospital, Dundee for paraffin embedding. 
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2.5.2 Methods: 
2.5.2.1 Cell culture 
Cells were subcultured 2-3 times a week (1:3 or 1:4) and the medium was 
changed every second day. Confluent cultures were frozen for storage by the 
following protocols: 
2.5.2.1.1 Subculturing 
 The cells on 90mm plates (Nunclon) were washed with Hanks balanced salt 
solution (HBBS) (4mls), trypsinised (EGTA) (2mls) at 37ºC for 5 minutes and 
neutralised with serum containing medium (5mls/plate). The cell suspension was spun 
at 900 rpm for 5 minutes. The pellet was resuspended in medium and split to other 
dishes and then incubated at 37 ºC and 5% CO2. 
2.5.2.1.2 Freezing down stock cultures 
 The confluent cells were washed with Hanks (4mls), trypsinised (EGTA) 
(2mls) at 37ºC for 5 minutes and neutralised with serum-containing medium 
(5mls/plate). The cell suspension was spun at 900 rpm for 5 minutes. The pellet was 
resuspended in freeze mix in a cryovial (Nunclon) and stored at -80 ºC. 
2.5.2.2 Cell number determination: 
Cell numbers (TYS, HSG, FSF44, and Endo 742) on plastic or gelatin coated 
dishes were obtained as follows: Cells were washed twice with 4ml Hanks balanced 
salt solution (HBBS). The cell layer was then trypsinised with 2ml trypsin solution 
(EGTA) and incubated at 37°C for 5 minutes. A single cell suspension was achieved 
by pipetting onto the monolayer. This suspension was aspirated from the dish and 
transferred to a 25ml universal containing 5ml of 15 % (v/v) DCS MEM. A 100µl 
aliquot of the cell suspension was then transferred to a Coulter vial containing 9.9mls 
of Isoton (Beckman Coulter. Germany). The total number of cells in 100µl of the cell 
suspension was determined using a Coulter particle counter. 
2.5.2.2 Boyden chamber Cell migration Assay.  
 
The migratory response of target cells to putative motogenic factors is most 
commonly studied in vitro with the transmembrane (Boyden chamber) assay. This 
experimental protocol may be used to distinguish between chemokinesis (random cell 
motility) and chemotaxis (directed cell motility toward increasing concentration of 
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soluble attractants) (Zigmond and Hirsch, 1973).   The Boyden chamber assay is 
based on two chambers separated by a filter (a polyvinylproplene-free polycarbonate 
membrane) through which cells can migrate. The polycarbonate membrane used in 
the transmembrane assay does not support cell attachment and must consequently be 
coated with an adhesive compound, gelatin (denatured type I collagen) being a 
popular choice. Different concentration of chemo-attractants can be set up by placing 
in the lower chamber, so cells from the wells of upper compartment migrate into the 
lower compartment wells in which chemo-attractants are present through the pores of 
the membrane. Cell migration is quantified by simply counting migrated cells under a 
light microscope after staining. 
  The benefit of the Boyden chamber benefit is that it discriminates between 
chemo-kinetic and chemotactic influences. In addition, the Boyden chamber assay is 
somewhat time saving in that cells migrate through a porous membrane within a few 
hours (4-6 h) which is considered a short time in comparison with the time required 
for cells to proceed through a cell cycle, furthermore the Boyden chamber assay 
allows for cell motility analysis on a basis without consideration of the effect of cell 
proliferation on their results. Some of the important factors of Boyden chamber assay 
are considered to be the number of cells to be loaded on the chamber, the type and 
concentration of the attractant, the pore size of the membrane and the incubation time. 
A number of different Boyden chamber devices are available which vary in their 
sample size and quantitation method. 
 
 
Figure 2.1: Neuro Probe standard 48-well chemotaxis chamber (adapted from Chen, 2004) 
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Chamber Construction: 
To construct the assay a set volume (30µl) of MEM containing 2µg/ml bovine 
serum albumin (BSA) ± a known concentration of the factor under investigation 
(forming a small positive meniscus) was added to the bottom wells of the 48-well 
chamber (Neuro Probe, Inc., Gaithersburg, MD, USA) (Fig 2.1). A 
polyvinylpropylene free polycarbonate Nucleopore membrane (0.5-0.8µm) (Whatman 
Ltd, Maidstone, Kent, UK) coated with native type I collagen was placed, shiny side 
down, over the filled wells. The chamber gasket and upper well section were fixed 
firmly with screws. The apparatus was equilibrated for 30-45 minutes at 37°C in a 
humid atmosphere of 5% CO2.    
 
Cell preparation: 
 Stock dishes of confluent cells were washed twice in HBSS. Cell were 
trypsinised with 2ml trypsin solution (EGTA), the trypsin was then inactivated with 
growth media containing 15% (v/v) DCS and cells pelleted by centrifugation at 
900rpm for 5 minutes. Cells were then resuspended in serum-free MEM containing 
2µg/ml BSA, cell numbers were counted using the Coulter Counter and resuspended 
at 5 x 105 cell/ml. 50µl of this cell suspension was added to each of the upper wells. 
The chamber was then incubated at 37°C in humid atmosphere of 5% CO2 for 5 
hours. 
 
Membrane Fixation and staining: 
The chamber was disassembled and the membrane removed using forceps. 
The membrane was gently rinsed in PBS and fixed in methanol for 10-15 minutes. 
Cells were stained overnight with Mayers Haematoxylin. Membranes were washed 
repeatedly in tap water and then cut into 4 sections. The unmigrated cells on the upper 
surface of each membrane section were removed by wiping off onto damp Whatman 
No.1 filter paper. Membrane sections were mounted onto glass slides under cover 
slips using Glycergel aqueous mountant (Sigma, Bucks, UK). 
 
Measurement of migration: 
Migrated cells were counted microscopically (magnification x200) under 
bright field illumination.  Six replicate wells were used per variable, with the number 
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of cells counted in 3 random fields per well (i.e. total of 18 fields) used to calculate 
mean cell number per field ± standard deviation 
Methodology: 
Migration assays were performed using a modified Boyden chamber assay as 
previously described [Schor et al, 1996; 2006]. The bottom wells of the 48-well 
chamber (Neuro Probe, Inc., Gaithersburg, MD, USA) were loaded with 30 µl of 
different concentrations (1pg/ml, 10pg/ml, 100pg/ml, 1ng/ml, 10ng/ml, and 
100ng/ml) of rhMSF dissolved in SF-MEM with 2µg/ml bovine serum albumin 
(BSA).  The 0.8 µm pore polycarbonate Nucleopore membranes (Whatman Ltd, 
Maidstone, Kent, UK) (coated with native type I collagen) were then applied and the 
upper wells of the assembled chamber loaded with 50µl of HSG cells (at 1.2 x 
10
6
cells/ml) in SF-MEM containing 2µg/ml BSA.  After a 5 hour incubation period at 
37°C in a humidified CO2 incubator, the membranes were removed, fixed in methanol 
and stained with Mayer’s Haemotoxylin. The cells remaining on upper surface of the 
membrane were scraped off and the cells that had migrated through the pores to the 
under surface were assessed microscopically (x200) under bright field illumination.  
Six replicate wells were used per variable, with the number of cells counted in 3 
random fields per well (i.e. total of 18 fields) used to calculate mean cell number per 
field ± standard deviation. 
 
 
2.6 Isolation of proteins produced by cultured cells 
 
2.6.1 Conditioned Medium Collection and Storage: 
Cells (TYS, HSG) were grown to confluence on 90mm dishes. Confluent 
cultures were rinsed once with 4ml of Hanks and then twice with 5ml serum-free 
MEM. Dishes were incubated for 2 hours at 37°C in 5 ml of SF-MEM. The medium 
was discarded and dishes were washed again with SF-MEM. Cells were then 
incubated in fresh SF-MEM for 48 hours. The CM was collected, spun for 5 minutes 
at 900rpm and the supernatant was collected and stored at -20°C. 
 
2.6.2 Cell lysate preparation 
  TYS cells plated on five 90mm dishes (90% confluences) were washed with 
cold PBS, the cells were lysed with 500 µl/plate of an RIPA buffer (50 mM Tris–HCl 
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pH 7.4, 150 mM sodium chloride, 1% (v/v) Triton X-100, 0.1 % (w/v) SDS, 1% 
sodium deoxycholate, 5 mM EDTA). Cells were incubated on ice until completely 
lysed, then surface of the Petri-dish was then scraped with 1mL syringe stopper. The 
lysates were spun in a bench-top centrifuge at full speed for 10 min, and the resultant 
pellet was discarded. The protein extract was then added to the resin following the 
same methods as for RpVSI immunoprecipitation as described in page (66). The 
eluted fractions were tested to identify MSF by using Indirect ELISA and Western 
blot. Detect protein by ELISA or Western or place in –20 freezer. 
 
2.6.3 Cell Membrane Protein Extraction: 
2.6.3.1 Materials  
Mammalian cell pellet, protease inhibitor (Roche Complete Mini, EDTA-free. 
lot; 11051600), Mem-PER Eukaryotic Membrane Protein Extraction Reagent Kit 
(Pierce # 89826). Target cells as in (Table 2.2). 
 
 
 Table 2.2: Cell types  
Tumour cell lines 
 
Definition 
FSF44 Human foreskin fibroblast cells 
HSG   Human salivary gland tumour cells 
 
TYS  
 
Human oral tumour cell line 
Endo 742 
 
Human Endothelial cells 
 
2.6.3.2 Methodology 
 
Membrane proteins were extracted from pellets of cultured cells using the 
Mem- PER Eukaryotic Membrane Protein Extraction Reagent Kit from Pierce, 
essentially according to the manufacturer’s instructions. Cells were cultured as 
previously described (page 76) and collected as cell pellets and frozen at -70ºC. 5 x 
106 cells for each cell line were extracted. The mixture was then centrifuged at 
10,000g and incubated at 37°C to isolate the hydrophobic proteins (bottom layer) 
from the hydrophilic proteins (top layer). The hydrophobic fraction contained the 
majority of membrane proteins required for downstream analysis. Identification of 
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integrin αvβ3 from membrane proteins extracted from these cell lines was by ELISA, 
Western blotting and Mass Spectroscopy. 
 
2.7 Statistical analysis: 
Statistical analyses were carried out with the Prism 5 (Graphpad Inc. La Jolla, 
CA, USA) software package. Each experiment was repeated a minimum of two times. 
Differences among groups of tissues were determined either by chi-squared and 
Fisher’s exact tests or one ANOVA Bonferroni Test and two-tailed Mann–Whitney 
tests, as appropriate. Differences in cell migration were analysed by ANOVA and 
Bonferroni tests. Significance differences were defined at 95% level of confidence (P 
< 0.05). Survival analysis was undertaken using Kaplan-Meier curve followed by the 
long rank test. 
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Table 2.3: Total primary and secondary antibody used in this study   
 
 
MSF Antibodies: 
 
 
 
Primary -Ab Stock origin Secondary-Ab origin 
RpVSI 20µg/ml In house Rabbit anti-mouse 
HRP 
DAKO 
 
Goat Anti- human 
integrin αV lCD 51 
AF1219 
200µg/ml R&D Systems Rabbit anti-goat 
HRP 
R&D 
Systems 
Mouse Anti- human 
integrin β3 (CD61) 
mab 
100µg/ml R&D Systems Rabbit anti-mouse 
HRP 
R&D 
Systems 
Anti-cell binding 
domain of 
Fibronectin antibody 
MAB1937 
1mg/ml  CHEMICON Goat anti-rabbit 
(GAR-HRP) 
DAKO or 
Pierce 
Anti-human 
Lipocalin (Goat 
Polyclonal AF1757) 
200µg/ml R&D systems Rabbit anti-mouse 
RAM-HRP 
DAKO 
αvβ3 antibody 
MAB3050 
500µg/ml R&D Systems Rabbit anti-goat 
RAG-HRP 
DAKO 
 
IGFBP7 antibody 
AF1334 
100µg/ml R&D Systems Goat -anti- mouse ab MSD 
Sulph-Tag 
Mouse monoclonal 
antibody TYN 1.2 
221µg/ml 
288µg/ml 
In house Goat anti-mouse IgG MSD 
Sulph-Tag 
RpabVSI 1.28mg/ml In house Goat -anti- rabbit ab MSD 
Sulph-Tag 
MAB 2.1VSI 592µg/ml 
 
In house Biotinylated rabbit 
anti-mouse IgG 
Dako 
Mouse monoclonal 
antibody HYB7.1b1 
592µg/ml 
0.243mg/ml 
In house Biotinylated goat 
anti-mouse IgG 
Dako 
Normal mouse IgG 100µg/ml Dako Biotinylated goat 
anti-mouse IgG 
Vector Labs 
Mab PEPQ 1.1 61.4µg/ml In house   
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3. Chapter three: Expression and bioactivities of MSF in vitro 
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3.1 Introduction: 
Recombinant MSF exhibits a number of potent bioactivities in vitro and in 
vivo relevant to cancer progression and wound healing. This study focusses mainly on 
the motogenic activity of MSF, studying the stimulation of migration/invasion by 
tumour cells, fibroblast and endothelial cells. Schor et al, (2003) indicated that 
mutations of IGD to DGI in fibronectin type I module at 7 and 9 (7FnI and 9FnI) 
eliminate the motogenic activity of MSF on fibroblasts migration. Therefore, the 
motogenic activity of MSF on fibroblasts is mediated by two IGD amino acid motifs 
located in MSF modules 7FnI and 9FnI. Ellis et al, (2010) reported that MSF contain 
a cryptic motogenic activity in the 3FnI and 5FnI modules released when MSF is 
degraded into small fragments.  
Another active motif has been reported in MSF. This motif is a putative zinc 
binding amino acid motif (HEEGH), located in module 8FnI of MSF and fibronectin, 
and is essential for fibronectin proteinase activity (Houard et al., 2005). Houard et al, 
(2005) reported that this motif is also necessary to stimulate the migration of a breast 
tumour cell line (MCF-7), as the proteinase and motogenic activities of MSF were 
abolished by the mutagenesis of the two histidine residues to phenylalanine (FEEGF).  
3.2 Aims:  
The objectives of this study were to: 
1- Determine the effect of MSF on different types of cells (oral tumour cell line 
       TYS, salivary gland tumour HSG, human endothelial cell Endo 742 and    
        human fibroblast FSF44) in terms of migration. 
2-  Determine the specific amino acid motifs of MSF (IGD and/or HEEGH that 
are responsible for its bioactivity.  
3- Determine the modulation of MSF bioactivity by antibodies (PEPQ and, TYN) 
and other proteins (NGAL, BP-7)  
4- Determine the expression of MSF by oral tumour cell lines.  
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3.3 Materials and Methods:  
3.3.1 Cells: The following human cells were used:  
TYS: Oral tumour cell line (Shirasuna et al., 1981) 
HSG: Salivary gland tumour cell line (Shirasuna et al., 1981) 
Endo 742: Microvascular endothelial cells (O'Hare et al., 2001) 
FSF44: Foreskin fibroblasts (Schor, 1980) 
Tumour cells HSG and TYS and endothelial cells Endo 742 were gifted from 
the laboratories where originated by Professor M. Sato and Dr Michael O’Hare, 
respectively.  FSF44 fibroblasts were established in the laboratory of Prof S.L.Schor 
by explant culture from foreskin obtained from a healthy 1 year old male donor.  
 
3.3.2 Proteins and antibodies 
The proteins and antibodies used in this study are listed in Tables 3.1, 2 and 3; 
 
Table 3.1:  MSF and its mutant proteins   
PROTEIN 
NAME 
 
MUTATIONS 
 
 
ABBREVIATED 
NAME 
 
rhMSF+aa WT NONE rhMSF+aa  
rhMSF-aa WT 
15 amino acid 
deletion 
rhMSF-aa  
rhMSF+aa DGI 3,5  
IGD 3  DGI 
IGD 5  DGI 
MSF 3,5m  
rhMSF+aa DGI 7,9 
IGD 7  DGI 
IGD 9  DGI 
MSF 7,9m 
rhMSF+aa DGI 
3,5,7,9 
IGD 3  DGI 
IGD 5  DGI 
IGD 7  DGI 
IGD 9  DGI 
MSF Qm 
rhMSF+aa FEEGF HEEGH  FEEGF MSF Hm 
rhMSF+aa DGI 
3,5,7,9 FEEGF 
HEEGH  FEEGF 
IGD 3  DGI 
IGD 5  DGI 
IGD 7  DGI 
IGD 9  DGI 
MSF QmHm 
rhMSF+aa DGI 7,9 
FEEGF  
HEEGH  FEEGF 
IGD 7  DGI 
IGD 9  DGI 
MSF 7,9m Hm  
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Table 3.2: Proteins used in this study 
PROTEIN 
NAME 
ABBREVIATED 
NAME 
Migration stimulating factor 
 
rhMSF+aa  
rhMSF-aa 
Neutrophil gelatinase-
associated lipocalin 
rhNGAL 
Recombinant Insulin-like 
Growth Factor Binding 
Protein-7 
rhBP-7 
Insulin-like Growth Factor 
Binding Protein-7 purified from 
endothelial cell CM 
eBP-7 
 
Table 3.3: Antibodies used in the migration assay study  
ANTIBODY 
NAME 
ABBREVIATED 
NAME 
MSF Function-neutralising antibody 
 
PEPQ 
 
 
Identification Anti total MSF 
antibody  
VSI 
 
 
Anti MSF-aa antibody 
 
TYN 
 
 
 
 
3.3.3 Methods: 
-  Cell culture 
-  Collection of conditioned medium 
-  Immunocytochemisrty 
-  Transmembrane migration assay (Boyden chamber).  
-  Affinity purification of Conditioned medium.  
-  Preparation of cell lysates 
These methods are described in chapter two (Materials and Methods). 
3.3.4 Statistical analysis: 
Statistical analyses were carried out with the Prism 5 software package 
(Graphpad Inc. La Jolla, CA, USA). The distribution (parametric / non-parametric) of 
the data was determined with the Kilmogorov-Smiroff test.  Since the data followed a 
normal distribution, differences among experimental groups were analysed by 
ANOVA and Bonferroni tests. Significance differences were defined at the 95% level 
of confidence (P < 0.05). 
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3.4 Results: 
 
3.4.1 Effects of MSF on cell migration 
 
 The effect of MSF proteins was investigated in the transmembrane assay as 
described in Materials and Methods.   Briefly, the proteins were diluted in serum-free- 
MEM containing 2µg/ml BSA (SF-BSA).   SF-BSA was used as control (baseline) 
and the number of cells that had migrated was determined microscopically after a 5 
hours incubation period. Experiments were repeated 3-6 times. 
 
3.4.1.1 Effects of rhMSF+aa on cell migration 
The motogenic effect of rhMSF+aa was tested on TYS, HSG and Endo 742 
cells. Results are presented in (Fig. 3.1A, B, and C). By comparison, results 
previously published with fibroblasts (Schor et al., 2003) are shown in (Fig 3.1D).  
Different concentrations of rhMSF +aa had a significant stimulatory effect on the 
migration of all four cell types (Bonferroni’s test).  Significant stimulation was 
detected at concentrations of 0.1- 10pg/ml (Fig 1). In the case of TYS, Endo 742 and 
FSF44 higher concentrations induced less stimulation, reaching baseline levels at 
500ng/ml -1µg/ml. Therefore, MSF biological activity displayed a bell shaped dose-
response curve, with maximal stimulation of migration achieved at a concentration 
100pg/ml.  However, in the case of HSG cells all concentrations of MSF tested 
(1pg/ml-1µg/ml) exhibited significant motogenic activity by comparison to the 
negative control or baseline, with a plateau reached at 10ng/ml. 
 
3.4.1.2 Effects of rhMSF-aa on cells migration 
The effect of rhMSF-aa on the same four cell lines was investigated in the 
transmembrane migration assay as described above. Fig 3.2 shows that significant 
differences on the migration of TYS, HSG, Endo 742 and FSF44 occurred between 
baseline control levels and different concentrations of rhMSF-aa tested (P < 0.05; 
ANOVA and Bonferroni tests). These results are similar to those obtained with 
rhMSF+aa regarding dose-response patterns. 
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Figure 3.1: Effects of different concentrations of rhMSF+aa on the migration of TYS, HSG, Endo 
742 and FSF44 cell lines.     
Cells were plated on collagen coated filters and the number of cells that had migrated was 
determined after 5 hours. The minimal concentration of rhMSF+aa needed to stimulate 
migration was around 0.1 pg/ml for TYS, 1pg/ml for HSG (this was the lowest concentration 
tested), and 10 pg/ml for both Endo742 and FSF44. MSF biological activity on TYS, 
Endo742 and FSF44 displayed a bell shaped dose-response curve, with maximal stimulation 
of migration achieved at a concentration of 100pg/ml.  However, in the case of HSG cells all 
the concentrations of MSF tested (1pg/ml-1µg/ml) exhibited significant motogenic activity by 
comparison to the negative control, with a plateau reached at 10ng/ml. 
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Figure 3.2: Effects of different concentrations of rhMSF-aa on the migration of TYS, HSG, Endo 
742 and FSF44 cell lines.  
Cells were plated on collagen coated filters and the number of cells that had migrated was 
determined after 5 hours. The minimal concentration of rhMSF-aa needed to stimulate 
migration was around 0.1 pg/ml for TYS, 1pg/ml (lowest concentration tested) for both HSG 
and Endo742, and 10pg/ml for FSF44.  MSF biological activity on TYS, Endo742 and FSF44 
displayed a bell shaped dose-response curve, with maximal stimulation of migration achieved 
at a concentration of 100pg/ml.  However, in the case of HSG cells all the concentrations of 
MSF tested (1pg/ml-1µg/ml) exhibited significant motogenic activity by comparison to the 
negative control, with a plateau reached at 10ng/ml. 
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3.4.2. Bioactive motifs of MSF 
rhMSF mutant proteins (Table 3.1) were produced by in vitro mutagenesis and 
prokaryotic expression (Schor et al., 2003) and were made available for my study by 
SL Schor, AM Schor and SJ Jones, at the Cell and Molecular Biology Unit, Dundee 
Dental Hospital. 
3.4.2.1 Effects of rhMSF mutants on cell migration  
The biological activity of rhMSF mutants was compared in the transmembrane 
migration assay. The statistical analysis of the results for rhMSF mutants (including 
MSF 3,5m, MSF 7,9m, MSF 7,9m Hm,  MSF Hm, of MSF Qm, and MSF QmHm) 
were similar in all experiments, proving there was no significant stimulatory effect of 
rhMSF mutants on the migration of TYS( Fig 3.3 & 3.4) and HSG  cell lines (Fig 
3.5A) (ANOVA and Bonferroni’s p>0.05). Therefore, the biological activity of MSF 
appears to be mediated by both IGD and HEEGH motifs for the stimulation of both 
oral tumour cells (TYS) and salivary gland tumour cells (HSG). In contrast, data 
presented in (Fig 3.5B) indicates that the migration of Endo 742 was stimulated by 
rhMSF mutants involving either IGD or HEEGH motifs (MSF 3,5m MSF+aa 7,9m, 
MSF 7,9mHm,  MSF Hm, and MSF Qm),  whilst mutation of both the HEEGH and 
all four IGD motifs in MSF  abolished the motogenic response of endothelial cells.  
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Figure 3.3: Effects of different concentrations of rhMSF mutants (3,5m, 7,9m, Qm and Hm) on 
the migration of TYS cell line. 
 A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. There was no significant effect of all 
these rhMSF mutants on cell migration by comparison to the negative control (Bonferroni’s 
test) 
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Figure 3.4: Effects of different concentrations of rhMSF mutants (7,9mHm and Hm) on the 
migration of TYS cell line.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. There was no significant effect of both 
mutants on cell migration by comparison to the negative control (Bonferroni’s P>0.05). 
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Figure 3.5: Effects of different concentrations of rhMSF 3,5m, 7,9m and Hm on the migration of 
HSG and Endo 742 cell lines.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. (A) There was no significant effect of 
all mutants on the migration of HSG cells by comparison to the negative control (Bonferroni’s 
>0.05.). (B) There was significant effects of all mutants on the migration of Endo742 by 
comparison to the negative control (Bonferroni’s P<0.05). 
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Figure 3.6: Effects of different concentrations of rhMSF QmHm on the migration of Endo 742 
cell line.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. (A) There was no significant effect of 
rhMSF QmHm at (1ng/ml and 10ng/ml) on the migration in comparison to the negative 
control (Bonferroni’s >0.05).  
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3.4.3 Characterisation of antibodies to MSF  
 
Antibodies used for MSF identification (VSI, TYN) and function-neutralising 
(PEPQ) were produced by Schor and Schor (Principal Investigators) contracted to 
Borek Vojtesek (Schor et al., 2003 and unpublished data).  Characterisation of these 
antibodies was performed by Dr. B.Vojtesek, Dr. K. Kankova, members of the Cell 
and Molecular Biology Unit, Dental School (Dr. S. Jones, Dr. I. Ellis, Mrs. J. Cox, 
and Mrs. M. Florence. L Aljorani) and members of the Cancer Research Technology, 
Development Laboratory, London (Dr. D. Snary, Dr S. Foo) in collaboration with 
Schor and Schor or under their supervision.  Results presented below are either 
published (Schor et al., 2003) or with acknowledgment to the researchers involved, as 
indicated.   
 
3.4.3.1 Unique MSF-C-terminal identification antibodies (VSI)  
 
A panel of polyclonal and monoclonal antibodies have been generated against 
the MSF-unique C-terminal decamer (VSIPPRNLGY). Specificity and cross-
reactivity of these VSI antibodies were assessed by ELISA (Fig 3.7a & b), dot-blots 
(Fig 3.7c).These antibodies recognise MSF and do not cross-react with full-length 
cellular fibronectin (Fn) or proteolytically derived fibronectin fragments, such as Gel-
BD (Fig. 3.7b).  
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Figure 3.7: Recognition of MSF and Fn proteolytic fragments by VSI antibody.   
(a) MSF standard curve by indirect ELISA (Aljorani). There was no detectable cross-
reactivity with FN or its proteolysis fragments by sandwich ELISA (b) (Dr. Kankova) or dot 
blots (c) (Dr. Ellis). 
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3.4.3.2 MSF-aa identification antibodies (TYN) 
 
  TYN (1.1 and 1.2) monoclonal antibodies were raised against the peptide 
TYNDRTDSTTSNY, an amino acid sequence that is present in MSF-aa only.  TYN 
antibodies were tested against rhMSF-aa, rhMSF+aa, cFn and GBD by both indirect 
and sandwich ELISA (Dr S.Jones). The results showed good standard curves with 
rhMSF-aa and no cross reactivity with rhMSF+aa, cFn and GBD (Table. 3.4). 
 
Table 3.4: Standard curve for rhMSF-aa and negative controls by sandwich 
ELISA   
 
Antibody Antigen 
Concentration 
ng/ml 
Reading Blank 
Final 
Reading 
200 3.060 2.804 
100 1.609 1.353 
50 0.963 0.707 
25 0.609 0.353 
12.5 0.448 0.192 
6.25 0.358 0.102 
MSF-aa 
3.125 0.325 
0.256 
0.069 
MSF+aa 200 0.293 0.037 
cFn 1000 0.261 0.005 
TYN 1.2 
1µg/ml 
GBD 1000 0.247 
0.256 
0.009 
 
3.4.3.3 Function-neutralising monoclonal antibodies (PEPQ)  
Function-neutralising antibodies (PEPQ) recognise the IGDQ sequence in 
module 7FnI (Schor et al., 2003; Jones et al., 2007 and Ellis et al., 2010). The 
following proteolytic fragments of Fn and related proteins had been tested for cross-
reactivity with these antibodies: (i) 30kDa Fn fragment containing only heparin-
binding domain 1 (HBD), (ii) 45kDa fragment containing only gel-binding domain 
(GBD) (iii) rhMSF and (iv) full-length human plasma Fn. Results were in agreement 
with the theoretically predicted specificity, HBD and full-length Fn are recognized 
neither by PEPQ nor by VSI antibodies.  The 45kDa GBD is recognized by PEPQ but 
not VSI Ab (Fig. 3.8).  
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Figure 3.8: Recognition of Fn and its proteolytic fragments by VSI and PEPQ antibodies by 
indirect ELISA. (Schor et al., 2003) 
 
3.4.4 Inhibition of MSF bioactivity by antibodies and other proteins  
3.4.4.1 The effect of MSF-function-neutralising antibodies (PEPQ) 
MSF bioactivities can be abrogated by the function-neutralising anti-MSF 
antibodies (PEPQ 1.1). Exposure of target cells to PEPQ 1.1 did not affect the control 
or baseline migration, it also had no stimulatory effect on cell migration (TYS, HSG 
and Endo 742) when tested on its own at 1ng/ml-1µg/ml.  However, different 
concentrations of antibody (10pg/ml–1µg/ml) effectively neutralised the motogenic 
activity of 100pg/ml of rhMSF.  The addition of PEPQ 1.1 together with rhMSF at 
100 pg/ml, reduced the number of cells migrated from values comparable to those of 
positive controls (100pg/ml rhMSF+aa) to baseline levels (Fig 3.9 & 3.10). The 
addition of PEPQ also abrogated the stimulatory effect of rhMSF+7,9mHm on the 
migration of Endo 742 cells (Fig 3.11).  
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Figure 3.9: Effects of PEPQ antibody on the migration of TYS cells in the transmembrane 
migration assay.   
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa was used as a positive control. MSF function-neutralising 
antibody inhibited the motogenic activity of rhMSF+aa down to the level of the negative 
control (Bonferroni’s test). 
 
 
 
 
 
 
 
 
 
 
 
 TYS cell line
ba
se
lin
e
10
0p
g/
m
l M
S
F+
 1
0p
g/
m
l P
E
PQ
10
0p
g/
m
l M
SF
+ 
10
0p
g/
m
l P
EP
Q
10
0p
g/
m
l M
SF
+ 
1n
g/
m
l P
E
PQ
10
0p
g/
m
l M
SF
+1
0n
g
/m
l P
E
PQ
10
0p
g/
m
l M
SF
+ 
10
0n
g/
m
l P
EP
Q
10
0p
g/
m
l M
SF
+1
µg
 P
EP
Q
+v
e 
co
nt
ro
l
0
10
20
30
40
50
60
70
80
90
C
e
ll
s
 m
ig
ra
te
d
 p
e
r 
fi
e
ld
(m
e
a
n
±± ±±
 S
D
)
Concentrations 
  
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Effects of PEPQ antibody on the migration of HSG cells in the transmembran 
migration assay.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml and 100ng/ml rhMSF+aa as a positive control. MSF function-
neutralising antibody inhibited the motogenic activity of rhMSF down to the level of the 
negative control (Bonferroni’s test). 
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Figure 3.11: Effects of PEPQ antibody and MSF 7,9mHm on the migration of Endo 742 cells in 
the transmembrane migratiion assay.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. MSF function-neutralising antibody 
inhibited the motogenic activity of rhMSF 7,9mHm down to the level of the negative control 
(Bonferroni’s P>0.05 against baseline), whilst a significant effect of rhMSF 7,9m Hm on the 
migration was observed in comparison to the negative control (Bonferroni’s P<0.05). 
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3.4.4.2 The effect of anti MSF-aa antibody (TYN) 
Exposure of target cells (TYS and Endo 742) to antibody TYN1.2 did not 
affect the control or baseline migration and also had no stimulatory effect on cell 
migration when tested on its own at 1µg/ml and had no effect on the motogenic 
activity when added together with rhMSF-aa at 100pg/ml and 1ng/ml. (Fig. 3.12). 
This finding is similar to the VSI identification antibody result by Schor et al, (2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Effects of TYN antibody on the migration of TYS and Endo 742 cells in the 
transmembrane migration assay.   
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. No significant effects of TYN antibody 
on the migration of both cells were shown neither alone nor in combination with rhMSF-aa 
when compared to the negative control (Bonferroni’s P>0.05). 
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3.4.4.4 The effect of Lipocalin (NGAL)  
 
The stimulation of target cell migration by MSF is also abrogated by various 
soluble factors, including the MSF inhibitor NGAL (Jones et al., 2003). Recombinant 
human NGAL was tested in the transmembrane migration assay at a range of 
concentrations (1ng/ml, 10ng/ml, and 100ng/ml) in the presence or absence of a single 
concentration of rhMSF+aa and rhMSF-aa at (100pg/ml).  rhNGAL did not affect the 
baseline level of migration when tested on its own.  The chemotactic effect of 
100pg/ml rhMSF+aa on TYS (Fig. 3.13) and HSG cells (Fig. 3.33) was completely 
neutralised by rhNGAL at all above concentrations to the baseline levels, whereas the 
stimulation of TYS, Endo 742 and HSG migration  by 100pg/ml rhMSF-aa was not 
affected by NGAL at all the above concentrations (Fig. 3.14 & 3.15 & 3.16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Effects of different concentrations of rhNGAL on the migration of TYS cells in the 
transmembrane migration assay.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. No significant effect of rhNGAL on 
the migration was shown in comparison to the negative control. Whilst, addition of rhNGAL 
and rhMSF +aa reduced the migration of TYS cells to baseline levels (Bonferroni’s P<0.05). 
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Figure 3.14: Effects of different concentrations of rhNGAL on the motogenic activity of rhMSF-
aa on TYS cells in the transmembran migration assay.    
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF-aa as a positive control. NGAL alone did not affect the baseline 
migration. Addition of rhNGAL did not affect the motogenic activity of rhMSF-aa on the 
migration of TYS cells (Bonferroni’s test). 
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Figure 3.15: Effects of different concentrations of rhNGAL on the motogenic activity of rhMSF-
aa on Endo 742 cells in the transmembrane migration assay.   
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF-aa as a positive control. rhNGAL alone did not affect the 
baseline migration. Addition of NGAL did not affect the motogenic activity of rhMSF-aa on 
the migration of Endo 742 cells (Bonferroni’s P>0.05). 
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Figure 3.16: Effect of different concentrations of rhNGAL on the motogenic activity of rhMSF-aa 
on HSG cells in the transmembrane migration assay.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF-aa as a positive control. NGAL alone did not affect the baseline 
migration. Addition of rhNGAL did not affect the motogenic activity of rhMSF-aa on the 
migration of HSG cells (Bonferroni’s P>0.05). 
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3.4.4.5 The effect of Insulin-like growth factor binding protein-7 (IGFBP-7).   
Recent data obtained in the CMB laboratory (Schor, Jones and Florence 
unpublished; personal communication by Dr Ana Schor) has indicated that IGFBP-7 is 
an inhibitor of MSF+aa-stimulated fibroblast migration.  The effects of recombinant 
human rhBP-7 on the migration of TYS and Endo742 cells were tested. rhBP-7 was 
tested at concentrations of 10ng/ml, 100ng/ml and 1µg/ml, on its own and in 
combination with MSF+aa and MSF-aa at 100pg/ml. When both compounds were 
added together, the chemotactic effects of MSF on TYS (Fig. 3.17A and 3.18) and 
Endo 742 cells were completely neutralised by rhIGFBP at all above concentrations 
(Fig. 3.17B). 
 
 
 
 
Figure 3.17: Effects of different concentrations rhBP-7 on the migration of TYS (A) and Endo 
(742) cells (B) in the transmembrane migration assay.  
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. No significant effect of rhBP-7 on the 
migration was shown in comparison to the negative control (Bonferroni’s P<0.05). Addition 
of rhBP-7 inhibited the motogenic activity of rhMSF+aa on the migration of both cells to the 
baseline levels. 
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Figure 3.18: Effects of different concentrations of rhBP-7 on the migration of TYS cells in the 
transmembrane migration assay.   
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin)was used as a negative 
control and 100pg/ml rhMSF-aa as a positive control. No significant effect of rhBP-7 on the 
migration was shown in comparison to the negative control (Bonferroni’s P<0.05.). Addition 
of rhBP-7 inhibited the motogenic activity of rhMSF-aa on the migration of TYS cells to the 
baseline levels. 
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3.4.5 The production of MSF by tumour cell lines  
3.4.5.1. MSF identification by ICC 
The expression and the presence of MSF in the TYS and HSG cells were first 
examined by immunocytochemistry (ICC). TYS cells were plated either within 
collagen gels or on plastic tissue culture dishes as described in Chapter two (Materials 
and Methods). Briefly, cells were plated at high density (2 x 106 cells/2 ml gel) within 
and on the surface of 3D collagen gels. The gels were maintained under standard 
tissue culture conditions for 2 days and then pelleted by gentle centrifugation, 
formalin fixed and paraffin-embedded. Paraffin-embedded blocks were sectioned and 
stained with monoclonal MSF-specific identification antibodies mab 7.1 and mab 
TYN 1.2 as described in Chapter two. 
TYS cells were also plated onto plastic surfaces namely 35mm dishes, 
chamber slides and 24 well plates (Nunclon) at densities ranging from   5-9 x 104/cm2, 
2.2 x104 /cm2 and 2.0 x 105 /well respectively. The cells were fixed with 2% (v/v) 
formalin two days later. Then standard IHC procedures were used to stain with two 
antibodies mab7.1 and mabTYN 1.2 as outlined in Chapter two. 
Data presented in (Fig. 3.19A & B) shows that TYS cells stained positively 
with monoclonal MSF-specific identification antibodies mab 7.1 and mab TYN 1.2. 
The same results were obtained irrespective of whether the cells were embedded into 
collagen gels, paraffin-embedded and sectioned or stained directly on tissue culture 
dishes, (Fig 3.19G), negative controls, incubated with normal mouse IgG, showed no 
staining. Identical results were obtained using the salivary gland tumour cell line HSG 
(Fig 3.19F & H).  
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 Figure 3.19: Expreesion of MSF by TYS and HSG cells.   
Immunostaining with antibodies 7.1 (for total MSF) and TYN (for MSF-aa) (A) TYS cells on 
tissue culture dishes; positive staining with Ab 7.1. (B) Positive MSF-aa staining in TYS cells 
on tissue culture dishes by Ab TYN. (C) Positive total MSF staining in HSG cells on tissue 
culture dishes by Ab 7.1. (D) Positive MSF-aa staining in HSG cells on tissue culture dishes 
by Ab TYN. (E) Positive MSF staining in HSG cells embedded into collagen gels. (F, H) 
Negative control stained (HSG) and (G) in TYS with normal mouse IgG. Original 
photographs were taken at magnification x100 (A, B, C, D, G, H) or x 400 (E, F). 
F E 
A 
C D 
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3.4.5.2. MSF identification in cell lysates 
An affinity chromatography column was prepared by binding MSF-specific 
rabbit polyclonal antibody (RpVSI) to reactigel resin (Pierce CDI- Agarose). TYS 
cells and FSF44 fibroblasts were lysed; the cell lysates were then incubated with 
resin-bound MSF-specific antibody and the bound material was then eluted with 
20mM Tris HCl + NaCl 2M pH 7.4. The cell lysates and resultant fractions (unbound, 
bound) were tested to identify MSF by using indirect ELISA and Western blots. The 
affinity chromatography methods used are described in chapter two (Materials and 
Methods).    
 Indirect ELISA was performed using a specific anti-MSF antibody 
(Monoclonal VSI antibody).  Unknown samples were compared with a standard curve 
for rhMSF (0.78ng/ml - 50ng/ml) (Fig 3.20, Table 3.5) and the concentration of MSF 
present in the unknown samples was estimated by linear regression and Fit spline 
tests. The results indicated the presence of MSF in the whole TYS cell lysate and in 
the fraction of TYS lysate that was bound and then eluted from the column (E-TYS-
VSI), but not in the unbound fraction. On the other hand, MSF was not present in any 
of the fractions isolated from FSF44 fibroblasts. The concentration of total MSF in the 
whole TYS cell lysate was 11-13ng/ml (0.5 ml were obtained from 6 x 106 cells), the 
concentration in the eluted TYS sample was 4-6ng/ml (1ml obtained from 3ml whole 
cell lysate). The sensitivity of this assay was found to be 3ng/ml (Table 3.5). 
The Western blot results are shown in (Fig 3.21). It is apparent that TYS cells 
(eluted fraction and whole lysate) expressed MSF protein, corresponding to an 
approximate molecular weight of 70 kDa. 
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Figure 3.20: Indirect ELISA. rhMSF+aa standard curve.   
 
 
 
Table 3.5: Summary of MSF+aa standard curve ( concentration / OD 450-570nm) unknown 
fractions (sample / OD 450-570nm) estimated concentrations.   
 
rhMSF standard curve unknown fractions 
estimated concentration Concentrati
on in ng/ml 
OD sample OD 
Fit/spline 
test 
Linear 
regression 
50 4.1795±0.05 E-TYS (VSI) 
 
0.345±0.02 6.428ng/ml 4.403 ng/ml 
25 2.735±0.195 TYS 
(whole cell lysate) 
 
0.9355±0.006 12.86 ng/ml 11.015 
ng/ml 
12.5 0.8925±0.01 FSF44 fraction 
 
0.0205±0.03 0 0.686 ng/ml 
6.25 0.3415±0.06 Unbound fraction- 
TYS (VSI) 
0.069±0.003 1.4ng/ml 1.233 ng/ml 
3.125 0.152±0.008 
1.56 0.0785±0.02 
0.58 0.04± 0 
0 
 (PBS) blank 
0.048±0.048 
 
Sensitivity: 
SD of blank x 3= 0.048 x 3= 0.144 ~ 3 ng/ml Fit/spline 
                                                                ~ 2.08 ng/ml Linear         
regression  
         
E-TYS (VSI) = eluted fraction of TYS sample across VSI affinity column, FSF44 fraction= the 
fractions isolated from FSF44 fibroblasts 
 
The table shows the concentrations of Total MSF present in the whole TYS cells, 
unbound proteins, RpVSI column eluted fractions. 
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Figure 3.21: Identification of MSF in TYS cell lysates.   
Lane1(Magic marker), lane 2 correspond to the eluted fraction E-TYS (VSI), lane 3 positive 
control (500ng/ml MSF), lane 4 protein from whole TYS cell lysates and lane 5 the negative 
control ( FSF44 cell lysate).  
                   
                                                                                                                                                                                                                      
3.4.5.3 MSF identification by the motogenic activity present in conditioned 
medium 
 
3.4.5.3.1 Motogenic activity present in the CM of TYS and HSG cells  
 
In order to ascertain whether  the motogenic activity produced by oral tumour 
cell line TYS involved MSF, SF-CM from TYS cells (TYS-CM) was obtained and 
stored as described in Chapter two (Materials and Methods ).  
The potential motogenic activity of the TYS-CM was tested at various 
dilutions in the transmembrane migration assay using TYS as target cells. TYS- CM 
was diluted (1:2, 1:4, 1:10 and 1:20) in serum-free- MEM containing 2µg/ml BSA. 
The chamber was prepared and cells added as described in Chapter two. Cell 
migration was determined after a 5 hour incubation period. Experiments were 
repeated 3-4 times. Consistent stimulation of TYS migration was observed with TYS-
CM at a range of dilutions from neat to 1:10 (Fig 3.22). 
 
 
   M    E-TYS    +ve   L-TYS   L-FSF44 (-ve C) 
    1          2           3          4       5  
MW: 70KDa 
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Figure 3.22: Motogenic effects of TYS-CM on TYS cells.    
SF-MEM containing 2µg/ml BSA was used as a negative control (baseline) and. 100pg/ml 
rhMSF+aa as a positive control. Data showed that TYS-CM (neat-1:10) had significant 
stimulatory effect on the migration of TYS cells by comparison to the negative control 
(Bonferroni’s P<0.05). No significant effect was shown at 1:20 dilution. 
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HSG-CM: 
The chemotactic activity of conditioned medium from HSG cells in promoting 
their own migration was ascertained as described above for TYS cells. Using the 
transmembrane migration assay, HSG-CM was diluted (1:2) in serum-free- MEM 
containing 2µg/ml BSA. The chamber was prepared and cells added as described in 
Materials and Methods. Experiments were repeated 2 times. Consistent stimulation of 
HSG migration was observed with HSG-CM at both concentrations tested (neat and 
1:2 dilution) (Fig 3.23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: Motogenic effects of HSG-CM on HSG cells.  
SF-MEM containing 2µg/ml BSA was used as a negative control (baseline) and. 100pg/ml 
rhMSF+aa as a positive control.  Data showed that (HSG-CM) (neat and 1:2 dilution had a 
significant stimulatory effect on the migration of HSG cells by comparison to the negative 
control (Bonferroni’s P<0.05). 
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3.4.5.3.2 Inhibition of CM motogenic activity by MSF-function-neutralising antibodies 
(PEPQ) 
Identification of MSF bioactivity in TYS-CM was tested using the 
transmembrane assay and anti-MSF function-neutralising antibodies (PEPQ). 
Addition of antibody PEPQ at 1ng/ml, 10ng/ml, and 100ng/ml reduced the TYS-CM-
stimulated migration of TYS cells to or under the baseline levels. The antibody by 
itself had no effect on migration (Fig 3.24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 3.24: Neutralisation of TYS-CM motogenic activity by MSF-function neutralising Ab 
(PEPQ). Effect on target TYS cells 
TYS-CM (neat and 1:2 dilution) significantly stimulated the migration of TYS cells 
(Bonferroni’s P<0.05, relative to the baseline).  Addition of Ab PEPQ at different 
concentrations, together with TYS-CM reduced cell migration to baseline levels. Negative 
and positive controls were as in previous graphs.  
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3.4.5.3.3 Binding of CM motogenic activity to MSF identification antibodies (VSI) 
MSF was identified in the oral tumour cell line (TYS) conditioned medium 
(TYS-CM) using affinity chromatography as described for cell lysates (3.4.5.2) and in 
chapter two.  TYS-CM was incubated with the MSF-specific antibody (RpVSI) 
column and the bound material was eluted with 2M NaCl + 20mM Tris HCl pH 7.4. 
The resulting fractions are referred to as unbound (U-[TYS CM]-VSI) or bound and 
eluted (E-[TYS CM]-VSI).  The various fractions were tested for motogenic activity 
in the transmembrane assay, using TYS as a target cells (Figs. 3.25 & 3.26) The 
results, indicated that the motogenic activity of TYS-CM was due to the presence of 
MSF, as it was only recovered from the material specifically bound to RpVSI and 
then eluted from the column (E-[TYS CM]-VSI).  Significantly, no motogenic activity 
was detected in the unbound fraction (Fig 3.25 & 3.26).  Motogenic activity was 
recovered in the first eluted fraction (E1-[TYS CM]-VSI) (Fig 3.26). Fig 3.25 also 
shows the chemotactic effect of unfractionated TYS-CM, used as positive control, and 
the lack of activity of the elution buffer, used as an additional negative control.  
Identical results were obtained using fibroblasts (FSF44) and human endothelial cells 
(Endo 742) as a target cells (Fig. 3.27 & 3.32). 
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Figure 3.25: Identification of MSF in TYS-CM. Fractions were obtained by affinity 
chromatography using MSF-specific antibody (RpVSI) column.  
The original sample (unfractionated TYS-CM, diluted 1:2), unbound fraction (U-[TYS CM]-
VSI) and eluted fraction (E1-[TYS CM]-VSI) were tested for migration stimulating activity in 
the transmembrane assay. SF-MEM was used for the baseline and 100pg/ml rhMSF as a 
positive control. Data show that the motogenic activity present in TYS-CM was recovered in 
the material bound to RpVSI and then eluted.  The unbound material and the eluted buffer had 
no significant effect on the migration of TYS, by comparison to the negative control 
(Bonferroni’s P<0.05). 
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Figure 3.26: Identification of MSF in TYS-CM using affinity chromatography RpVSI column.  
The unbound CM and first three eluted samples (E1, E2, and E3) were tested for migration 
stimulating activity in the transmembrane migration assay. A baseline control level 
(containing 2µg ⁄ml bovine serum albumin) was used as a negative control was tested and 
100pg/ml rhMSF+aa used as a positive control.  Data show that the motogenic activity 
present in TYS-CM was recovered in the first eluted material bound to RpVSI. The unbound 
(U-[TYS CM]-VSI) and the second and third elutions had no significant effect on the 
migration of TYS cells (Bonferroni’s P<0.05).  
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Figure 3.27: Identification of MSF in TYS-CM, after fractionation by RpVSI affinity 
chromatography column (FSF44).   
Fractions were obtained by affinity chromatography as in Figure 3.24 The original sample 
(unfractionated TYS-CM, diluted 1:2), unbound fraction (U-[TYS CM]-VSI) and eluted 
fraction (E1-[TYS CM]-VSI) were tested for migration stimulating activity in the 
transmembrane assay. SF-MEM was used for the baseline and 100pg/ml rhMSF as a positive 
control. Data show that the motogenic activity present in TYS-CM was recovered in the 
material bound to RpVSI and then eluted.  The unbound material and the eluted buffer had no 
significant effect on the migration of FSF44, by comparison to the negative control 
(Bonferroni’s P<0.05.).  
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3.4.5.3.4 Binding of CM motogenic activity to MSF-aa identification antibodies 
(TYN) 
MSF-aa was identified in the oral tumour cell line conditioned medium (TYS-
CM) using affinity chromatography to an antibody (TYN) that recognises MSF-aa, 
not MSF+aa.  An affinity chromatography column was prepared by binding MSF-aa-
specific monoclonal antibody (TYN) to Reactigel resin (Pierce CDI- Agarose). The 
TYS-CM fraction previously bound to and eluted from the MSF-specific antibody 
(RpVSI) column (E-[TYS CM]-VSI) (see section 3.4.5.3.3, above)  was incubated 
with the MSF-aa antibody column and the bound material was eluted with 2M NaCl + 
20mM Tris HCl pH 7.4. The resulting factions are referred to as unbound (U-[E TYS 
VSI]-TYN) or bound and then eluted  (E-[E TYS VSI]-TYN) The various fractions 
were tested for motogenic activity in the transmembrane assay, using TYS, FSF44 
and HSG as a target cells (Figs. 3.28, 29 & 33)   Data show that the motogenic 
activity was present in both the unbound and the bound fractions, suggesting that the 
starting material (B-E-VSI) contains MSF+aa (which binds to Ab VSI, but not to Ab 
TYN) as well as MSF-aa (which binds to both Abs) (Fig 3.28 & 3.29). This 
hypothesis was tested by examining the effects of NGAL, BP7 and MSF-function- 
neutralising Ab (PEPQ) on the bioactivity of those fractions containing migration 
stimulating activity.  All these factors inhibit the motogenic activity of MSF+aa, 
whereas the motogenic activity of MSF-aa is inhibited by BP-7 and Ab PEPQ, but is 
not inhibited by NGAL.  
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Figure 3.28: Identification of MSF-aa in TYS-CM by TYN affinity chromatography (TYS cell). 
Fractions were obtained by affinity chromatography as in Figure 24 The original sample 
(unfractionated TYS-CM, diluted 1:2), unbound fraction (U-[E TYS VSI]-TYN) and eluted 
fraction (E-[E TYS VSI]-TYN) were tested for migration stimulating activity in the 
transmembrane assay. SF-MEM was used for the baseline and 100pg/ml rhMSF as a positive 
control. Data show that the motogenic activity present in TYS-CM was recovered in the 
material bound to TYN. A significant effect of eluted material sample (MSF-aa), unbound 
material ( expected MSF+aa) and orginal sample (1:2 TYS-CM) on the migration of TYS 
cells was shown in comparison to the negative control (Bonferroni’s P<0.05).  
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Figure 3.29: Identification of MSF-aa in TYS-CM by TYN affinity chromatography (FSF44).   
The fractions containing migration stimulating activity were analysed for the presence of 
MSF-aa using the transmembrane migration assay. A baseline control level was used as a 
negative control and 100pg/ml rhMSF+aa as a positive control. Data show that the motogenic 
activity present in eluted sample was recovered in the material bound to TYN. A significant 
effect of eluted material sample (MSF-aa), unbound fraction ( expected MSF+aa) and orginal 
sample (1:2 TYS-CM) on the migration of FSF44cells was shown in comparison to the 
negative control (Bonferroni’s P<0.05).  
 
Representative results shown in (Figs 3.30, 3.31, 3.32, 3.33 & 3.34) confirmed 
that TYS-CM, and the motogenic fractions obtained by affinity chromatography (E-
VSI and  E-TYN) stimulated the migration of target cells TYS and FSF  to the same 
extent as the positive control (rhMSF),  The motogenic activities of TYS-CM and E-
VSI were inhibited by NGAL, PEPQ and  BP-7. In contrast, the motogenic activity of 
B-E-TYN was inhibited by PEPQ and BP-7 but not by NGAL. The three inhibitory 
factors tested did not affect baseline migration when tested on their own. The same 
results were obtained using HSG and Endo 742 as target cells.  
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Figure 3.30: Identification of MSF in TYS-CM by RpVSI affinity chromatography (TYS cells).  
The fractions containing migration stimulating activity was analysed for the presence of MSF 
using the transmembrane migration assay and an anti-MSF function-neutralising (PEPQ) 
antibody and rhNGAL. A baseline control level was used as a negative control and 100pg/ml 
rhMSF+aa as a positive control. Addition of antibody (PEPQ) and rhNGAL reduced the 
migration of TYS cells to baseline levels. Data show that the motogenic activity present in the 
CM (MSF) is recovered in the material bound to RpVSI.  
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 Figure 3.31: Effects of eBP-7 on the motogenic activity of TYS-CM after characterisation by 
RpVSI affinity chromatography column (TYS cells). 
A baseline SF-MEM (containing 2µg ⁄ml bovine serum albumin) was used as a negative 
control and 100pg/ml rhMSF+aa as a positive control. The motogenic activity of the eluted 
sample (MSF) was abrogated by the presence of eBP-7 in the migration assay. A significant 
effect of eluted material sample (MSF) on the migration of TYS cells was shown in 
comparison to the negative control (Bonferroni’s P<0.05).  
 
 
 
 
 
 
 
 
TYS cell line
ba
se
lin
e
eB
P
-7
 1
:1
00
0
eB
P
-7
 1
:1
00
0 
+(
E
-[
TY
S
-C
M
]-V
S
I)
(E
-[
TY
S
-C
M
]-V
S
I)
+v
e 
co
nt
ro
l
0
10
20
30
40
50
60
70
80
90
C
e
ll
s
 m
ig
ra
te
d
 p
e
r 
fi
e
ld
(m
e
a
n
±± ±±
S
D
)
  
125 
 
 
 
 
 
Figure 3.32: Identification of MSF as the induced motogen, after characterisation by RpVSI 
affinity chromatography column (Endo 742 cells).   
The fractions containing migration stimulating activity were analysed for the presence of 
MSF using the migration assay and specific MSF function-neutralising antibody (PEPQ). A 
baseline control level was used as a negative control and 100pg/ml rhMSF+aa as a positive 
control. Addition of Ab PEPQ, together with the eluted sample (MSF), reduced the Endo 742 
cell migration to the baseline levels. A significant effect of eluted material sample (MSF) on 
the migration of Endo 742 cells was shown in comparison to the negative control 
(Bonferroni’s P<0.05).  
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Figure 3.33: Identification of MSF-aa in TYS-CM by TYN affinity chromatography (HSG cells). 
 The fractions containing migration stimulating activity were analysed for the presence of 
MSF-aa using the transmembrane migration assay and rhNGAL. A baseline control level was 
used as negative control and 100pg/ml rhMSF+aa as positive control. Addition of rhNGAL to 
the eluted material (MSF-aa) did not affect the migration of HSG cells, whilst a combination 
of rhNGAL and MSF+aa reduced the migration to the baseline level. This relates to 
specificity alone to rhMSF+aa leaving MSF-aa to show its bioactivity in the TYS-CM. Data 
show that the motogenic activity present in the sample eluted from the RpVSI column is 
recovered in the material bound to TYN affinity column. 
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Figure 3.34: Identification of MSF-aa in TYS-CM through TYN affinity chromatography column 
(FSF44 cells).   
The fractions containing migration stimulating activity were analysed for the presence of 
MSF-aa using the transmembrane migration assay and NGAL and eBP-7. A baseline control 
level was used as a negative control and 100pg/ml rhMSF-aa as a positive control. Addition 
of NGAL did not affect on the migration of HSG cells. Whilst, the motogenic activity of 
eluted bound-TYN (MSF-aa) was abrogated by eBP-7. Data show that the motogenic activity 
present in the sample eluted from the RpVSI column is recovered in the material bound to 
TYN. 
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3.4.6 Possible mechanism of action of the inhibitors of MSF 
3.4.6.1 Binding of rhNGAL to MSF 
Affinity chromatography techniques as outlined in chapter two (Materials and 
Methods) and above sections (3.4.5.3.3) were used to investigate whether rhNGAL 
binds to MSF or there is no direct association. For these experiments, three affinity 
columns were prepared by binding rhMSF+aa, rhMSF-aa and BSA to Reactigel resin 
(Pierce CDI- Agarose).  rhNGAL (2µg/ml  diluted in 20mM Tris HCL pH 7.4) was 
passed through each of the  columns  and the bound material was eluted with 2M 
NaCl + 20mM Tris HCl pH 7.4.  This process was repeated 3 times; the eluted 
samples were pooled, dialysed against distilled water (dH2O) and then concentrated 
by freeze drying and redissolved in 0.5ml of PBS. The resultant bound and then eluted 
fractions are referred to as E-[NGAL]-MSF+aa, E-[NGAL]-MSF-aa and E-[NGAL]-
BSA, indicating the affinity column used.  These fractions were assayed for the 
presence of NGAL by indirect MSD ELISA using a specific anti-NGAL antibody 
(polyclonal antibody AF1757), as described in Chapter two (Materials and Methods).  
The unknown samples were compared with a standard curve for rhNGAL (0.4ng/ml, 
2ng/ml, 10ng/ml and 50ng/ml) and their concentrations estimated by linear regression 
test (Fig. 3.34). Data in (Table 3.6) shows that NGAL was detected in the sample 
eluted from the MSF+aa column, but not in the samples eluted from the MSF-aa or 
the BSA columns. Therefore the results indicate that NGAL binds to MSF+aa and not 
to MSF-aa.  The same results were obtained in three independent experiments.  
 
Figure 3.35: Indirect MSD ELISA standard curve of rhNGAL.   
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 Table 3.6: MSD ELISA legend explains Ab and general methods 
             Concentration of NGAL in samples eluted from different affinity chromatography columns.   
The concentration was estimated by linear regression. 
       
Sample  Affinity 
column 
OD (620nm ) 
Blank 
substracted 
estimated 
concentration 
Comments  
E-[NGAL]-
MSF-aa 
MSF-aa  - 437.5 0 undetectable 
E-[NGAL]-
MSF+aa 
MSF+aa  1381 / 1038 
 
1.6-2.0ng/ml 
detectable 
E-[NGAL]-
BSA 
BSA - 515 
 
0 
undetectable 
 
 
The fraction containing rhNGAL according to the ELISA results (E-[NGAL]-
MSF+aa) was tested for NGAL bioactivity in the transmembrane assay using HSG 
and TYS as target cells. E-[NGAL]-MSF+aa did not affect the control or baseline 
migration when tested alone.  However, in combination with rhMSF+aa (at 100pg/ml 
and 1ng/ml) it effectively inhibited MSF+aa-stimulated migration to baseline levels 
(Fig. 3.36 & 3.37).  In contrast, it had no effect in combination with rhMSF-aa (Fig. 
3.38).   
 
 
 
 
 
  
130 
 
 
Figure 3.36: Effect of NGAL fraction eluted from MSF+aa column [E-(rhNGAL)-MSF+aa] on 
HSG target cells.  
Motogenic activity was tested in the transmembrane assay using SF-MEM as a negative 
control (baseline) and 100pg/ml rhMSF+aa as a positive control.   [E-(rhNGAL)-MSF+aa] 
did not affect baseline migration, but it inhibited the migration stmulated by MSF+aa 
(100pg/ml & 1ng/ml) to baseline levels. There was no significant effect of the eluted sample 
(NGAL) on the migration of the HSG cells when compared to the negative control 
(Bonferroni’s test). 
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Figure 3.37: Effect of NGAL fraction eluted from MSF+aa column [E-(rhNGAL)-MSF+aa] on 
TYS target cells.   
Motogenic activity was tested in the transmembrane assay using SF-MEM as a negative 
control (baseline) and 100pg/ml rhMSF+aa as a positive control.   [E-(rhNGAL)-MSF+aa] 
did not affect baseline migration, but it inhibited the migration stmulated by MSF+aa 
(100pg/ml & 1ng/ml) to baseline levels. There was no significant effect of the eluted sample 
(NGAL) on the migration of the TYS cells when compared to the negative control 
(Bonferroni’s test). 
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Figure 3.38: Effect of NGAL fraction eluted from MSF+aa column [E-(rhNGAL)-MSF+aa] on 
HSG target cells.   
Motogenic activity was tested in the transmembrane assay using SF-MEM as a negative 
control (baseline) and 100pg/ml rhMSF-aa as a positive control.   [E-(rhNGAL)-MSF+aa] did 
not affect baseline migration. There was no significant effect of the eluted NGAL on the 
migration of HSG cells when compared to the negative control (Bonferroni’s test).  
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3.4.6.2 Binding of BP-7 to MSF 
Following the same protocol as described for NGAL (3.4.6.1) I examined the 
possible binding of BP-7 to rhMSF+aa, rhMSF-aa and BSA by affinity 
chromatography. BP-7 was obtained from two different sources: (a) rhIGFBP-7 
purchased from (R&D system) and (b) IGFBP7 purified from Endo742 CM by DEAE 
chromatography by Dr Sarah Jones This will be referred to as e-BP-7. (2µg/ml) rhBP-
7 was incubated with the columns and eluted with 2M NaCl + 20mM Tris HCl pH 
7.4. The resultant fractions were assayed for BP-7 concentration by indirect MSD 
ELISA using specific anti-BP-7 antibody (goat antibody AF 1334) (Fig. 3.39), as 
described in Materials and Methods Chapter two. Data presented in (Table 3.7) is 
representative of 3 separate experiments and indicate a direct association between BP-
7 and both MSF isoforms. These results indicate a possible mechanism whereby BP-7 
neutralises MSF bioactivity. 
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Figure 3.39: Indirect MSD ELISA standard curve of rhBP-7 and e-BP-7.    
            
Table 3.7: MSD ELISA legend explains Ab and general methods.   
             Concentration of BP-7 in samples eluted from different affinity chromatography columns.   
The concentration was estimated by linear regression 
       
OD (620nm  ) 
Blank subtracted 
Sample  Affinity 
column 
rhBP-7 e-BP-7 
estimated 
concentration 
Comments  
E-[BP-7]-MSF-aa MSF-aa  29820 
 
112962 
 
Less than  40ng/ml detectable 
E-[BP-7]-MSF+aa MSF+aa  6761 
 
103535.5 
 
More than 10ng/ml 
 
detectable 
E-[BP-7]-BSA BSA -187.5 
 
-200 0 
undetectable 
 
The transmembrane assay on TYS cells was used to identify BP-7 bioactivity 
in the fractions eluted from MSF+aa affinity column chromatography [E-(rhBP-7)-
MSF+aa] and [E-(e-BP-7)-MSF+aa].These fractions did not affect the control or 
baseline migration when tested on their own, but in combination with rhMSF+aa at 
100pg/ml and 1ng/ml it effectively inhibited cell (TYS) migration to baseline levels 
(Fig 3.40 & 3.41). 
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Figure 3.40: Effect of BP-7 fraction eluted from MSF+aa column [E-(e-BP-7)-MSF+aa] on TYS 
target cells. 
Motogenic activity was tested in the transmembrane assay using SF-MEM as a negative 
control (baseline) and 100pg/ml rhMSF-aa as a positive control. Addition of [E-(e-BP-7)-
MSF+aa] recovered in the material bound to MSF+aa affinity column reduced the migration 
of TYS cells to baseline levels. There was no significant effect of [E-(e-BP7)-MSF+aa] on the 
migration of TYS cells when compared to the negative control (Bonferroni’s test).  
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Figure 3.41: Effect of BP-7 fraction eluted from MSF+aa column [E-(rhBP-7)-MSF+aa] on TYS 
target cells..   
Motogenic activity was tested in the transmembrane assay using SF-MEM as a negative 
control (baseline) and 100pg/ml rhMSF-aa as a positive control. Addition of [E-(rhBP-7)-
MSF+aa] recovered in the material bound to MSF+aa affinity column reduced the migration 
of TYS cells to baseline levels. There was no significant effect of [E-(rhBP7)-MSF+aa] on the 
migration of TYS cells when compared to the negative control (Bonferroni’s test).  
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3.5 Discussion 
MSF is a potent motogenic factor, able to stimulate the migration of 
fibroblasts, epithelial and endothelial cells. MSF also stimulates HA synthesis and 
angiogenesis (Schor et al., 1988 and Grey et al., 1989). Cell migration is most 
commonly studied using the transmembrane or Boyden Chamber assay. By using this 
assay, the chemotactic activity of rhMSF and its mutants have been examined on 
different human cell types, namely TYS (oral tumour cell line) HSG (salivary tumour 
cell line) Endo 742 (microvascular endothelial cells) and FSF44  (foreskin fibroblast). 
The aims of this study were to determine the expression of MSF by oral 
tumour cell lines, the effects of MSF on the different types of cells, the amino acid 
motifs which are responsible for MSF bioactivity and the modulation of MSF 
bioactivity by antibodies and other proteins.  In this study previous results are 
confirmed and novel data is presented, as discussed under the following headings: 
 
3.5.1 Identification of MSF isoforms 
 
Two MSF isoforms have been cloned. These differ by a 15 amino acid 
deletion in the first type II fibronectin structural module and are referred to as 
MSF+aa and MSF-aa (see chapter one, Introduction).  The general term MSF (or total 
MSF) will be used to refer to both isoforms.   In this thesis I demonstrate that  
(a) VSI antibodies (to C-terminus decapeptide VSIPPRNLGY) recognise both isofrms 
MSF+aa and MSF-aa. 
(b) TYN antibodies (TYNDRTDSTTSNY, an amino acid sequence that is present in 
MSF-aa only) recognise MSF-aa but not and MSF+aa. 
(c) Both isoforms of MSF are produced by TYS and HSG cell lines  
(d) MSF+aa and MSF-aa differ in their interaction with NGAL 
(e) The bioactive motifs of MSF are different for fibroblasts, endothelial cells and oral 
or salivary tumour cells 
 
3.5.2 Production of MSF by tumour cell lines 
 
Conditioned medium from oral tumour cell line (TYS) was collected. This was 
tested for migration stimulating activity, which gave a positive result. The CM was 
then tested for MSF by affinity chromatography to investigate if a soluble factor 
secreted into the medium stimulates migration. Testing of the eluted fractions on their 
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own or by both RpVSI and TYN affinity columns revealed the presence of MSF and 
the bioactivity of this conditioned medium in promoting the migration of oral tumour 
cell lines and other cell types was ascertained using the transmembrane migration 
assay.  The MSF found was further characterised by its sensitivity to the MSF 
inhibitors NGAL and both human recombinant rhBP-7 and endothelial purified (e-
BP-7) and to the functional neutralising antibodies PEPQ. The results indicated that 
baseline migration showed more than two fold increases in cell migration with CM 
alone or in the eluted fractions from RpVSI and TYN affinity columns, also with 
different concentrations of rhMSF+aa, but in combination with MSF inhibitors and 
functional neutralising antibodies PEPQ effectively inhibited the cells migrated (HSG, 
TYS, Endo and FSF44) from values comparable to those of positive controls to 
baseline levels. These result indicated that conditioned medium from TYS contained 
both types of MSF isoforms, which is confirmed by the inhibitory effect of rhNGAL 
to the MSF+aa rather than to MSF-aa, on different target cells.  
The presence of MSF in the bioactive CM of TYS cells was confirmed by the 
specific abrogation of motogenic activity by the MSF-specific function-neutralising 
antibody and by affinity chromatography with MSF-specific identification antibodies. 
 
3.5.3 Effects of MSF on different target cells  
The motogenic activity of MSF was investigated, because cell migration is an 
important feature of tumour progression. Our results indicated that rhMSF+aa and 
rhMSF-aa stimulate the migration of different cell types oral tumour cell lines (TYS), 
salivary tumour cell line (HSG), endothelial cells (Endo 742), and foreskin fibroblast 
cell line (FSF44) (p<0.05). The profile of cell migration at different concentrations 
produced a bell shaped dose-response curve in TYS, Endo 742 and FSF44 
demonstrating that for initiation of cell migration a threshold concentration is required 
and at higher concentrations a negative feed back mechanism occurs. This result is 
similar to the previous observations (Ellis et al., 2010). On the other hand, in the case 
of HSG cells all concentrations of MSF tested (1pg/ml-1µg/ml)) exhibited significant 
motogenic activity by comparison to the negative control or baseline, with a plateau 
reached at 10 ng/ml. Schor et al., (1999) have previously shown that IGD motif 
stimulated fibroblast cell migration and it depends on both integrin αvβ3 functionality 
and tyrosine phosphorylation of FAK. Integrin clustering and/or downstream 
signalling may be the possible reasons of reduced migration at higher concentrations. 
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3.5.4 Bioactive motifs of MSF 
 
In order to investigate the possible active amino acid motif for these cells 
migration stimulation, rhMSF +aa mutants have been used as followed; MSF+3,5m 
(No IGD 3, 5); MSF+7,9m (No IGD7, 9); MSF QUAD mutant (No IGD motif in its 
structure i.e. all the four IGD motif has been mutated to DGI) and MSF+HEEGH 
mutant (No FEEGF motif) and MSF+QmHm (No IGD and FEEGF).  Mutation of the 
IGD motifs separately or all together inhibited the migration stimulating activity of 
MSF to the baseline level in both TYS and HSG cell lines. Mutation of MSF HEEGH 
motif and mutation of both the IGD and HEEGH motif also show similar results to 
the MSF QUAD mutant, which provide evidence that both IGD and HEEGH motifs 
are required for the stimulation of migration of the oral tumour cell lines (TYS) and 
salivary gland tumour cell lines (HSG). In contrast, mutation of IGD either separately 
or all together, and mutation of HEEGH motif alone had no effect on the migration 
stimulating activity of MSF on the endothelial cells (Endo 742). Whilst mutation of 
both MSF QUAD and HEEGH motifs together inhibited the migration of endothelial 
cells to the baseline level, this indicated that both the HEEGH and IGD motifs in MSF 
must be mutated in order to abolish the motogenic response of these cells. 
MSF also may affect cell migration through its fibronectin proteinase activity 
by directly digesting ECM molecules or by processing cell surface molecules. Houard 
et al, (2005) shown that Fn-proteinase activity was totally abolished when 2 histidine 
residue from HEEGH motif were replaced by phenylalanine (FEEGF). This type of 
mutation is known to eliminate the catalytic activity of zinc-dependent 
metalloenzymes (Wang and Cooper, 1993).  Houard et al, (2005) also suggested that 
MSF migratory activity was dependent on Fn-proteinase activity when they observed 
65% inhibition of breast adenocarcinoma cells (MCF-7) migration after mutating the 
HEEGH motif.  Our data presented here indicated that five bioactive motifs (four IGD 
and HEEGH) are required for migration stimulating activity of MSF.  
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3.5.5 Modulation of MSF bioactivity by antibodies and other proteins 
 
Data presented in this study indicate that both MSF isoforms display the same 
spectrum of potent motogenic bioactivities and these are effectively inhibited by 
PEPQ function-neutralising antibodies, this is in agreement with the result (regarding 
MSF+aa) of Schor et al., (2003) on fibroblast cells. MSF+aa and MSF-aa differ in 
their functional interaction with NGAL (neutrophil gelatinase-associated lipocalin) an 
inhibitor of MSF present in serum and certain tumours (Jones et al., 2007):  MSF+aa 
is inhibited by NGAL, whereas MSF-aa is not. Both isoforms contain the same MSF-
specific 10 amino sequence and IGD functional domains; consequently they are 
equally active in the absence of NGAL. In addition to that our results suggest a 
mechanism of action by a direct association between NGAL and MSF+aa, whilst 
there is no binding with MSF-aa. However, the direct association between NGAL and 
MSF+aa, reflect that the possible mechanism of action whereby MSF+aa is inhibited 
by NGAL, whereas MSF-aa is not. In contrast,  Jones et al, (2007) reported that no 
evident of binding between MSF and NGAL in the keratinocyte conditioned media, 
they suggested that NGAL may block an MSF activated signal transduction pathway 
or may be active indirectly by inducing the expression of an intermediate inhibitory 
factor.  
This is the first report of the inhibitory effect of BP-7 on both MSF isoforms 
motogenic activities. In addition to that, these data indicate a direct association between BP-7 
and both MSF isoforms, which may reflect the mechanism of action whereby BP-7 neutralises 
MSF bioactivity. Our data indicate a novel function of BP-7 and its possible role in inhibition 
of MSF bioactivity. 
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3.6 Conclusions  
 
- Tumour cell lines derived from salivary gland tumours or from oral tumours secreted 
bioactive MSF in culture. MSF stimulated the migration of these tumour cells. In vitro 
mutagenesis indicated that five bioactive motifs are required for MSF bioactivity.   
 
 
3.7 Further studies 
- Using other types of tissue target cells. 
- Investigate the role of other soluble molecules on the MSF bioactivity. 
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4. Chapter four: MSF Expression in Oral squamous cell 
carcinoma  
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4.1. Introduction 
Oral cancer is the most common type of cancer in developing countries, where 
it constitutes a major health problem and commonly leads to death. More than 
750,000 patients worldwide suffer from oral cancer (Parkin et al., 2005). 
In the United Kingdom there are approximately 5400 new cases of oral cancer 
each year and approximately 1800 deaths (Cancer Research UK, 2007). Scotland has 
the highest occurrence of oral cancers in the UK; the incidence is still increasing. 
Survival rates of oral cancer are still very poor with 42% for men and 48% for women 
five years survival reported, and these have not improved in the last few decades 
(Cancer Research UK, 2007) despite advances in the therapeutic interventions and our 
increased understanding of the disease. The results of standard therapy, including 
surgery and/or irradiation, have remained at a disappointingly stable level for many 
years despite significant development in the multimodal treatment of the disease. 
Furthermore, the current cornerstones of therapeutic decision-making, namely the 
tumour-node-metastasis (TNM) system supplemented with conventional 
histopathological tumour grading, have proven to be imperfect prognostic indicators. 
There is therefore a continuing need to evaluate potential new biomarkers that may be 
useful in diagnosis and prognosis.  The most common type of oral cancer is squamous 
cell carcinoma. For further background information see Chapter one. 
4.2. Aims 
 
The aims of this study were to determine (i) the expression of total MSF and 
MSF-aa in oral squamous cell carcinoma (OSCC) and adjacent non-tumour tissues; 
and (ii) evaluate the potential usefulness of MSF expression in the diagnosis and 
prognosis of OSCC. 
 
4.3. Materials and Methods 
4.3.1 Specimens: OSCC study 
A total of 64 paraffin-embedded archival oral SCC specimens were obtained 
from the Domagk-Institute of Pathology, University Clinic of Munster, Germany. The 
available details of the patients are presented in Table 4.1. Adjacent non-tumour 
tissue, (also stained and evaluated in this study), included regions of histologically 
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normal salivary gland (NSG, in 31/64 specimens) and epithelial hyperplasia (Hp, in 
37/64specimens). 
 
4.3.2 Immunohistochemistry: 
  Standard immunohistochemical procedures were used to stain paraffin 
embedded OSCC with two antibodies: mab7.1 (Schor et al., 2003) and mabTYN 1.2, 
as outlined in chapter two (Materials and Methods). Mab7.1 recognises MSF+aa and 
MSF-aa (total MSF) whereas mabTYN 1.2 only recognises MSF-aa (Chapter three). 
 
4.3.3 Assessment of MSF expression 
Expression of MSF was assessed as described in Chapter two (Materials and 
Methods).  MSF overall grade was determined separately in areas of the invasive 
tumour front (ITF) and in the keratin pearl areas in the centre of the tumours (Kp), as 
negative (grade 0), weak (grade 1), moderate (grade 2), or strong (grade 3) positive.  
The % of area stained, final score, stroma and adjacent non-tumour tissues were 
assessed in the whole section. 
 
4.3.4 Statistical analyses  
The two-tailed Mann–Whitney tests were used to determine the difference in 
MSF isoform expression. Correlation between MSF at the ITF and other 
clinicopathologic parameters were studied by Fisher Exact and chi-squared tests. 
Survival probabilities were estimated by the Kaplan-Meier method and survival 
curves were compared with the log-rank test. P value lesser than or equal to 0.05 was 
considered as statistically significant. 
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 Table 4.1: Summary of clinical details of OSCC patients  
 
Parameters Classification No of patients 
for Ab 7.1 
No of patients 
for Ab TYN 
Grade 1 7 6 
Grade 2 51 40 
Grade 3 6 4 
Pathological grade 
 
All N=64 N=50 
1= Male 47 42 
2=Female 8 8 
Sex  
All N=55 N=50 
Range 
Mean 
Median 
33-80 
53.9 
54 
33-80 
54.5 
54 
Age  (years) 
All N=55 N=50 
0 =Alive 22 20 
1 =Dead 33 30 
Censor  
All N=55 N=50 
 
 
4.4. Results 
 
4.4.1 Immunolocalisation of total MSF and MSF-aa in oral squamous cell 
carcinoma (OSCC) and adjacent non-tumour tissue 
Duplicate sections of OSCC were stained with antibodies mab7.1 (for total MSF, 
referred to also as MSF) and TYN (for MSF-aa). Both antibodies stained most of the 
tumours examined, with heterogeneous staining observed in the carcinoma and 
associated stromal tissue, including fibroblasts, blood vessels and inflammatory cells. 
Histologically normal salivary gland (NSG) and epithelial hyperplasia (Hp) were 
present adjacent to some of the tumours. Representative examples of total MSF and 
MSF-aa expression by OSCC and associated stromal cells are presented in (Fig 4.1, 
4.2D and Fig 4.3A, B, C, F).  Staining in the carcinoma cells was generally stronger in 
the keratin pearl central areas (Kp) than in the invasive tumour front (ITF). Positively 
stained acinar cells were rarely present in NSG, whilst most of salivary ducts were 
positively stained (Fig 4.2C and Fig 4.3E). In the adjacent epithelial hyperplasia, 
positively stained suprabasal cells (Hpsb) were detected in some sections, whilst no 
staining was found in the basal cell layers (Hpb) (Fig 4.2A and Fig 4.3D). Sections 
incubated with normal mouse IgG, instead of MSF antibody (negative controls), 
showed no staining (Fig 4.2E and Fig 4.3G). 
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4.4.2 Differences in total MSF expression among tissues 
MSF expression was first graded as negative (0), weak positive (1), moderate 
(2) or strong positive (3) by three independent observers.   Keratin pearl (Kp) and 
invasive tumour front (ITF) areas were evaluated separately. The semi-quantitative 
results obtained are summarised in Table 4.2. Results presented in Fig 4.4A and 4.4B 
demonstrate a significant difference in MSF overall grade between Kp and ITF, 
indicating that overall MSF expression was significantly higher in Kp than in ITF 
(P<0.0001, 0.0029). 
The overall MSF grade gives a general assessment of the staining in OSCC 
tissue sections, including epithelial and stromal compartments. More detailed 
observations of the tumour-associated stroma revealed that MSF was heterogeneously 
distributed among stromal cells, fibroblasts, blood vessels and inflammatory cells, 
with some amount of staining being detected in most specimens. The percentage of 
specimens that showed positive fibroblasts, blood vessels and inflammatory cells 
represented 94%, 94% and 78% of the total, respectively (Fig 4.5A).    
MSF was also detected in certain non-tumour structures adjacent to OSCC 
(Fig 4.6A). Overall MSF grade of the NSG reflected mainly the staining present in the 
acinar cells. More detailed observation of the different NSG cell types indicated that 
mucous and serous acinar cells were indeed predominantly negative for MSF, 
whereas ductal cells commonly exhibited a diffuse positivity, this being stronger in 
the luminal cells compared with basal and myoepithelial cells. Of 31 NSG specimens 
examined, 18, 23 and 28 (58%, 74% and 90%) showed positive intercalated, striated 
and excretory salivary ducts, respectively. Only 3 specimen (5%) showed MSF 
staining in acinar (serous) cells and 16 (52%) in myoepithelial cells. Further 
information on NSG is presented in chapter five. 
In the epithelial hyperplasia, staining was restricted to the suprabasal cell 
layers (Hpsb) (Fig 4.6A).  The percentage of specimens that showed positive staining 
was similar when comparing Hpsb, Kp and ITF assessments; all these three being 
significantly higher than for Hpb or NSG (P< 0.0002–0.0001).  
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Table 4.2: Tissues compared and P value (for number and %) for Ab 7.1   
Tissues 
compared 
MSF grades compared (Ab 7.1) 
 for actual number of specimens (n) for % of 
specimens 
 0/1  v  2/3 (a) 0  v  1/2/3 (a) 0  v  1  v  2/3 (b) 0/1  v  2/3 (a) 
KP v ITF <0.0001 <0.0029 < 0.0001 < 0.0001 
 
KP v NSG <0.0001 <0.0001 < 0.0001 < 0.0001 
 
ITF v NSG <0.0024 <0.0001 < 0.0001 < 0.0001 
 
KP v Hpsb <0.0001 <0.366 < 0.0001 < 0.0001 
 
ITF v Hpsb <0.0959 <0.0877 <0.0785 <0.0155 
 
Hpsb v NSG <0.0001 <0.0001 < 0.0001 < 0.0001 
 
KP v Hpb <0.0001 <0.0001 < 0.0001 < 0.0001 
 
ITF v Hpb <0.0001 <0.0001 < 0.0001 < 0.0001 
 
Hpb v NSG <0.204 <0.089 < 0.153 < 0.028 
 
Hpb v Hpsb <0.0001 <0.0001 < 0.0001 < 0.0001 
 
(a)Fisher's exact test; (b) Chi-squared test, Hpsb= hyperplasia in suprabasal layers, 
Hpb=hyperplasia in basal layer, NSG= normal salivary gland 
The percentage of MSF-positive specimens may be represented as NSG=Hpb< 
Hpsb=ITF<K.   
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Figure 4.1: Immunolocalisation of total MSF in OSCC.  
(A, B) Total MAF expression in Kp (A) and ITF (B). (C, D) showing total MSF staining in 
the tumour cells, associated blood vessels and fibroblasts. Original photographs were taken at 
magnification x100 (A, B, D) or x 400 (C). 
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Figure 4.2: Immunolocalisation of total MSF in OSCC.   
 (A) Positive total MSF staining in the Hpsb and negative staining in Hpb. (B) Negative total 
MSF staining in OSCC. (C) Negative total MSF staining in histologically normal salivary 
gland (NSG) (mucous cells) adjacent to positive OSCC. (D) Positive inflammatory cells and 
carcinoma cells. (E) Showed no staining with normal mouse IgG, instead of MSF antibody 
(negative control). Original photographs were taken at magnification x 100. 
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Figure 4.3: Immunolocalisation of MSF-aa in OSCC.   
(A, B) MSF-aa expression in Kp (A) and ITF (B). (C) Showing MSF-aa staining in the 
tumour cells and associated blood vessels and fibroblasts. (D) Positive MSF-aa staining in the 
Hpsb and negative staining in Hpb. (E) Negative MSF-aa staining in histologically normal 
salivary gland (NSG) (mucous cells) and positive ductal epithelial cells adjacent to positive 
OSCC. (F) Positive inflammatory cells. (G) Showed no staining with normal mouse IgG, 
instead of MSF antibody (negative control). Original photographs were taken at magnification 
x 100 (A, B, D, E, G) or x 400 (C, F). 
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Figure 4.4: MSF overall grade in the OSCC.   
The tissues were stained with 7.1 and TYN antibodies, as indicated. MSF expression in the 
epithelium of keratin pearl (Kp) (n= 64, 50) and invasive tumour front (ITF) (n=64, 50) for 
7.1 Ab & TYN Ab respectively was evaluated and compared. Significant differences between 
Kp and ITF occurred in terms of the MSF overall grade.  (Fisher’s Exact Test).  
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Figure 4.5: Stromal MSF (Both isoforms) expression in the OSCC.  
 Results show the percentage of specimens graded positively stained by antibody 7.1 (A) and 
TYN (B) for different cellular compartments, including fibroblasts (Fb); blood vessels (Bv) 
and inflammatory cells (Ic).  The difference between the two antibodies (C) was analysed by 
Fisher’s exact test for the actual number of specimens assessed (n) and for the percentage of 
specimens (%, as shown in the graph). The respective p values for (n) and (%) were: 0.001 
and 0.0002 for Fb; 0.005 and 0.001 for Bv; and there was no significant difference between 
the two antibodies regarding Ic.  
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4.4.3 Differences in MSF-aa expression among tissues 
Specimens stained with mabTYN (for MSF-aa) were graded according to 
MSF overall grade, as for mab7.1.  The assessment included 50 OSCC specimens. 
Adjacent NSG was present in 26/50 and Hp in 31/50 of these specimens.  
The results are summarised in Table 4.3. MSF-aa was detected in Kp in 98% 
(49/50) specimens and in ITF in 84% (42/50) specimens (Fig 4.4C, D).  In the 
adjacent tissue, MSF-aa was found in the NSG in 8% cases (2/26) (serous cells), in 
Hpsb in 97% cases (30/31) and in Hpb in 0% cases (0/31).   In the stromal 
compartment of OSCC (Fig  4.5B),  positive stained specimens represented 80%, 84% 
and 78% of total specimens examined for  fibroblasts, blood vessels and inflammatory 
cells, respectively. 
 
Table 4.3: Tissues compared and P value (for number and %) for Ab TYN   
 
Tissues 
compared 
MSF grades compared 
N= 50  for actual number of specimens(n) for % of 
specimens 
 0/1  v  2/3 (a) 0  v  1/2/3 (a) 0  v  1  v  2/3 (b) 0/1  v  2/3 (a) 
KP v ITF <0.0001 0.030 < 0.0001 < 0.0001 
 
KP v NSG < 0.0001 < 0.0001 
 
< 0.0001 < 0.0001 
ITF v NSG < 0.0001 < 0.0001 
 
< 0.0001 < 0.0001 
KP v Hpsb <0.0001 
 
Ns 1 0.0001 < 0.0001 
ITF v Hpsb <0.040 
 
0.142 0.0053 <0.0003 
Hpsb v NSG 0.0172 
 
<0.0001 < 0.0001 < 0.0001 
KP v Hpb <0.0001 <0.0001 < 0.0001 
 
< 0.0001 
ITF v Hpb <0.0001 <0.0001 < 0.0001 
 
< 0.0001 
Hpb v NSG <0.456 <0.203 0.290 
 
< 0.121 
Hpb v Hpsb 0.002 
 
<0.0001 < 0.0001 < 0.0001 
(a)Fisher's exact test; (b) Chi-square test, Hpsb= hyperplasia in suprabasal layers, 
Hpb=hyperplasia in basal layer, NSG= normal salivary gland 
 
 
  
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Percentage of OSCC specimens showing the indicated MSF (Both isoforms) grades   
The tissues were stained with antibody 7.1(A) and TYN (B), as indicated.  The tissues 
examined included histologically normal salivary gland (NSG, n=31or 26), pathological 
invasive tumour front (ITF) (n=64, 50), keratinpearl (Kp) (n=64, 50), hyperplasia suprabasal 
cell layers (Hpsb) (n=37, 31) and hyperplasia basal cell layers (Hpb)(n= 37, 31). Chi square 
tests (MSF grades 0 v. 1 v. 2/3) and Fisher’s exact Test (MSF grades 0 v. 1/2/3) demonstrated 
statistical tests as shown in (Table 4.2 & 4.3).  
 
4.4.4 Comparison of staining with antibodies 7.1 and TYN: 
 Fifty specimens were stained with both anti total MSF antibody (7.1) and 
anti-MSF-aa antibody (TYN).  Comparison of the staining in these specimens is 
shown in Table 4.4 and Fig 4.7.  Most OSCC specimens stained positively with both 
antibodies; however, a small number (1/50) showed positive staining with 7.1 but 
were negative with TYN. No significant differences were found between the two 
antibodies regarding MSF overall grades in Kp (P=1) and in ITF (P<0.553) (Fig 4.7). 
However, significant differences (7.1 > TYN) were found regarding percentage of 
area stained and final score (P< 0.008 and P<0.016) respectively (Fig 4.8), significant 
differences (7.1 > TYN) were also observed regarding MSF overall grade in stromal 
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fibroblasts (P< 0.001) and blood vessels (P< 0.005), but not in the inflammatory cells 
(Fig 4.5C).    
No significant differences were observed in the NSG for both antibodies (Fig 
4.7), acinar cells were predominantly negative whereas ductal cells commonly 
exhibited a diffuse positivity, this being stronger in the luminal cells compared with 
basal and myoepithelial cells. However, there was no significant difference between 
the two antibodies regarding epithelial hyperplasia. 
 
Table 4.4: Statistical comarison of antibodies; Tissues and p value (for number 
and %) between Abs 7.1 and TYN   
 MSF grades compared 
Tissues 
compared 
Abs for actual number of specimens(n) for % of 
specimens 
  0/1  v  2/3 (a) 0  v  1/2/3 (a) 0  v  1  v  2/3 
(b) 
0/1  v  2/3 (a) 
KP v KP 7.1 &TYN 
(n=50) 
1 1 0.367 0.497 
ITF v ITF 7.1 &TYN 
(n=50) 
0.105 0.553 0.053 0.015 
Hpsb v Hpsb 7.1 & TYN 
(n=50) 
0.022 1 0.065 0.0001 
(a)Fisher's exact test; (b) Chi-square test, Hpsb= hyperplasia in suprabasal layers, 
Hpb=hyperplasia in basal layer 
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Figure 4.7: Number of OSCC specimens showing the indicated MSF grades of both isoforms.   
The tissues were stained with antibody 7.1and TYN (n=50) as indicated.  The tissues 
examined included pathological invasive tumour front (ITF) (n=50), keratinpearl (Kp) (n=50), 
histologically normal salivary gland (NSG, n=26), hyperplasia suprabasal cell layers (Hpsb) 
(n=31) and hyperplasia basal cell layers (Hpb) (n= 31).   Chi square tests (MSF grades 0 v. 1 
v. 2/3) and Fisher’s Exact test (MSF grades 0 v. 1/2/3) demonstrated statistical tests as shown 
in (Table 4.2 & 4.3).  
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Figure 4.8: Comparison between two MSF isoforms antibodies (7.1 and TYN).  
 MSF expression in the epithelium of OSCC was evaluated and compared. There were 
significant differences between the two antibodies in terms of the (A) % of area stained (P 
<0.008 Mann–Whitney test) and (B) final score (% area x intensity; P <0.016, Mann–Whitney 
test) respectively. 
 
4.4.5 Survival analysis 
Survival data was available for 46 OSCC patients; clinical details of these are 
presented in Table 4.5.  Specimens from the 46 patients were stained and evaluated 
for MSF expression using 7.1 Ab; TYN Ab was evaluated on 45 specimens. The 
prognostic value of MSF expression was determined by Kaplan-Meier survival curves 
and log rank analyses.  The results, (summarised in Table 4.6) showed a significant 
association between high MSF expression in the invasive tumour front (ITF) and poor 
patient survival. In contrast, MSF expression in the keratinised areas (Kp) was not 
associated with patient survival.  The 5 year overall survival rates for patients with 
high MSF grades (2/3) in ITF were significantly worse than for those patients with 
low MSF grades (0/1) (log-rank test: p< 0.001 and p<0.023 for total MSF and MSF-aa 
respectively) (Fig 4.9 & 4.10).  Among the various MSF indices examined MSF grade 
(divided 0/1 vs 2/3) was the most informative, although results obtained with MSF 
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final score and the % area stained also reached statistical significance or near 
significance in some cases (P= 0.04-0.08) (Table 4.6).  Of the two antibodies used, 
TYN produced more informative results than 7.1 (Table 4.6).  Significant differences 
in overall survival according to MSF grade expression were most apparent at 60 
months follow-up time.Tumour-free survival and overall survival were also 
significantly different at 125 months follow-up time according to MSF grade assessed 
with TYN antibody.  Clinical variables (pathology grade and T, N, Stage grouping) 
were not associated with patient survival (Table 4.7).   
 
Table 4.5: Clinical details of OSCC patients   
Variable  Description 7.1 Ab 
N =46 
TYN Ab 
N =45 
Median 61.5 56.02 
IQR 12-85 12-120 
Mean 55.2 63 
Overall survival 
(years) 
SD 37.47 37.8 
    
Median 46 48.31 
IQR 8.5-60 8.5-120 
Mean 36.9 47 
Tumour-free survival 
(years) 
SD 23.7 37.1 
    
(0) dead 16 16 Censor  
(dead/alive) (1) alive 30 29 
    
(1) male 39 38 Gender  
(2) female 7 7 
    
Median 54 54 
IQR 47-62 48-62 
Mean 54.1 54.2 
Age (years) 
SD 10.3 10.4 
    
1 5 5 
2 36 36 
Pathology grade  
3 5 4 
    
1 5 5 
2 29 28 
3 4 4 
Pathological. T 
4 8 8 
    
N 0 21 21 
N 1 15 15 
Pathological. N 
N 2 9 8 
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 Table 4.6: The prognostic significance of the clinical characteristics of OSCC 
stained by ant-MSF ( Ab 7.1) as derived from a long rank test   
Experimen
tal index. 
Clinical 
index 
Division Ab giving 
significant 
differences 
 (p value) 
7.1 
(p value) 
TYN 
    n=46 n=45 
MSF grade O.S- ITF  
125 months 
0/1 v 2 TYN>7.1? P=0.057 P=0.010* 
MSF grade O.S- ITF  
48 months 
0/1 v 2 7.1>TYN? P= 0.004* P= 0.065 
MSF grade O.S- ITF  
60 months 
0/1 v 2 TYN & 7.1* P= 0.001* P= 0.023* 
      
MSF grade TFSurv-ITF 
125 months 
0/1 v 2 TYN>7.1 P=0.113 P=0.004 
MSF grade TFSurv-ITF 
48 months 
0/1 v 2 TYN>7.1? P= 0.062 P= 0.049 
MSF grade TFSurv-ITF 
60 months  
0/1 v 2 TYN>7.1? P= 0.089 P= 0.027* 
      
MSF grade O.S- Kp 
125 months 
0/1 v 2  P=0.276 P=0.275 
MSF grade O.S- Kp 
60 months 
0/1 v 2  P=0.428 P=0.437 
      
MSF grade TFsurv- Kp 
125 months 
0/1 v 2  P=0.286 P=0.291 
MSF grade TFsurv- Kp 
60 months 
0/1 v 2  P=0.340 P=0.346 
      
% area 
stained 
O.S 
125 
medians  P=0.576 P=0.491 
% area 
stained 
O.S 
48 months 
medians  P= 0.909 P= 0.205 
% area 
stained 
O.S 
60 months 
medians  p=0.825 p=0.194 
      
% area 
stained 
TFsurv 
125 months 
medians  p=0.964 p=0.302 
% area 
stained 
TFsurv – 
48 months 
medians  p=0.685 p=0.113 
% area 
stained 
TFsurv – 
60 month 
medians TYN>7.1 p=0.634 p=0.060 
      
Final score O.S medians  p=0.560 p=0.330 
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125 
Final score O.S 
48 months 
medians 7.1>TYN? p=0.041* p=0.076 
Final score O.S 
60 months 
medians TYN?>7.1? p=0.085 p=0.063 
      
Final score TFsurv 
125 months 
medians  p=0.682 p=0.340 
Final score TFsurv – 
48 months 
medians  p=0.449 p=0.412 
Final score TFsurv – 
60 month 
medians  p=0.515 p=0.489 
O.S= overall survival, TFsur= tumour free survival, ? = significant at the 90% level of 
Confidence, * = significant differences 
 
 
Table 4.7: The relationship between clinical characteristics (Path-grade, Path-T 
and Path-N) and overall and tumour free survival rates as derived from Kaplan-
Meier Test.  
 
Experiment
al index. 
Clinical 
index 
Division  (p value) 
 
Test/comments 
Path- grade OS –  
125 months 
1 v 2 v 3 p=0.643 Log rank test 
Path- grade OS –  
125 months 
1 v 2/3 p=0.346 Log rank test 
     
Path-grade TFsurv 
125 months 
1 v 2 v 3 p=0.601 Log rank test 
Path-grade TFsurv 
125 months 
1/2 v 3 p=0.860 Log rank test 
     
Path-T OS –  
125 months 
1 v 2 v 3 v 4 p=0.360 Log rank test 
Path-T TFsurv 
125 months 
1 v 2 v 3 v 4 p=0.388 Log rank test 
     
Path-N OS –  
125 months 
0 v1 v 2 p=0.206 Log rank test 
Path-N TFsurv 
125 months 
0 v1 v 2 p=0.337 Log rank test 
 
Path = pathological, T = size, N = lymphnode involvment 
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Figure 4.9: Correlation between MSF isoforms expression and survival rate in patients with 
OSCC.  
as determined by the Kaplan–Meier method. The overall survival of patients with high 
expression of MSF was statistically worse than that of those with no/ low MSF expression 
(log-rank; p<0.001, 0.023). No association was found in the keratin pearl (Kp) for both 
isoforms. 
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Figure 4.10: Correlation between MSF isoforms expression and tumour free survival rate in  the 
OSCC patients.   
as determined by the Kaplan–Meier method. The disease (tumour)-free survival of patients 
with expression of MSF-aa was statistically worse than that of those with low MSF 
expression (log-rank; p < 0.027). Patients with highly expression of total MSF was trend but 
not significant. No association was found in the keratin pearl (Kp) for both isoforms. 
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4.5 Discussion 
Staining of formalin-fixed paraffin-embedded specimens by 
immunohistochemistry (IHC) is commonly used, as the specimens can be stored for a 
long time, thereby allowing retrospective studies of a large population.  The 
identification of novel biomarkers in oral squamous cell carcinoma (OSCC) is aimed 
at improving the diagnostic and or prognostic indicators in these tumours and 
evaluating the possible functional importance of molecules that may become the 
target for new therapies. In the past few years, significant progress has been made in 
the identification and understanding of prognostic biomarkers involved in predicting 
OSCC aggressiveness (Chapter one introduction). The TNM classification system 
cannot predict the biological features of tumour cells and, therefore, is unable to 
individualise the prognosis. The identification of novel biomarkers could help in 
definitive treatment planning and improve survival consequently.  
Important molecular interactions that enhance or inhibit tumour progression 
occur at the tumour-host interface (Bryne et al., 1998).  It had been suggested that the 
invasive tumour front (ITF) comprises the most aggressive cells, which have the 
capacity to invade neighbouring tissue structures, including vessels, and thereby 
metastasise.  Previous studies have reported that the characteristics of the ITF are 
most important for the diagnosis and prognosis of oral cancer (Bryne et al., 1998; 
Bankfalve and Piffko, 2000). Interactions between stromal and tumour cells at the ITF 
are expected to play a significant role in modulating tumour progression.  Fibroblasts 
and endothelial cells are the main stromal cells involved in these interactions; changes 
in the behaviour of these stromal cells at the ITF, are reflected by displaying a number 
of fetal characteristics, this may therefore provide independent prognostic indices 
(Bankfavi and Piffko, 2002).   
In the present study, the expression of MSF in OSCC tissue sections was 
quantified using IHC and two different antibodies: 7.1, and TYN.  As shown in 
chapter three, Ab7.1 recognises MSF+aa and MSF-aa whereas TYN recognises MSF-
aa only.  The ITF and the centre of the tumour, including keratin pearls (Kp) were 
assessed independently. The results may be summarised as follows:  
• Both antibodies stained most OSCC specimens (100 % and 98% 
positive specimens with 7.1 and TYN, respectively). Staining was 
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observed, to different extents, in carcinoma cells and associated 
stromal cells.   
• In adjacent non-tumour tissue, staining was observed, to different 
extents, in NSG and Hp. Staining was restricted to epithelial ductal 
cells in the NSG and to the Hpsb area of Hp. 
• Some specimens showed positive staining with 7.1 and negative with 
TYN, the reverse pattern was not observed. 
• The percentage of MSF-positive specimens followed a pattern, 
represented as NSG=Hpb<Hpsb<ITF<Kp, for TYN Ab and as 
NSG=Hpb< Hpsb=ITF<Kp for 7.1 Ab. 
• High MSF expression in the invasive tumour front (ITF) was 
significantly associated with shorter patient survival. In contrast, MSF 
expression in the keratinised areas (Kp) was not associated with patient 
survival.  More informative results were obtained with TYN antibody 
than with 7.1 antibody. 
Differences in staining between ITF and Kp areas has been noted previously 
regarding the expression of different molecules, Wang et al, (2009) reported that E-
cadherin expression at the ITF is lower than that in centre/superficial part for most of 
OSCC. E-cadherin at the ITF is statistically associated with poor survival of OSCC 
patients. 
MSF exhibits an oncofoetal pattern of expression as defined by its (i) constitutive 
production by keratinocytes, fibroblasts and endothelial cells in foetal skin, (ii) reduced or 
undetectable expression in skin and other tissues in healthy adults, and (iii) re-expression 
by both carcinoma and stromal cells in the majority of common human tumours, including 
those of the breast, lung, colon, prostate and oral mucosa (Schor et al., 2003 and 
unpublished observations).  This study demonstrates that MSF is expressed by carcinoma 
and stromal cells in OSCC.  Re-expression of MSF in previously negative epithelium 
during malignant transformation might be regarded as a return to an embryonic expression 
pattern.  The foetal-like characteristics of the cells at the ITF have been previously noted 
(Bankfavi and Piffko, 2002).   
Results presented here suggest that a small number of OSCC specimens 
express MSF+aa only. However, most OSCC specimens express either MSF-aa only 
or a mixture of MSF+aa and MSF-aa.  In chapter three it was demonstrated that 
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NGAL inhibits MSF+aa, but not MSF-aa.  Since NGAL is also expressed in OSCC 
and Hp (results not shown), it is speculated that MSF-aa is the most relevant MSF 
isoform in terms of diagnosis, prognosis and functionality.   
In agreement with this hypothesis, the results presented in this chapter indicate 
that MSF expression assessed with TYN antibody is more informative than results 
obtained with 7.1 antibody regarding the prognosis of OSCC patients.  With both 
antibodies, high MSF expression at the ITF was significantly associated with shorter 
patient survival. 
 
4.6 Conclusion 
- Data presented here provide an initial indication that MSF isoforms expression is up-
regulated in both the epithelial and stromal cell compartments of OSCC. 
 
- This is the first report that the expression of MSF is a novel independent poor 
prognostic factor in OSCC. Therefore, MSF is a useful marker for choosing therapy 
and for predicting the poor outcome of patients with OSCC. Patients with OSCC who 
show positive MSF expression should be followed-up carefully. In addition, MSF 
might be a strong candidate to target for future therapy in OSCC. 
 
4.7 Further work  
- To assess the presence of MSF message in OSCC by using in situ hybridization  
 
- To study the expression of MSF in the normal oral mucosa and epithelial dysplastic 
tissue and compare it with the result of MSF in OSCC, to provide a rational platform 
for subsequent more extensive investigation of the possible diagnostic significance of 
MSF expression in OSCC. 
 
- To examine a larger number of patients 
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5. Chapter five: MSF Expression in Salivary gland tumours  
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5.1 Introduction: 
Salivary gland tumours (SGT) are relatively rare lesions, accounting for only 
3–6% of all head and neck neoplasms. They are a morphologically and clinically 
diverse group which present a challenge to head and neck surgeons and pathologists, 
both in terms of diagnosis and clinical management. The majority of tumours arising 
from the minor salivary glands are malignant (Speight and Barrett, 2002; WHO 
Classification of Tumours, 2005; Ward and Levine, 1998). The identification and 
validation of novel stratification and predictive biomarkers for SGT would 
consequently be of significant clinical utility. Migration-stimulating factor (MSF), a 
soluble genetically truncated isoform of fibronectin, is a potent oncofoetal regulatory 
molecule. The expression of MSF in salivary gland tumours has not been examined 
previously; it will be of great clinical value to identify effective early markers such as 
MSF for the diagnosis and prognosis of salivary gland tumours. 
5.2 Aims: 
  The aims of this study have been to ascertain the possible presence, diagnostic 
significance and role of MSF in salivary gland tumours. Immunohistochemistry was 
used to compare the expression pattern of MSF in histologically normal salivary gland 
tissue adjacent to benign and malignant SGT. 
 
5.3 Materials and Methods: 
5.3.1 Specimens: SGT study 
Formalin-fixed, paraffin-embedded, archival tissue specimens of benign (n=7) 
malignant (n=27) minor salivary gland tumours (SGT) were obtained from the 
Domagk-Institute of Pathology, University Clinic of Munster, Germany.  The 
majority of the malignant tumours were adenoid-cystic carcinomas (n=16) and 
mucoepidermoid carcinomas (n=6).  The majority of the benign tumours (6) were 
pleomorphic adenomas.  The anatomical location of the tumours and relevant patient 
information are presented in Table 5.1.  Sixteen of the tumour specimens (15 
malignant and 1 benign) included regions of adjacent histologically normal salivary 
gland (NSG), as indicated in Table 5.2.  
5.3.2 Immunohistochemistry: 
  Tissues were stained with two monoclonal antibodies:  identification antibody 
7.1, that recognise the MSF-unique sequence and antibody TYN that recognises 
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MSF–aa but not MSF+aa (as described in Chapter three characterisation of 
identification antibodies to MSF). MSF expression in paraffin-embedded archival 
specimens of salivary gland tumours was examined by standard 
immunohistochemistry as outlined in chapter two (Materials and Methods). 
 
Table 5.1: Clinical characteristics of the malignant and benign salivary gland 
tumours examined were stained by two antibodies (7.1 and TYN).  Malignant 
tumours included: Adenoid cystic carcinomas (ACC stained by 7,1 Ab n=16  and  by TYN 
Ab n=13 , three missing 2 in upper jaw and 1 in palate) ,  mucoepidermoid carcinomas (MC), 
adenocarcinomas (AC),  basal cell adenocarcinoma (BcAC), sebaceous adenocarcinoma (SA, 
SC), Benign tumours included pleomorphic adenoma (PA) and angiolieomyoma (Ang). 
 
Anatomical location 
 
 
 
Tumour 
 
 
n lip Oral 
mucosa 
Upper 
Jaw 
palate cheek Lower 
jaw 
Sub 
Mand  
Floor 
of the 
mouth 
Age 
Average 
(range) 
 
Gender 
(F:M) 
ACC 16 1 1 8 3 1 1  1 57.1 
(35-83) 
13:3 
MC 6   2 2 1  1  47.5 
(32-66) 
2:4 
AC 
 
2  1 1      43.5 
(36-51) 
1:1 
BcAC 2  
 
  1 1    58-59 0:2 
SA 1  
 
 1      79 1:0 
 
All 
malignant 
27 1 2 12 6 3 1 1 1 55.7 
(32-83) 
17:10 
PA 6   2 1 1  2  41.6 
(20 -75) 
4:2 
Ang 1  
 
  1     29 0:1 
All 
benign 
7   2 2 1  2  39.8 
(20 -75) 
4:3 
All 
tumours 
34 1 2 14 8 4 1 3 1 52.5 
(20-83) 
21:13 
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 Table 5.2: Tumour specimens containing histologically normal salivary glands 
adjacent to the tumour. Normal salivary gland (NSG) was found adjacent to adenoid 
cystic carcinoma (n=9 ACC stained by 7.1 Ab; and n=7 by TYN Ab), mucoepidermoid 
carcinoma (MC), adenocarcinoma not otherwise specified (AC), basal cell adenocarcinoma 
(BcAC) and pleomorphic adenoma (PA). 
 
Anatomical location 
 
 
Adjacent 
tumour 
 
 
n lip Oral 
mucosa 
Upper 
Jaw 
palate cheek Lower 
jaw 
Sub 
Mand  
Age 
Average 
(range) 
Gender 
(F:M) 
ACC 9 1  6 
 
1 1   58 
(35-80) 
8:1 
MC 3   1 1   1 41.3 
(32-59) 
1:2 
AC 2  1 1     43.5 
(36-51) 
1:1 
BcAC 1  
 
   1   58 0:1 
All 
malignant 
with 
adjacent 
NSG 
15 1 1 8 2 2  1 50.2 
(32-80) 
 
10:5 
Benign 
(PA) with 
adjacent 
NSG 
1   1     36 
 
1:0 
All 
tumours 
16 1 1 9 2 2  1 43.1 
(32-80) 
11:5 
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5.4 Results: 
5.4.1 Immunolocalisation of total MSF 
Duplicate sections of benign and malignant small salivary gland tumours 
(SGT) (Table5.1) were stained with MSF-specific antibody mab7.1 (Schor et al., 
2003). Histologically NSG was presented adjacent to some of the tumours (Table 5.2). 
MSF was differentially expressed in the salivary gland tissues examined. Positive 
staining was observed in the majority of malignant tumours, both in the tumour and in 
the associated stromal cells. Representative examples of MSF expression by 
malignant tumour cells and tumour-associated stromal cells are presented in (Fig 
5.1A, B). Examples of negative and positive benign tumours were also encountered 
(Fig 5.1C, D). Positively stained acinar cells were rarely present in NSG (Fig 5.1E, F). 
Positively stained inflammatory cells were occasionally detected in association with 
malignant tumours (Fig 5.1G). Sections incubated with normal mouse IgG, instead of 
MSF antibody, showed no staining (Fig 5.1H).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
B A 
C D 
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Figure 5.1: Immunolocalisation of total MSF in salivary gland tumours.   
(A, B) MSF expression in malignant tumours, adenoid cystic carcinoma (A) and 
mucoepidermoid carcinoma (B) showing MSF staining in the tumour cells and associated 
blood vessels and fibroblasts. (C) Negative MSF staining in benign tumour (pleomorphic 
adenoma). (D) MSF-positive pleomorphic adenoma. (E) Adenoid cystic carcinoma showing 
negative MSF staining in histologically normal salivary gland (NSG) (mucous cells) adjacent 
to positive tumour. (F) Positive excretory and striated ducts next to negative serous cells in 
NSG. (G) Positive inflammatory cells and carcinoma cells in a mucoepidermoid carcinoma. 
(H) Sections incubated with normal mouse IgG, instead of MSF antibody, showed no staining 
(negative controls Original photographs were taken at magnification x 100 (A, D, E, F, G, H) 
or x 400 (B, C). 
 
 
 
 
 
G H 
E F 
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5.4.2 Differential expression of total MSF in salivary gland tissues 
MSF expression was evaluated in NSG (n = 16), benign SGT (B; n = 7) and 
malignant SGT (M; n = 27). The group of benign SGT consisted of six epithelial-
derived tumours (pleomorphic adenomas) and one stromal-derived tumour 
(angiomyoma). MSF expression was first graded as negative (0), weak positive (1), 
moderate (2) or strong positive (3) by four independent observers. To compare the 
different tissues, results are presented in Fig 5.2A as the percentage of specimens 
showing the various MSF grades. This initial classification (overall MSF grade) 
indicated that a significantly greater proportion of the malignant tumours were 
positively stained for MSF compared with benign lesions or NSG. A significant 
difference was also observed between benign tumours and NSG. Therefore, overall 
MSF expression increased significantly in a step-wise fashion from normal salivary 
gland to benign and malignant tumours (P <0.006-0.0001, Fig 5.2A); with moderate ⁄ 
strong positive specimens representing 6%, 29% and 81% of the normal, benign and 
malignant specimens, respectively. The inclusion of (angiomyoma) brought the 
percentage of moderate ⁄ strong positive specimens to 33%, but did not alter the 
significance of the results (P<0.005–0.001). Significant differences between 
pleomorphic adenomas and malignant tumours were also observed even when 
comparing specific sub-groups of the latter (Table 5.1), such as adenoid cystic 
carcinomas (P<0.045) and mucoepidermoid carcinomas (P<0.049), in spite of the 
small number of specimens involved. Within the group of SGT specimens examined, 
MSF expression was not related to the anatomical site of origin or to the age or gender 
of the patient. The overall MSF grade (Fig 5.3A) gives a general assessment of the 
sections, including epithelial and stromal compartments. More detailed observations 
of the tumours revealed that MSF was heterogeneously distributed within both the 
tumour and stromal compartments (such as fibroblasts, blood vessels and 
inflammatory cells), with a greater proportion of the specimens being positively 
stained in malignant than in benign tumours in all cellular compartments (Fig 5.3A). 
A benign tumour derived from the vascular smooth muscle cells (angiomyoma) was 
positive for MSF, whereas the blood vessels of the normal salivary gland were MSF-
negative. Within the epithelium, (Fig 5.5) significant differences between benign and 
malignant tumours occurred in terms of highest (hot spot) intensity, percentage of area 
stained and final score, (i.e. area x intensity). Overall MSF grade of the NSG reflects 
mainly the staining present in the acinar cells. More detailed observation of the 
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different NSG cell types indicated that mucous and serous acinar cells were indeed 
predominantly negative for MSF, whereas ductal cells commonly exhibited a diffuse 
positivity, this being stronger in the luminal cells compared with basal and 
myoepithelial cells (Fig 5.1E, F). Of 16 NSG specimens examined, 10, 11 and 15 
(63%, 69% and 94%) showed positive intercalated, striated and excretory salivary 
ducts, respectively. Only one specimen (6%) showed MSF staining in acinar (serous) 
cells and nine (56%) in myoepithelial cells (Table 5.3). A comparison of NSG 
adjacent to SGT (as above) and NSG adjacent to OSCC (chapter 4) revealed no 
significant differences regarding MSF expression (Table 5.3). 
 
 
 
Figure 5.2: Percentage of SGT specimens showing the indicated MSF isofroms grades.  
The tissues were stained with antibody 7.1(A) and TYN (B), as indicated.  The tissues 
examined included histologically normal salivary gland (NSG, n=16 or 14), benign (B, n=7) 
and malignant salivary gland tumours (M, n=27 or 24).   Chi square tests (MSF grades 0 v. 1 
v. 2/3) and Fisher’s Exact test (MSF grades 0 v. 1/2/3) demonstrated significant differences 
between M and B (p<0.006-0.021 0.01-0.006 for 7.1 and for TYN 0.037-0.0520.02-0.03), 
between M and NSG (p< 0.0001) for both antibodies and between B and NSG (p<0.017 0.04) 
for antibody 7.1, whilst no significant differences between B and NSG for TYN antibody.  All 
p values were p< 0.0001 when the percentages of specimens (as shown in the graph) were 
compared. 
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Figure 5.3: Epithelial and stromal MSF expression in benign (B) and Malignant (M) salivary 
gland tumours.  
 Results show the percentage of specimens graded positive (grades 1/2/3) stained by antibody 
7.1 (A) and TYN (B) for different cellular compartments, including tumour epithelial cells 
(TC), blood vessels (Bv), fibroblasts (Fb); M=24 and B=7 and inflammatory cells (Ic; M=19 
and B=7).  The difference between malignant and benign tumours was analysed by Fisher’s 
exact test for the actual number of specimens assessed (n) and for the percentage of 
specimens (%, as shown in the graph). The respective p values for (n) and (%) were:  0.02 and 
0.001 for Tc (7.1 Ab) and 0.05 - 0.001 for (TYN Ab); 0.19 and 0.0001 for Bv (7.1 Ab) and 
0.675 - 0.075 for (TYN Ab); 0.19 and 0.0001 for Fb (7.1 Ab) and 0.675-0.075 for (TYN Ab); 
0.178 and 0.0001 for Ic (7.1 Ab) and 0.133-0.0001 for (TYN Ab).  
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5.4.3 Immunolocalisation of MSF-aa 
Following the same standard immunohistochemical procedures and the same 
methods of assessment for mab7.1 specific total MSF antibody, 31 duplicate sections 
of benign and malignant small salivary gland tumours (SGT) were stained with mouse 
monoclonal antibody specific to MSF-aa (TYN1.2) (Chapter 4). Histologically NSG 
was present adjacent to some of the tumours. MSF was differentially expressed in the 
salivary gland tissues examined. Positive staining was observed in the majority of 
malignant tumours, both in the tumour and in the associated stromal cells (Fig 5.4).  
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Figure 5.4: Immunolocalisation of MSF-aa in the salivary gland tumours.   
(A, B) MSF expression in malignant tumours, adenoid cystic carcinoma adjacent to negative 
NSG (A) and mucoepidermoid carcinoma (B) Mucoepidermoid carcinoma (C) Negative MSF 
staining in benign tumour (pleomorphic adenoma). (D) MSF-positive pleomorphic adenoma. 
(E) Positive excretory and striated ducts next to negative serous cells in NSG. (F) Showing 
MSF staining in the tumour cells and associated blood vessels and fibroblasts.(G) Sections 
incubated with normal mouse IgG, instead of MSF antibody, showed no staining (negative 
controls). Original photographs were taken at magnification x100 (A, B, C, D, E, F and G)   
 
5.4.4 Differential expression of MSF-aa in salivary gland tissues 
Differential expression of MSF in salivary gland tissues was evaluated in NSG 
(n = 14), benign SGT (B; n = 7) and malignant SGT (M; n = 24). MSF-aa expression 
was graded in a similar way with mab 7.1, by two independent observers. To compare 
the different tissues, results are presented in (Fig 5.2B) as the percentage of specimens 
showing the various MSF-aa grades. This initial classification (overall MSF-aa grade) 
indicated that a significantly greater proportion of the malignant tumours were 
E 
F 
G 
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positively stained for MSF-aa compared with benign lesions (P< 0.037) or NSG (P< 
0.0001). There was no significant difference observed between benign tumours and 
NSG (Fig 5.2B). The results presented in (Fig 5.5) indicate significant differences 
between benign and malignant tumours within the epithelium in terms of highest (hot 
spot) intensity, percentage of area stained  and final score, (i.e. area x intensity) (P< 
0.028, P< 0.042 and P< 0.027) respectively. The overall MSF-aa grade gives a general 
assessment of the sections, including epithelial and stromal compartments. More 
detailed observations of the tumours revealed that MSF-aa was heterogeneously 
distributed within both the tumour and stromal compartments (fibroblasts, blood 
vessels and inflammatory cells), with a greater proportion of the specimens being 
positively stained in malignant than in benign tumours in all cellular compartments 
(Fig 5.3B) 
 Overall MSF grade of the NSG reflects mainly the staining present in the 
acinar cells. More detailed observation of the different NSG cell types indicated that 
mucous and serous acinar cells were indeed predominantly negative for MSF, 
whereas ductal cells commonly exhibited a diffuse positivity, this being stronger in 
the luminal cells compared with basal and myoepithelial cells. Of 14 NSG specimens 
examined, 2, 9 and 12 (14%, 64% and 86%) showed positive intercalated, striated and 
excretory salivary ducts, respectively. Only one specimen (7%) showed MSF staining 
in acinar (serous) cells and seven (50%) in myoepithelial cells (Table 5.3). 
 
Table 5.3: Number and percentage of normal salivary gland specimens adjacent 
to both SGT and OSCC which are graded as MSF positive for Ab 7.1 and Ab 
TYN   
 Ad OSCC Ad SGT Ad OSCC Ad SGT 
Cell type Positive  
7.1 (n=31) 
Positive  
7.1 (n=16) 
Positive  
TYN (n=26) 
Positive  
TYN (n=14) 
serous and 
mucous 
3 (5%) 1(6%) 2 (8%) 0/14 
myoepithelial  16 (52%) 9(56%) 10 (38%) 
 
7(50%) 
ICD 18 (58%) 10(63%) 15 (58%) 
 
2(14%)* 
Sd 23 (74%) 11 (69%) 20 (77%) 
 
9 (64%) 
Exd 28 (90%) 15(94%) 24 (92%) 
 
12(86%) 
Ad= adjacent, ICD=intercalated ducts, Sd =striated duct, Exd=excretory duct 
* Positive in the MC 1/6 & AC 1/2 and negative in the rest. 
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 5.4.4 Comparison between 7.1 and TYN Antibodies: 
The immunohistochemical identification of total MSF and MSF-aa in  sections 
of paraffin embedded salivary gland tumour was performed using two antibodies 
(Mouse Monoclonal: mab 7.1 for total MSF and mab TYN 1.1 for MSF-aa). Most of 
the specimens stained positively for both antibodies. Both antibodies produced intense 
staining of epithelial tumours, and there was no statistically significant differences 
between the two antibodies for the total samples including epithelial tumours (benign 
v benign and malignant v malignant) regarding percentage of area stained, final score 
and highest intensity of staining (Fig 5.6). Similarly, data present in (Fig 5.3C) shows 
no significant differences were found between the two antibodies regarding stromal 
cells compartment. 
No significant difference was detected between these antibodies among 
normal salivary ductal epithelial cell types except for ACC the results indicated that 
MSF-aa was not expressed in the intercalated duct.  
The similar staining pattern of both antibodies suggests that the MSF-aa is the 
predominant form of MSF in the salivary gland tumours. However, we can-not 
exclude expression of MSF +aa. 
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Figure 5.5: Epithelial MSF expression in salivary gland tumours.   
The tissues were stained with antibody 7.1 and TYN, as indicated. MSF expression in the 
epithelium of benign (B; n = 7) and malignant (M; n = 27 for 7.1 Ab & 24 for TYN) tumours 
was evaluated and compared. Significant differences between B and M occurred in terms of 
the highest intensity (P = 0.0001, Fisher’s exact test), the % of area stained (P< 0.040-0.042, 
Mann–Whitney test) and final score (% area x · intensity; P<0.003-0.027, Mann–Whitney 
test) for 7.1 Ab and TYN respectively.  
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Figure 5.6: Comarison between two MSF antibodies (7.1 and TYN).   
MSF expression in the epithelium of benign (B; n = 7) and malignant (M; n = 27 for 7.1 Ab & 
24 for TYN) tumours was evaluated and compared. No significant differences between the 
two antibodies occurred in terms of the highest intensity regarding benign v benign (A) and 
malignant v malignant (B) (P=1-0.517 Fisher’s exact test) respectively. similarly, no 
significant differences between the two antibodies occurred in terms of the % of area stained 
regarding B v B (C) and M v M (D) (P = 0.317-0.664, Mann–Whitney test) and final score (E, 
F) (% area x  intensity; P =0.223-0. 0.243, Mann–Whitney test) respectively. 
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5.5 Discussion 
The present study revealed that (i) significantly higher levels of total MSF and 
MSF-aa were detected in malignant than in benign salivary gland tumours, (ii) MSF 
staining was also apparent in some histologically normal salivary gland tissue, 
although this was significantly less than in either benign or malignant tumours. The 
expression of MSF in NSG showed the same pattern irrespective of whether the NSG 
was adjacent to SGT or OSCC.  The difference in MSF expression between 
histologically normal tissue (adjacent to tumours) and benign tumours suggests that 
up-regulation of MSF expression may be a significant feature of early salivary gland 
tumour inception and ⁄ or progression. Furthermore, the observed higher expression of 
MSF by malignant tumours may prove to be a useful marker of later stage disease 
progression. Schor et al, (2003) previously reported that both MSF protein and 
mRNA are expressed by the same cell types in foetal skin and breast tissues. As is the 
case with breast cancers (Schor et al., 2003; Schor and Schor, 2010). Some MSF 
expression was associated with the ductal epithelium of histologically normal salivary 
gland tissue adjacent to malignant tumours. It is important to note that normal salivary 
gland tissue from healthy adults was not available for examination in this study. This 
may be of significance in light of previous observations that MSF is expressed by 
fibroblasts obtained from histologically normal breast adjacent to mammary 
carcinomas, but not by normal breast tissue from healthy adults (i.e. reduction 
mammoplasty biopsies) (Schor et al., 1994). It is therefore possible that MSF 
expression by the normal appearing salivary gland tissue represents a ‘functional 
aberration’ reflecting the proximal location of a malignant tumour and ⁄ or the result 
of a ‘field cancerisation’ effect resulting from previous exposure to a carcinogenic 
agent (Yoshino et al., 2007, Slaughter et al., 1953). In the case of the stromal 
vasculature, it is of interest that MSF was not detected in the blood vessels of the 
normal salivary gland, whereas a benign tumour derived from the vascular smooth 
muscle cells (angiomyoma) showed MSF staining. The complex histo-cytological 
structure of the salivary glands and their tumours leads to diagnostic difficulties.  
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5.6 Conclusion 
Data presented here provide an initial indication that the expression of MSF 
isoforms expressions is up-regulated in both the epithelial and stromal cell 
compartments of malignant salivary gland tumours. This study provides a rational 
platform for subsequent more extensive investigation of the possible diagnostic and 
prognostic significance of MSF expression in this currently difficult to manage patient 
group. It also suggests that developing means to inhibit MSF expression and ⁄ or 
functionality may provide novel therapeutic strategies to improve the management of 
patients with salivary gland tumours. 
 
5.7 Further studies 
- A more detailed cytological study will be required to ascertain the possible 
   relationship between MSF expression and the histological characteristics of the 
   tumours. 
- It would be of value to increase the numbers of benign tumour specimens to improve  
  the statistical viability of the study. 
- To assess the presence of MSF mRNA in salivary gland tumours by using in situ 
   hybridization. 
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6. Chapter six: Identification of MSF Receptors 
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6.1 Introduction 
Cell–cell and cell–matrix interactions play important roles in tumour 
metastasis and angiogenesis. One of the most important classes of receptors involved 
in these processes are the integrins. Integrins are a group of extracellular matrix 
receptors made up of an alpha and a beta chain, each chain being approximately 130-
210kDa (alpha chain) and 95-130kDa (beta chain) in molecular weight. There are at 
least 14-18 different α subunits and 8 different β subunits, forming more than 20 
heterodimers, many with numerous ECM ligands (Hynes, 1992; 2002). These proteins 
play an important role in the regulation of cell proliferation, growth, differentiation 
and migration of cells (Geiger et al., 2001 and Danen, 2005). In addition to their role 
in the maintenance of tissue integrity (Thomas and Speight, 2001), integrins transduce 
messages through various signalling pathways and influence proliferation and 
apoptosis of tumour cells, as well as of activated endothelial cells.  
Specific amino acid sequences within ECM macromolecules, for example 
RGD, associate with the extracellular domain of integrin receptors. Integrins do not 
exhibit enzyme activity and require accessory proteins for signalling (Juliano and 
Haskill, 1993; Juliano, 1994; Clark and Brugge, 1995). Activation of integrins results 
in integrin clustering and assembly of focal adhesion complexes, linking the ECM to 
cytoskeletal components. Mueller et al., (1989) demonstrated that fibronectin-coated 
beads induced organisation of cytoskeletal components on the inner membrane 
surface. Competitive inhibition of integrin binding using specific amino acid motifs, 
such as GRGDS for α5β1 integrin, caused dissolution of cytoskeletal components from 
matrix focal adhesions (Stickel and Wang, 1988). The cytoskeletal molecules in focal 
adhesion contacts include α-actinin, talin, vinculin, paxillin and tensin. The 
cytoplasmic domain of the integrin β subunit interacts directly with α-actinin and 
talin. Mutations in the β1 subunit result in reduced cell spreading and motility (Balzac 
et al., 1994). Furthermore, whilst the β1 and β5 subunit support cell adhesion equally, 
β5 showed less recruitment into focal adhesions and was associated with migration of 
fibronectin (Pasqualini and Hemler, 1994). 
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Integrin αvβ3 
Integrin αvβ3 is one of the most prominent members of these receptor classes. 
It has been demonstrated that αvβ3 is an important receptor affecting tumour growth, 
local invasiveness, and metastatic potential (Hood and Cheresh, 2002). This integrin 
is expressed on various malignant tumours and mediates adhesion of tumour cells on a 
variety of extracellular matrix proteins, allowing these cells to migrate during 
invasion and extravasations (Felding-Habermann, 2003). 
The integrin αvβ3 is also highly expressed on activated endothelial cells 
during angiogenesis (Brooks, 1994). In contrast, expression of αvβ3 is weak in resting 
endothelial cells and most normal organ systems (Brooks et al., 1994). On activated 
endothelial cells, the receptor mediates migration through the basement membrane 
during formation of the new vessel, which is essential to provide sufficient nutrient 
supply for the growing tumour. Inhibition of the αvβ3-mediated cell–matrix 
interaction has been found to induce apoptosis. 
Erdreich-Epstein et al, (2005) reported that integrin αvβ3-mediated adhesion 
to the extracellular matrix (ECM) and it is essential for endothelial cell growth and 
survival, while αvβ3 antagonism may induce endothelial apoptosis during 
angiogenesis. 
Binding of any matrix macromolecule to the receptor elicits a chain of events 
including integrin clustering and consequent integrin-mediated intracellular signal 
transduction. After binding, integrins (which have no intrinsic enzymatic or kinase 
activities) activate complex signaling pathways by combining with kinases and 
adaptor proteins in focal adhesion complexes (Giancotti and Tarone, 2003). The 
complexes known as specialised adhesive structures, are composed of integrins, 
protein kinases – such as focal adhesion kinase (FAK) and the non-receptor tyrosine 
kinase receptor Src – adaptor protein such as Shc, signaling intermediates such as Rho 
family GTPases, actin-binding cytoskeletal proteins (such as talin, α-actinin, paxillin, 
tensin and vinculin), and other signaling proteins (Lo, 2006; Mitra, and Schlaepfer, 
2006).  
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6.2 Aims 
The objective of this study was to identify the receptors responsible for the 
motogenic activity of MSF and to determine whether the motogenic activity of MSF 
on various types of cells (oral tumour, salivary gland tumour and human endothelial 
cell lines) is mediated by αvβ3 receptor. 
 
6.3 Materials and Methods: 
 
Recombinant proteins:  Recombinant αvβ3 (R&D Systems), rhMSF+aa and rhMSF-aa 
(prepared in house) 
Antibodies: 
PrimaryAb:  
- Mab VSI 2.1. 
- RpVSI, 2µg/ml.  
- Anti- human integrin αVβ3 antibody Mouse. 
- Anti- human integrin αVlCD 51 antibody Goat AF 1219.  
- Anti-human Integrin β3/CD61 Monoclonal Antibody, MAB2266. 
- TYN 1.1 (batch 3). Mouse monoclonal antibody to MSF- aa. 
Secondary Ab:  
- Goat anti-rabbit conjugated with horse radish peroxidase (GAR-HRP), (DAKO) 
- Rabbit anti-mouse conjugated with horse radish peroxidase (RAM-HRP), (DAKO). 
- Rabbit anti-goat conjugated with horse radish peroxidase (RAG-HRP), (DAKO) 
 
Cells:  
Different types of cell lines have been used in this study as in described in (Table 2.2) 
Chapter two Materials and Methods. 
 
Affinity chromatography: Three affinity chromatography columns (rhMSF+aa, 
thMSF-aa and BSA) were prepared as described in Chapter two Materials and 
Methods.  
Membrane proteins were extracted from pellets of cultured cells using the 
Mem- PER Eukaryotic Membrane Protein Extraction Reagent Kit from Pierce as 
described in Chapter two (Materials and Methods). In addition to the transmembrane 
migration assay as outlined also in Chapter two (Materials and Methods). 
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6.4 Results  
 
6.4.1 Effects of anti- αvβ3 antibody on the MSF bioactivity Inhibition of MSF 
bioactivity by anti- αvβ3 antibody  
 
          The integrin αvβ3 integrin has been reported to mediate MSF activity on 
fibroblasts (Schor et al., 1999; Ellis et al., 2010).  In this study the effects of 
neutralising antibody to this integrin on MSF-stimulated migration, on different target 
cells was investigated. Data presented in Fig 6.1, 6.2 and 6.3 indicate that stimulation 
of migration by MSF on HSG, TYS, and Endo 742 cells was abrogated by the 
addition of αvβ3 neutralising antibody.  These data show that anti-αvβ3 antibody on 
its own did not affect the migration of these cells. However, when added together with 
rhMSF (100pg/ml), the chemotactic effects of MSF at 100pg/ml were completely 
neutralised by anti-αvβ3 at 1µg/ml concentration, suggesting that the motogenic 
activity of MSF is mediated by αvβ3 integrin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Effect of anti-alpha v beta 3 antibody on the motogenic activity of rhMSF on the HSG 
cells in the transmembrane assay.   
Serum-free- MEM containing 2µg/ml BSA (baseline) was used as a negative control and two 
batches (15 & 16) of rhMSF+aa, 100pg/ml rhMSF-aa as a positive controls. A significant 
inhibitory effect of anti- αvβ3 on the motogenic activity of rhMSF on the migration of the 
HSG cell line was shown when compared to the negative control (Bonferroni’s test). 
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Figure 6.2: Effect of anti-alpha v beta 3 antibody on the motogenic activity of rhMSF on the TYS 
in the transmembrane migration assay.  
Serum-free- MEM containing 2µg/ml BSA (baseline) was used as a negative control and 
100pg/ml of rhMSF+aa & rhMSF-aa as a positive controls. A significant inhibitory effect of 
anti-αvβ3 on the motogenic activity of rhMSF on the migration of the TYS cell line was 
shown in comparison to the negative control (Bonferroni’s test).  
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Figure 6.3: Effect of anti-alpha v beta 3 antibody on the motogenic activity of rhMSF on the 
Endo 742 cells in the transmembrane migration assay.   
Serum-free- MEM containing 2µg/ml BSA (baseline) was used as a negative control and 
100pg/ml rhMSF+aa (A) and rhMSF-aa (B) as a positive controls. All concentrations of anti- 
αvβ3 antibody inhibited the motogenic activity of rhMSF compared to the negative control 
(Bonferroni’s P>0.05), furthermore there was no  significant effect of anti- αvβ3(alone) on the 
migration of the Endo 742 cells in comparison to the negative control (Bonferroni’s test). 
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The effect of anti-αvβ3 antibody on the bioactivities of MSF 3, 5m and 7, 9m 
mutants on the migration of Endo 742 cells were tested to determine the possible 
binding site of αvβ3 integrin with MSF. Data presented in (Fig 6.4) indicate that anti- 
αvβ3 antibody neutralised the motogenic activity of all mutants comparing to negative 
control (Bonferroni’s test).   
 
 
 
 
 
 
Figure 6.4: Effect of anti-alphav beta 3 antibody on the motogenic activity of MSF 3,5m, 7,9m 
and Qm on the Endo 742 cells in the transmembrane migration assay.  
Serum-free- MEM containing 2µg/ml BSA (baseline) was used as a negative control and 
100pg/ml rhMSF+aa as a positive control. Anti- αvβ3 antibody inhibited the motogenic 
activity of all MSF mutants in comparison to the negative control (Bonferroni’s test), all these 
mutants alone stimulate the migration of Endo 742 cells in comparison to the negative control 
(Bonferroni’s test). 
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After TYS-CM affinity column chromatography with RpVSI MSF 
identification antibodies, fractions containing migration stimulating activity was 
analysed for the presence of MSF using the transmembrane assay and anti αvβ3 on 
different target cells. Anti αvβ3 did not affect the control or baseline migration of 
TYS cells when tested on its own, but in combination with the eluted fraction purified 
with RpVSI, it effectively reduced  the cells migrated from values comparable to 
those of positive controls(100pg/ml rhMSF+aa) to baseline levels (Fig 6.5). 
 
 
Figure 6.5: Effect of anti-alpha v beta 3 antibody on the motogenic activity of TYS-CM after 
characterisation by RpVSI affinity chromatography on the TYS cells.  
Serum-free- MEM containing 2µg/ml BSA (baseline) was used as a negative control and 
100pg/ml rhMSF+aa as a positive control. The motogenic activity of the eluted sample (MSF) 
was abrogated by the presence of anti-αvβ3 antibody in the migration assay. A significant 
effect of the eluted sample (MSF) on the migration of TYS cells was shown, in comparison to 
the negative control (Bonferroni’s P<0.05).  
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6.4.2 Recombinant αvβ3 binding with rhMSF 
 
In two preliminary experiments polystyrene 96-well microplates (Costar) were 
coated overnight with rhMSF, rhαvβ3 and cellular fibronectin (cFn). The second 
protein (rhMSF and rhαvβ3) was then applied to the plate diluted in PBS, the indirect 
ELISA method as described in Materials and Methods Chapter two was then 
followed. Data presented in (Table 6.1) indicated a direct association between rhαvβ3 
and rhMSF.  
 Table 6.1: Summary of intial results; Binding between recombinant alph v beta 
3 and rhMSF in indirect ELISA    
 
 Basic ELISA 
Exp 
No 
Coating 
Protein 
(500ng/ml) 
Second 
Protein 
(500ng/ml) 
First Ab 
(1 or 
10µg/ml) 
OD 
450-570nm 
mean of 2 
wells 
Comment 
αvβ3 MSF Mab VSI 2.1 
Anti-MSF 
500ng/ml 
0.272 
 
Positive  binding  
MSF αvβ3 Mab3050 
Anti-αvβ3 
500ng/ml 
0.186 Positive  binding  
cFn αvβ3 Mab3050 
Anti-αvβ3 
500ng/ml 
0.275 Positive  binding 
(positive control) 
1 
MSF none Mab3050 
Anti-αvβ3 
500ng/ml 
0.058 No binding  
(Negative control) 
 CB none Mab3050 
Anti-αvβ3 
500ng/ml 
0.028 No binding  
(Negative control) 
αvβ3 MSF RpVSI 
10µg/ml Anti- 
MSF 
0.479 Positive  binding  
MSF αvβ3 Anti αVlCD 
51, 1µg/ml 
0.808 Positive  binding  
cFn αvβ3 Anti αVlCD 
51, 1µg/ml 
0.774 Positive  binding 
(positive control) 
2 
αvβ3 none RpVSI 
10µg/ml Anti- 
MSF 
0.038 No binding  
(Negative control) 
 cFn= cellular fibronectin (+ve control), CB= coated buffer 
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6.4.3 Binding of integrin αvβ3 with both MSF isoforms  
Binding of integrin αvβ3 with rhMSF+aa, rhMSF-aa and BSA  affinity 
chromatography columns was carried out as described in section (2.3.3) of Materials 
and Methods in Chapter two. The resultant fractions were assayed for αvβ3 
concentration by indirect MSD ELISA, the plate was coated overnight with; rhαvβ3 at 
(0, 0.4, 2, 10, 50ng/ml) as a standard curve and eluted fractions from three affinity 
columns, using specific anti- αv antibody (Anti-human Integrin αV/CD51, AF 1219 
antibody), and anti-β3 (Anti-human Integrin β3/CD61 Monoclonal Antibody, 
MAB2266). Data presented in (Table 6.2) (Fig 6.7 and 6.8A) indicate a direct 
association between αv, β3 subunits and both MSF isoforms, whilst there was no 
effect with BSA (negative control), in addition the concentration of αv and β3 in 
eluted fractions was measured by using linear regressions statistical test. Fig 6.6 
showed standard curve of rhαvβ3 with both anti-αv and anti-β3 antibodies.  
 
 
 
Figure 6.6: Indirect MSD ELISA standard curve of recombinant alpha v beta 3 using anti-alpha 
v and anti-beta 3 antibodies.   
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Table 6.2: Indirect MSD ELISA summary of eluted recombinant alpha v beta 3 
across three affinity chromatography columns    
antibody  Sample 
eluted from 
OD mean 
value  
(counts) 
Equivalent to  
Recombinant protein 
standard curve 
(ng/ml) 
Linear regression test  
Comments 
MSF-aa 
column 
3381±26.2 
 
 
2.224ng/ml 
 
 
Detectable  
 
MSF+aa 
column 
6928.5± 38.8 
 
 
4.834ng/ml 
 
 
Detectable 
 
Anti- human 
integrin 
αVlCD 51 
antibody AF 
1219 
BSA column 86± 8.4 
 
-5.876 
 
undetectable 
MSF-aa 
column 
1247±141 
 
1.039ng/ml 
 
Detectable 
 
MSF+aa 
column 
29512±735.3  
 
8.820ng/ml 
 
Detectable 
Mouse Anti- 
human 
integrin beta 
3 (CD61) 
antibody BSA column 24± 2.8 
 
- 4.898  
 
undetectable 
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Figure 6.7: Binding and identification of integrin alpha v beta 3 using anti-alpha v antibody.  
Recombinant αvβ3 (2µg/ml) was incubated with three chromatography affinity columns 
(rhMSF+aa, rhMSF-aa and BSA) as described in Materials and Methods in Chapter two. The 
eluted αvβ3 was fractionated by 7.5 % SDS PAGE under reducing conditions and 
immunoblotted with the commercial anti- αv. A clear band was seen at approximately 130 
kDa, confirming the binding of αv subunit with both MSF isoforms (lane 3, 4). Whilst no 
band was seen with the sample eluted from the BSA column (lane 12). αvβ3 was identified in 
cell membrane proteins that had been extracted from four cell lines (TYS, HSG, Endo 742 
and FSF44) (line 6-9), and also in the eluted fractions of TYS, HSG, Endo 742 (lanes 5, 10 
and 11) after affinity chromatography following the same methods as described in Materials 
and Methods. The data indicate the presence of αv subunit in these cell membranes and in the 
eluted fractions that binding with total MSF. (M=magic marker, +ve control= recombinant 
αvβ3, E= eluted αvβ3 across affinity column, Cm=cell membrane, Ub= unbound fraction) 
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Figure 6.8: Binding and identification of integrin alpha v beta 3 using anti-beta 3 antibody.  
(A) Recombinant αvβ3 (2µg/ml) was incubated with three chromatography affinity columns 
(rhMSF+aa, thMSF-aa and BSA) as described in Materials and Methods in Chapter two. The 
bound and subsequently eluted αvβ3 was fractionated by 7.5 % SDS PAGE under reducing 
conditions and immunoblotted with the commercial anti-β3. A clear band was seen at 
approximately 100 kDa, confirming the binding of β3 subunit with both MSF isoforms (lane 
3, 4). Whilst no band with BSA column and unbound fractions (lanes 5, 6 and 7). (B) αvβ3 
was identified in cell membrane proteins that had been extracted from (TYS, HSG, and Endo 
742) cell lines after affinity purification against rhMSF (lanes 3, 4 and 5), following the same 
methods as described in Materials and Methods. The data indicate the binding of β3 subunit in 
the eluted fractions of these cell membranes with total MSF, but not with BSA (lane 6). 
 
 
 
 
 
 
 
 
  
198 
6.4.4 Identification of integrin αvβ3 in cell membrane extracts 
Integrin αvβ3 was identified in samples of cell membrane proteins that had 
been extracted from three cell lines (TYS, HSG and Endo 742) using two 
chromatography affinity columns (rhMSF+aa and BSA as a negative control) 
following the same methods of RpVSI affinity chromatography as described in 
section (2.3.3) in Materials and Methods Chapter two. The eluted fractions for each 
sample were pooled after affinity chromatography and concentrated by freeze drying. 
Integrin αvβ3 was identified in the fractions by using indirect MSD ELISA and 
Western blot (Fig 6.7 and 6.8B) and Mass spectroscopy. Data presented in (Table 6.3) 
indicate that the integrin subunits αv and β3 are present in the cell membrane extracts 
and that both MSF isoforms bind to this receptor.  
 
Table 6.3: Indirect MSD ELISA summary of eluted cell membrane proteins 
across three affinity chromatography columns   
sample antibody Sample 
eluted from 
OD mean 
value 
 
Equivalent to 
Recombinant 
protein standard 
curve (ng/ml) 
linear regression 
test 
Comments 
MSF+aa 
column 
3319.5±6.3 
 
2.188ng/ml 
 
Detectable 
 
Endo 
742 
Anti- human 
integrin αVlCD 
51 antibody AF 
1219 
BSA 
column 
67±23 
 
 
0.33pg/ml 
 
 
Undetectable 
 
MSF+aa 
column 
13288±42.09 
 
42.815ng/ml Detectable 
 
 
Mouse Anti- 
human integrin 
beta 3 (CD61) 
antibody 
BSA 
column 
-552±13 
 
-19.3 
 
Undetectable 
 
Anti- human 
integrin αVlCD 
51 antibody AF 
1219 
MSF+aa 
column 
1113.5±7.07 
 
1.762ng/ml 
 
 
 
Detectable HSG  
Mouse Anti- 
human integrin 
beta 3 
(CD61)antibody 
MSF+aa 
column 
4140±24.9 
 
 
 
1.820ng/ml 
 
 
 
Detectable 
TYS Anti- human 
integrin αVlCD 
51 antibody AF  
1219 
MSF+aa 
column 
5737 ± 79.4 
 
 
 
3.565ng/ml 
 
 
 
Detectable 
 
Mouse Anti- 
human integrin 
beta 3 (CD61) 
antibody 
MSF+aa 
column 
9436.5±30.9 
 
 
 
2.695ng/ml 
 
 
 
Detectable 
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Figure 6.9: Schematic description of the modular structure of fibronectin.  
 
Fn consists of three different modules (type I, blue; type II, brown; type III, green). The 
alternatively spliced extradomains B, A, and variable region (V) are shown in ochre. The 
dimer forms via two disulfide bonds at the C-terminus. Integrin binding sites are indicated. 
The N-terminal type I domains marked with a red asterisk harbour an IGD motif. Binding 
domains for Fn, collagen, fibrin, heparin and bacteria are indicated. Besides providing a high 
affinity binding site for αvβ3, the isoDGR motif in the fifth type I repeat also mediates low 
affinity binding to α5β1. (Adapted from Leiss et al., 2008) 
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6.5 Discussion  
Integrins are a family of heterodimeric, cation–dependent transmembrane 
glycoproteins that mediate cell adhesion and are involved in many cells signalling 
pathways (Hynes, 1992). The majority of integrin ligands are either ECM molecules 
(e.g. fibronectin and vitronectin) or cell surface molecules of the immunoglobulin 
superfamily (e.g. intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1)). Some ligands, like fibronectin bind to several 
integrins including- α5β1, αvβ1, α4β1, αIIβ3, αvβ6 (Fig 6.9). Some integrins, like 
αvβ3 binds to several ligands including fibronectin, fibrinogen, bone sialoprotein, 
laminin, thrombospondin, vitronectin, and van Willebrand factor (Humphries, 1990; 
Felding-Habermann and Cheresh, 1993; Newham and Humphries, 1996; Horton, 
1997; Boettiger et al., 2001a and 2001b). The enormous and difficult network of 
receptor–ligand complexes permits integrins to contribute to a variety of cellular 
processes, such as cellular adhesion, migration, proliferation, differentiation, and 
survival (Geiger et al., 2001; Howe et al., 1998). 
Integrins may play an important role in tumour cell invasion and metastasis in 
OSCC, such as αvβ3, αvβ6, α5β1 which are not expressed in healthy oral epithelia but 
are upregulated during carcinogenesis, angiogenesis or wound healing. However, 
invasion can be reduced dramatically in OSSC cell lines using anti-αv or anti- αvβ6 
antibodies (Brooks et al., 1994; Eliceiri and Cheresh, 2000; Thomas et al., 2001 and 
Thomas et al., 2006)    
The aim of this study was to identify the receptors responsible for the 
motogenic activity of MSF and to verify that the motogenic activity of MSF in 
various types of cells (oral tumour, salivary gland tumour and human endothelial cell 
lines) is mediated by αvβ3 receptor. 
Data presented in this study indicates a direct association between αvβ3 
integrin and rhMSF protein. In addition to that, the direct association between αv, β3 
subunits (eluted fractions) and both MSF isoforms after affinity chromatograph. MSF 
can bind to and might be able to signal via integrin αvβ3.These result reflect that the 
possible mechanism whereby functional neutralising antibody to αvβ3 abolished the 
motogenic effects of MSF on different target cells (TYS, HSG and Endo742), our 
results are in agreement with Schor et al, (1999) and Ellis et al, (2010) who reported 
that fibroblast cell migration is activated by IGD and GBD of fibronectin but was 
blocked by a neutralising antibody to integrin αvβ3. They also showed that migration 
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is mediated by a signal transduction cascade involving the tyrosine phosphorylation of 
FAK. This may reflect the importance of integrin αvβ3 in IGD stimulated migration.  
Brooks et al, (1995) and Rathinam and Alahari, (2010) reported that in tumour 
cells, the αvβ3 integrin promotes growth and invasion, whereas its inhibition results in 
anoikis [apoptosis that is induced by inadequate or inappropriate cell-matrix 
interactions. It is involved in a wide diversity of tissue-homeostatic, developmental 
and oncogenic processes (Frisch and Screaton, 2001)] and tumour regression as an 
anti-angiogenic agent for the treatment of cancer.  
Thomas et al, (2001) showed in their study that αvβ6 increased matrix 
metalloproteinase production, stimulated cell migration and increased invasion of oral 
tumour cells. Schor et al, (1999) indicated that response of fibroblasts to MSF/IGD 
requires maintenance of integrin αvβ3 functionality and is mediated, at least in part, 
by the PI-3 kinase signal transduction pathway. Ellis et al, (2010) found that 
Migration stimulating activity of IGD containing molecules on fibroblasts was 
blocked by neutralising antibodies to integrin αvβ3 and is mediated by a signal 
transduction cascade involving the tyrosine phosphorylation of Focal adhesion kinase 
(FAK).  
Integrins are known to act via RGD containing peptide motifs and have been 
reported to cause the phosphorylation of integrin associated proteins such as FAK. 
The RGD loop has been recognised as key sequence for integrin αvβ3 (Xiong et al., 
2002) but changing IGD to RGD abolished the motgenic activity of fibroblast cells 
which may be due to inherent inflexibility of RGD in this circumstance (Millard et al., 
2007).   
Our results also indicate that the identification of integrin αvβ3 from cell 
membrane proteins of different target cells including; TYS, HSG and Endo 742 by 
using two MSF isoforms chromatography affinity columns reflect the bidirectional 
signaling mechanism of integrin αvβ3 in the cellular functions (migration) of these 
cells by the interaction with MSF ligand at the site at which αvβ3 binds MSF which 
might be IGD site rather than an RGD site which is not present in the MSF structure.  
Takahashi et al, (2007) reported that the absence of a functional RGD motif in 
fibronectin did not compromise the assembly of Fn fibrils in mutant embryos or cells. 
A possible explanation suggested was that Fn contains another integrin binding site in 
its N-terminal region other than RGD sequence (Fig 6.9). 
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On the other hand, Takahashi et al., (2007) reported that other sequences 
mimic RGD, these sequences are DGR, NGR of which MSF has three and RGF of 
which MSF has two.  The N-terminus of fibronectin (and hence MSF) contains two 
NGR which are located in 5Fn1 and 7Fn1 modules (Di Matteo et al., 2006). The 
conversion of NGR to isoDGR sequence through the deamidation and rearrangement 
of the asparagine residue could constitute a binding ligand for the αvβ3 integrin, 
which may regulate the protein functions (Curnis et al., 2006).  
Leiss et al, (2008) reported that the integrin αvβ3 binding site was located at 
the N-terminus of the Fn polypeptide and included the N-terminal type I domains (Fn-
I1–9 fragment; also called the 70 kDa fragment of Fn). 
Shpiro et al, (2005) designed and synthesised the first IGD peptidomimetic.  
These mimetics are able to stimulate the migration of human skin fibroblasts into 3D 
collagen gels (Shpiro et al., 2005 and Marquez, et al unpublished). Modelling of the 
active RGD binding region of the integrin αvβ3 showed that the peptido-mimetic IGD 
could be docked comfortably onto the integrin and shares some of the RGD binding 
site (Norman et al, unpublished; Shpiro et al., 2005).                
Data presented here suggest that the motogenic activity of MSF in various 
types of cells (oral tumour, salivary gland tumour and human endothelial cell lines) is 
mediated by αvβ3 receptor, and the potential integrin αvβ3 binding site was located at 
the IGD motifs.  
MSF affinity chromatography and MALDI (MS/MS) analysis were used to 
analyse membrane protein extracts of the cell line TYS, unfortunately no new 
candidate receptors for MSF were identified by the initial study. 
 
6.6 Further studies 
 
- Recombinant MSF-fragments as well as recombinant integrins are important tools, 
which are now available to perform ELISA- or Surface Plasmon Resonance-based 
binding studies to precisely map binding sites. 
 
- To corroborate the initial data suggesting that the effect of MSF upon cells is a direct 
result of MSF binding to αvβ3 by using Surface Plasmon Resonance (SPR). 
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7. Chapter seven: Discussion, Conclusions and Suggestions 
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7.1 Discussion  
Fibronectin is a multifunctional glycoprotein; expressed fibronectin 
bioactivities are dependent upon functional domains that are present in both the 
native-full length molecule and in its fragments. Fibronectin fragments created by 
proteolysis exhibit many properties not seen in the full length molecule, for instance 
GBD functional domain, which is generated proteolytically, exhibits a potent 
motogenic activity that is cryptic in full-length fibronectin (Schor et al., 1996). The 
main function of fibronectin is cell adhesion but it appears to have many cryptic 
activities (Clark et al., 1988; Hynes, 1990; Emod et al., 1990 and Fukai et al., 1993). 
MSF being a truncated form of fibronectin possesses different activities to full length 
fibronectin (Schor et al., 2003; Houard et al., 2005). 
MSF is a potent motogenic factor, able to stimulate the migration of 
fibroblasts, epithelial and endothelial cells. MSF also stimulates hyaluronic acid (HA) 
synthesis and angiogenesis. It is important to note that none of these bioactivities are 
manifest by all previously characterised full-length isoforms of fibronectin and are 
most likely a consequence of steric hindrance of their constitutive bioactive motifs 
(Schor et al., 2003; Millard et al., 2007; Vakonakis et al., 2009). In the 3D collagen 
gel migration assay MSF stimulates fibroblast migration whereas fibronectin has no 
effect (Schor et al., 2003; Schor et al., 1990). A study carried out by Schor et al., 
(2003) revealed that the motogenic activity of MSF on fibroblasts is totally dependent 
on the GBD, as the mutation of IGD sequences of 7Fn1 and 9Fn1 module of the GBD 
inhibited the migration stimulating activity of MSF. Ellis et al, (2010) found that IGD 
sequences in 3FnI and 5FnI have a cryptic motogenic activity present within MSF 
fragments. The bioactivities of MSF have been discussed in Chapter one, several 
studies have shown the effect of MSF on the proliferation and migration of fibroblast 
target cells, Schor et al, (1988) and Grey et al, (1989) found that MSF does not affect 
either proliferation or morphology of normal adult cells under any of the culture 
conditions (Fetal or breast cancer patient skin fibroblasts; CM examined). They 
reported that the ability of MSF to stimulate fibroblast migration is not dependent 
upon the initiation of cell proliferation.  
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7.1.1 MSF Role in tumour pathogenesis 
MSF is expressed by the three principal cell types of foetal skin 
(i.e. keratinocytes, fibroblasts and microvascular endothelial cells), not expressed by 
these cells in the majority of adult skin, and persistently re-expressed in tumours by 
both the carcinoma and stromal cell populations. MSF bioactivity in tumours may be 
responsible for increased levels of migration and invasion. The stimulation of tumour 
cell migration, biosynthesis of HA and angiogenesis are the mechanisms through 
which the potent bioactivities of MSF contribute to tumour pathogenesis (Schor et al., 
2003).   Foetal development and the maintenance of normal tissue structure and 
function in the adult are mediated by epithelial and stromal cells interactions. These 
interactions are mediated by various soluble molecules, matrix macromolecules and 
chemical signals. Disturbance in these interactions could contribute to the aetiology of 
various pathological conditions, like cancer.  
The precise response of potential target cells to MSF is modulated by a 
complex hierarchy of control mechanisms, including (i) the precise nature of the 
extracellular matrix and (ii) the presence of soluble and insoluble inhibitory 
molecules.  For example, MSF is a potent stimulator of fibroblast migration on a 
native type I collagen substratum, but is completely devoid of motogenic activity on 
denatured type I collagen (Schor et al., 2003).  Interestingly, the response of 
carcinoma cells, stromal fibroblasts and endothelial cells to MSF are differentially 
modulated by matrix molecules: i.e. a given matrix constituent may affect the 
behaviour of one cell type, but not another. In this regard, previous data suggest that 
the stimulation of adult fibroblast migration by MSF may be a secondary consequence 
of its primary effect upon the deposition of matrix macromolecules, in particular HA 
(Schor et al., 1989; Schor et al. unpublished data). However, this is not the case with 
endothelial or other types of cells, where MSF does not affect HA synthesis 
(unpublished data). TGF-β1, a well characterised cytokine, may act as either an 
activator or an inhibitor of MSF, depending on the nature of the extracellular matrix in 
contact with the cells (Ellis et al., 1992; Schor et al., 2010; unpublished data). 
In the present study the immunostaining with two MSF antibodies (7.1 and 
TYN) indicated that approximately 98% of OSCC (n = 50), 93% of malignant SGT 
(n= 24) and 43% of benign SGT (n=7) overexpressed total MSF and MSF-aa in both 
epithelial and stromal compartments. Oral tumour (TYS) and salivary gland tumour 
(HSG) cell lines produced MSF and secreted bioactive MSF into their conditioned 
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medium. Exogenous rhMSF stimulated the migration of tumour cells through 
collagen-coated membranes. Conversely, cell migration by MSF producing tumour 
cells was effectively abolished by MSF-function-neutralising antibodies (PEPQ) and 
anti-αvβ3 antibody. Of the two inhibitory factors examined, IGFBP7 inhibited both 
MSF isoforms whereas NGAL inhibited only MSF+aa. 
Taken together, previous observations and our results suggest that cellular 
response to MSF in tumours is not invariant, but dependent upon spatial and temporal 
changes in the expression of MSF inhibitors and matrix re-modelling which occur 
during tumour progression. 
The possible detrimental effects of MSF on disease outcome is supported by 
my present data indicating that high MSF expression by the cells in the invasive 
tumour front (ITF) is associated with poor survival in patients with OSCC.  Evidence 
supporting the suggested role for MSF in cancer pathogenesis has also been presented 
by Hu et al, (2009); using an unbiased proteomic screen these authors identified MSF 
as a critical angiogenic factor driving oesophageal cancer progression. 
The present study investigated the possible amino acid active motif that 
modulated the MSF migration stimulation for FSF44, Endo 742, TYS and HSG cells. 
The results indicated that the HEEGH motif functions in addition to the bioactive IGD 
motifs in stimulating the migration of target endothelial cells:  i.e. both the HEEGH 
and IGD motifs of MSF must be mutated in order to abolish the motogenic response 
of endothelial cells.  In the case of TYS and HSG cells, a single mutation in either 
IGD or HEEGH motifs is sufficient to abolish the motogenic response.  
Schor et al, (1999) reported that the presence of αvβ3 and its downstream 
signalling components (phosphatidylinositol 3 kinase and focal adhesion kinase) are 
required for IGD motogenic activity. Our data provide evidence that MSF was found 
to bind directly integrin αvβ3, this interaction may lead to localisation of MSF in a 
proteolytically active form on the cell surface. These findings might provide a 
molecular basis to explain that this cell-surface receptor may be the most important 
receptor amongst a complex of other integrin and non-integrin receptors that can 
regulate both cell migration and matrix degradation, thereby facilitating invasion. This 
supports work by Houard et al, (2005) who suggested that the localisation of MSF at 
the cell surface may be necessary for the biological activity of MSF as a Fn-
proteinase. Furthermore, Schor et al, (1999) reported that the IGD sequence resembles 
the integrin-binding sequence Arg-Gly-Asp (RGD), and it is possible that IGD 
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sequence targets MSF at the cell surface, thus initiating signal transduction pathways 
responsible for the migratory activity of MSF. Further studies are required to explain 
the exact mechanism of the IGD and HEEGH motifs for stimulating the migration of 
oral cancer cells. 
MSF was over-expressed in malignant salivary gland tumours and oral 
sequamous cell carcinomas by both tumour cells and tumour-associated stromal cells. 
It is of particular interest that several sub-sets of stromal cells, including fibroblasts, 
microvascular endothelial cells and inflammatory cells, were positively stained, thus 
indicating the coordinated up-regulation of MSF expression during tumour 
progression. In this regard, it should be noted that MSF expression by stromal 
fibroblasts has recently been reported to be induced by epigenetic mechanisms 
regulated by the concerted signalling of TGF-β and the matrix (Kay et al., 2005; 
Schor et al., 2005; Schor and Schor, 2010). Considering the strong association 
between tobacco consumption and head and neck cancer incidence, it is of interest 
that the tobacco carcinogen benzo(a)pyrene has been shown to induce MSF 
expression by a bronchioloalveolar carcinoma cell line (Yoshino et al., 2007). 
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7.2 Conclusions  
 
- Two MSF isoforms (MSF+aa and MSF-aa) have been detected in tissue culture and 
in tissue sections.  The general term MSF (or total MSF) is used here to refer to both 
isoforms.  MSF+aa and MSF-aa induced the same migration-stimulating effect upon 
oral tumour cell lines (TYS and HSG) and normal stromal cells: skin fibroblasts 
(FSF44) and microvascular endothelial cells (Endo 742).   
 
- Five bioactive motifs (4x IGD and 1x HEEGH) were found to be required for MSF 
bioactivity on TYS and HSG cells, whereas only one of these motifs was required for 
Endo 742 and two for FSF44.   
 
- MSF+aa and MSF-aa differed in their interaction with the MSF-inhibitor NGAL.  
NGAL was shown to bind to and inhibit MSF+aa, but not MSF-aa.  The bioactivity of  
MSF+aa and MSF-aa was inhibited by IGFBP7, MSF-function-neutralising antibody 
and antibody to the integrin αvβ3. 
 
- Oral tumour cell lines TYS and HSG cells secreted bioactive MSF in culture. 
Therefore, MSF stimulates tumour cell migration in an autocrine and paracrine 
manner, modulated by the type of MSF isoform expressed and by the presence of 
NGAL and other possible inhibitors.  MSF stimulated the migration of these cells. 
 
- The integrin αvβ3 was identified in the cell membrane material bound to MSF, 
suggesting that αvβ3 is a receptor for MSF.  
 
- In tissue sections, MSF was expressed by most OSCC and malignant SGT, being 
heterogeneously present in both carcinoma and stromal cells.  
 
- Significantly higher levels of total MSF and MSF-aa were detected in malignant 
than in benign SGT.  In OSCC, high MSF expression in the invasive tumour front was 
significantly associated with poor patient survival.  MSF-aa was more informative 
than total MSF. 
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- Data presented here provide an initial indication that expression of MSF is up-
regulated in both the epithelial and stromal cell compartments of malignant oral 
tumours.  This study provides a rational platform for subsequent more extensive 
investigation of the possible diagnostic and prognostic significance of MSF in these 
tumours. It also suggests that developing means to inhibit MSF expression and ⁄ or 
functionality may provide novel therapeutic strategies to improve the management of 
patients with oral tumours. 
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7.3 Suggestions  
 
- Study the expression of MSF in the normal oral mucosa and non-tumour 
lesions such as epithelial dysplastic tissue to provide a rational platform for 
subsequent more extensive investigation of the possible diagnostic 
significance of MSF expression in OSCC. 
 
- To examine the role of MSF expression, in Kp or at the ITF, as a prognostic 
factor in larger number of patient samples. 
 
- A more detailed cytological study will be required to ascertain the possible 
relationship between MSF expression and the histological characteristics of 
the salivary gland tumours. 
 
- Increase the numbers of benign tumour specimens to study the diagnostic role 
of MSF expression in salivary gland tumour. 
 
- Assessment the presence of MSF message in salivary gland tumours and 
OSCC by using in situ Hybridization. 
 
- Using other types of tissue target cells for testing the migration effect of MSF. 
 
- Investigate the role of other soluble molecules on the MSF bioactivity. 
 
- Recombinant MSF-fragments as well as recombinant integrins are important 
tools, which are now available to perform ELISA- or Surface Plasmon 
Resonance-based binding studies to precisely map binding sites. 
 
- To corroborate the initial data suggesting that the effect of MSF upon cells is a 
direct result of MSF binding to αvβ3 by using Surface Plasmon Resonance 
(SPR). 
 
-  
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- The study of the possible role of MSF on oro-facial development due to its 
oncofetal pattern of expression, and its possible role in facial deformities like 
cleft lip or palate. 
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APPENDICES 
Appendix 1: Boyden chamber migration assay of HSG cells and MSF 
Exp 31: Code: LA18/05/09  
 
Objective: To determine the inhibition effect of PEPQ 1.1 Ab on the migration of HSG. 
 
Cells: salivary gland tumour cells, HSG 
Cells: semi-confluent (85%), 3.6 x 10
6
 cells/90mm dish 
Cells have been grown on 90 mm dishes in 15% DCS-MEM- media 
Last farmed 1x90mm to 2 x90mm, 1 day before the experiment on 17/05/09 
 
Protien: 
- rhMSF +aa, Endotoxin free, batch 3, of Conc. 10µg/ml diluted in 1ml of SF- BSA 
to final concentration of 100pg/ml and 100ng/ml. 
 
Antibody: 
- PEPQ 1.1: Stock concentration 61.4 µg/ml, Batch no.2, tested at final concentrations  
             of 1µg/ml. 
 
Upper chamber: Cells in SF-BSA (2 µg/ml);  
4.5 x10
4
cells/50µl/well (9 x 10
5
 cells/ml) 
 
Lower chamber: with SF-BSA (2 µg/ml) 
 
SF-MEM (BSA) 
 
100pg/ml  MSF+aa 
 
100ng/ml  MSF+aa 
 
SF-MEM (BSA) 
 
SF-MEM (BSA) 
+ 
1µg/ml PEPQ1.1 
100pg/ml  MSF 
+ 
1µg/ml PEPQ1.1 
100ng/ml  MSF+aa 
+ 
  1µg/ml PEPQ1.1 
SF-MEM (BSA) 
+ 
1µg/ml PEPQ1.1 
 
Filter used: 8µm pore filter used, immersed in collagen at 4° for overnight. 
Native Collagen: 100 µg/ml used 1 times 
Incubation period: 5 hours 
Staining time: overnight 
Negative control: Serum free- bovine serum albumin (BSA) 
 
Result: Cells are counted 3 fields/well, and the mean of 6 wells per each variable using a 
microscope x 200(including eye piece magnification) under bright field conditions. 
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Conditions Well  Migrated cell number 
Mean/ 
well 
SD/ 
well 
Mean/6 
well  
SD/6 
well 
General 
mean 
General 
SD % 
Serum free 1 30 33 29 30.667 2.0817 30.33333 0.843274       
  2 32 31 29 30.667 1.5275           
5 hr 3 29 30 30 29.667 0.5774           
  4 30 28 29 29 1     30.02778 1.039214 100% 
d=-2 5 31 29 32 30.667 1.5275           
HSG 
6 31 31 32 31.333 0.5774           
  7 29 28 30 29 1 29.72222 1.200309       
  8 31 30 30 30.333 0.5774           
  9 32 30 28 30 2           
2 10 30 29 28 29 1           
  11 29 28 28 28.333 0.5774           
  12 31 33 31 31.667 1.1547           
Serum free 
+ PEPQ 1 29 30 30 29.667 0.5774 30.44444 1.772214       
  2 31 34 33 32.667 1.5275           
5 hr 3 28 28 27 27.667 0.5774           
  4 31 30 30 30.333 0.5774     30.36111 1.898741 101% 
d=-2 5 32 34 30 32 2           
HSG 
6 29 31 31 30.333 1.1547           
  7 28 27 29 28 1 30.27778 2.184965       
  8 32 31 31 31.333 0.5774           
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  9 31 34 34 33 1.7321           
2 10 31 28 30 29.667 1.5275           
  11 27 27 29 27.667 1.1547           
  12 32 33 31 32 1           
100pg/ml 1 58 56 56 56.667 1.1547 58.33333 1.763834       
rhMSF+aa 2 57 56 57 56.667 0.5774           
5 hr 3 57 58 57 57.333 0.5774           
  4 60 59 57 58.667 1.5275     58.33333 1.763834 194.20% 
  5 58 60 61 59.667 1.5275           
1 
6 60 61 62 61 1           
100pg/ml+ 
PEPQ 1 33 32 28 31 2.6458 30.66667 3.040468       
rhMSF +aa 2 34 30 35 33 2.6458         101.90% 
5 hr 3 24 25 26 25 1     30.66667 3.040468   
  4 32 30 28 30 2           
  5 31 35 34 33.333 2.0817           
1 
6 31 31 33 31.667 1.1547           
100ng/ml  1 70 71 68 69.667 1.5275 71.16667 1.94079       
rhMSF +aa 2 70 72 72 71.333 1.1547         236.80% 
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5 hr 3 74 73 74 73.667 0.5774           
  4 74 73 73 73.333 0.5774     71.16667 1.94079   
d=-2 5 69 70 70 69.667 0.5774           
1 6 69 70 69 69.333 0.5774           
100ng/ml 
+ PEPQ 1 29 31 33 31 2 31.16667 1.394433       
rhMSF+aa 2 28 32 31 30.333 2.0817         103.50% 
5 hr 3 34 34 32 33.333 1.1547           
  4 31 32 34 32.333 1.5275     31.16667 1.394433   
d=-2 5 30 29 30 29.667 0.5774           
1 
6 30 29 32 30.333 1.5275           
 
 
 
 
 
 
 
 
  
254 
 
 
Table: effect of  MSF +aa & PEPQ 1.1 Ab  on the migration of HSG cells  
  Mean SD % migration 
 
Significance 
    ANOVA & 
Bonferroni’s 
(P<0.05) 
SF-BSA 
1+2 
30.02 1.03  100  
 
SF-BSA+  1µg/ml 
PEPQ 
30.3 1.8 101 No  
100pg/ml MSF+aa 58.3 1.7 194.2 Yes  
100pg/ml MSF+aa+  
1µg/ml 
PEPQ 
30.6 3.04 101.9 No  
100ng/ml MSF+aa 71.1 1.9 236.8 yes 
100ng/ml MSF+aa+  
1µg/ml 
PEPQ 
31.1 1.3 103.5 No  
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Statistical analysis using One-way analysis of variance Bonferroni's test  
 
Parameter Value    
Table Analyzed     
Data 1     
One-way analysis of variance     
  P value P<0.0001    
  P value summary ***    
  Are means signif. different? (P < 0.05) Yes    
  Number of groups 6    
  F 657.1    
  R squared 0.9874    
     
Bartlett's test for equal variances    
  Bartlett's statistic (corrected) 8.855    
  P value 0.1150    
  P value summary ns    
  Do the variances differ signif. (P < 0.05) No    
     
ANOVA Table SS df MS  
  Treatment (between columns) 11100 5 2219  
  Residual (within columns) 141.9 42 3.378  
  Total 11240 47   
     
Bonferroni's Multiple Comparison Test Mean Diff. t P value 95% CI of diff 
  baseline vs SF(BSA) + 1mg/ml PEPQ -0.3333 0.4443 P > 0.05 -2.669 to 2.002 
  baseline vs 100pg/ml rhMSF+aa -28.31 30.80 P < 0.001 -31.17 to -25.45 
  baseline vs 100pg/ml MSF +aa +1mg/ml PEPQ -0.6389 0.6952 P > 0.05 -3.499 to 
2.221 
  baseline vs 100ng/ml MSF +aa -41.14 44.77 P < 0.001 -44.00 to -38.28 
  baseline vs 100ng/ml MSF +aa + 1mg/ml PEPQ -1.139 1.239 P > 0.05 -
3.999 to 1.721 
  SF(BSA) + 1mg/ml PEPQ vs 100pg/ml rhMSF+aa -27.97 30.44 P < 0.001 -
30.83 to -25.11 
  SF(BSA) + 1mg/ml PEPQ vs 100pg/ml MSF +aa +1mg/ml PEPQ -0.3056 0.3325 P > 
0.05 -3.166 to 2.555 
  SF(BSA) + 1mg/ml PEPQ vs 100ng/ml MSF +aa -40.81 44.40 P < 0.001 -
43.67 to -37.95 
  SF(BSA) + 1mg/ml PEPQ vs 100ng/ml MSF +aa + 1mg/ml PEPQ -0.8056 0.8766 P > 
0.05 -3.666 to 2.055 
  100pg/ml rhMSF+aa vs 100pg/ml MSF +aa +1mg/ml PEPQ 27.67 26.07 P < 0.001
 24.36 to 30.97 
  100pg/ml rhMSF+aa vs 100ng/ml MSF +aa -12.83 12.09 P < 0.001 -16.14 to -
9.531 
  100pg/ml rhMSF+aa vs 100ng/ml MSF +aa + 1mg/ml PEPQ 27.17 25.60 P < 0.001
 23.86 to 30.47 
  100pg/ml MSF +aa +1mg/ml PEPQ vs 100ng/ml MSF +aa -40.50 38.17 P < 0.001
 -43.80 to -37.20 
  100pg/ml MSF +aa +1mg/ml PEPQ vs 100ng/ml MSF +aa + 1mg/ml PEPQ -0.5000
 0.4712 P > 0.05 -3.803 to 2.803 
  100ng/ml MSF +aa vs 100ng/ml MSF +aa + 1mg/ml PEPQ 40.00 37.70 P < 0.001
 36.70 to 43.30 
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Appendix 2: Indirect MSD ELISA summary of eluted rhNGAL across 
three affinity chromatography columns    
 
               Concentration of NGAL in samples eluted from different affinity chromatography  
  columns. The concentration was estimated by linear regression. The average OD of the 
  buffer (PBS) was subtracted from the sample OD to obtain the OD result. 
 
1. rh protein   
 
- rhLipocalin Bach no 6 ( Endotoxin free)30µg/ml & 10µg/ml and batch  no 5, 5µg/ml at 
[50ng/ml, 10ng/ml, 2ng/ml, 0.4ng/ml, 0]. 
 
2. Recombinant  eluted rhNGAL: 
  
-  Exp 1: 2ml of Batch 6 rhNGAL (2µg/ml, diluted in 20mM Tris – HCL pH 7.4) was 
passed through MSF +aa affinity column. The sample that was bound to MSF was 
eluted by increasing salt ingredient 2M NaCl + 20mm tris HCl PH 7.4, this protocol 
repeated 3 times then pooled the eluted samples and dialysed against dH2O and then 
concentrated by Freeze dried, then dissolved with PBS. 
 
 
- Exp 2: 2ml of Batch 5 rhNGAL 2µg/ml, diluted as above, but eluted one time without 
dialysis and freeze drying. Using two MSF-aa columns (Agarose beads & Sepharose 
beads) and BSA column. 
 
- Exp 3: Using MSF+aa and MSF-aa. Affinity columns. 
 
 
Sensitivity defined as the analyte concentration resulting in absorption 
significantly higher than of the mean plus three standard deviations of the dilution 
medium (SD of the blank x 3). 
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Standard curve Exp 1 Standard curve Exp 2  
 
Standard curve Exp 3 
protein Dil/conc. OD ( ~ 620nm ) 
Blank substracted 
OD (  ~ 620nm) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 10089± 67.8 209564± 1298.7 45533± 4615.9 
10ng/ml 3570± 192.3 24298± 1689.2 7313.5± 504.1 
2ng/ml 1427± 7.07 2359± 190.2 846± 46.6 
400pg/ml 1010± 312.5 79± 2.1 178.5± 85.5 
rhLipocalin 
(Endotoxin 
free) 
0 704 ± 216.3 
 
1289.5 ± 4.9 
 
992 ± 86.2 
 
        SD of blank x 3 648.9 
 
14.7 258.6 
Sample 1 Sample 2  Sample 3  
Affinity column OD (  ) 
Blank 
 substracted 
estimated  
Conc 
OD (  ) 
Blank  
substracted 
estimated  
Conc 
OD (  ) 
Blank 
substracted 
Estimated 
 Conc 
E-[NGAL]-MSF+aa  
 
1381±143.5 
 
1.656ng/ml  
   
1958.5±225.5  
 
2.608ng/ml  
 
E-[NGAL]-MSF-aa Ag 
   
-583.5±69.2 
  
-146±55.1 
  
 E-[NGAL]-MSF-aa Sp 
  
-109±115.2 
    
E-[NGAL]-BSA  
   
-1035±361.3 
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Appendix 3: Indirect MSD ELISA summary of eluted Endo IGFBP7 & rh 
Human IGFBP-rp1/IGFBP-7 across three affinity chromatography 
columns    
 
                Concentration of BP-7 in samples eluted from different affinity chromatography  
     columns. The concentration was estimated by linear regression 
 
1. rh protein   
 
- rh Human IGFBP-rp1/IGFBP-7, 100µg/ml at [50ng/ml, 10ng/ml, 2ng/ml, 400pg/ml, 0]. 
 
2. Purified protein: 
 
- IGFBP7 (dialysed against 20mm Tris buffer PH 7.4) purified from ENDO742 CM by 
Diethylaminoethyl cellulose (DEAE) chromatography (2009) and gel elution. Dialysed 
against distilled water and then freeze dried. Resuspended to original concentration in PBS. 
Has not been quantified to check protein concentration but by comparison of biological 
activity to rhIGFBP7 is the equivalent of 10µg/. Standard curve at [50ng/ml, 10ng/ml, 2ng/ml, 
0.4ng/ml and 0]. 
 
3. Eluted BP-7: 
-  Sample 1 Exp 1: 2ml of BP-7 10µg/ml purified from Endo 742 Conditioned 
medium, diluted in 20mM Tris – HCL pH 7.4. The sample that was bound to MSF 
was eluted by increasing salt ingredient 2M NaCl + 20mm tris HCl PH 7.4, this 
protocol repeated 3 times then pooled the eluted samples and dialysed against dH2O 
and then concentrated by Freeze dried, then dissolved with PBS. Using MSF +aa, 
MSF –aa and BSA columns.  
 
      -    Sample 2 Exp 2: 2ml of rh Human IGFBP-rp1/IGFBP-7 10µg/ml, diluted as above, but 
eluted one time without dialysis and freeze dried. Using two MSF-aa columns (Agarose beads 
& Sepharose beads) and MSF +aa column. 
 
      -     Sample 3 Exp 3: 2ml of rh Human IGFBP-rp1/IGFBP-7 10µg/ml, diluted and eluted 
as in sample 2  
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Standard curve   
 
Standard curve Exp1 
rhBP-7 
Standard curve Exp 2 
e- BP-7 
Standard curve Exp 3 rhBP-7  
Detection Ab Dil/conc. OD (~ 620nm   ) 
Blank substracted 
OD ( ~ 620nm  ) 
Blank substracted 
OD ( ~ 620nm  ) 
Blank substracted 
50ng/ml 38355± 71.6 
 
45664± 
 
31526± 34.7 
 
10ng/ml 5266± 93.5 
 
5494± 89.5 
 
3826.5± 49.5 
 
2ng/ml 147± 29.6 
 
212 
 
450.5± 118.7 
 
400pg/m
l 
-448± 81.01 
 
-214 
 
56.5± 22.6 
 
IGFBP7 goat  
antibody AF 
1334  
0 1124 ± 98.9 
 
265.5 ± 85.5 
 
SD of blank x 3 296.7 256.5 
 rhBP-7 sample 1  sample 2 rhBP-7 sample 3  
Affinity column OD (  ) 
Blank 
 substracted 
estimated  
Conc 
OD (  ) 
Blank 
 substracted 
estimated  
Conc 
OD (  ) 
Blank 
 substracted 
estimated  
Conc 
E-[BP-7]-MSF+aa  
 
6761± 20.06 
 
9.737ng/ml 
 
103535.5±71.8 
 
113.254ng/ml 
 
5709± 64.1 
 
10.104ng/ml 
 
E-[BP-7]-MSF-aa Ag 29820± 17.5 
 
39.466ng/ml 
 
112962± 39.8 
 
123.460ng/ml 
 
28373.5± 55.37 
 
45.627ng/ml 
 
E-[BP-7]-MSF-aa Sp 65851.5±26.1 
 
85.919ng/ml 
 
 
    
E-[BP-7]-BSA -679±67 
 
0.144 
   
-687.5± 4.9 
 
0.078 
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Appendix 4: Indirect ELISA legend explains Ab and general methods of 
binding between rhNGAL& MSF .   
.   
The table above shows the concentration of rhNGAL in the unbound fractions, eluted 
fractions and also in the washes fractions across MSF+aa and MSF-aa affinity columns 
 
rhNGAL standard curve unknown fractions 
 
Concentration 
in ng/ml 
OD sample OD estimated concentration 
(linear regression test) 
50 1.1535 E-[NGAL]-MSF+aa 
 
0.125 2.340 ng/ml 
25 0.645 E-[NGAL]-MSF-aa 
 
0.007 -2.982 
10 0.3850 U-[NGAL]-MSF+aa 
 
0.045 - 1.268 
2 0.165 U-[NGAL]-MSF-aa 
 
2.561 112.21 ng/ml 
0.4 
 
0.014 W-[NGAL]-MSF+aa 
 
0.017 - 2.531 
0 (CB) 
 
0.014 W-[NGAL]-MSF-aa 
 
0.075 0.085 
 
 
Appendix 5: Indirect ELISA legend explains Ab and general methods of 
binding between rhBP-7 & MSF. 
   
The table above shows the concentration of rhBP-7 in the unbound fractions, eluted fractions 
and also in the washes fractions across MSF+aa and MSF-aa affinity columns 
 
rhBP-7 standard curve unknown fractions 
 
Concentration 
in ng/ml 
OD sample OD estimated concentration 
(linear regression test) 
50 1.17765 E-[rhBP-7]-MSF+aa 
 
0.209 7.417 ng/ml 
25 0.6000 E-[rhBP-7]-MSF-aa 
 
0.359 13.949 ng/ml 
10 0.3485 U-[rhBP-7]-MSF+aa 
 
0.30 - 0.400 
2 0.0805 U-[rhBP-7]-MSF-aa 
 
0.0055 - 1.445 
0.4 
 
0.0195 W-[rhBP-7]-MSF+aa 
 
0.078 1.712 ng/ml 
0 (CB) 
 
0.0130 W-[rhBP-7]-MSF-aa 
 
0.075 1.582 ng/ml 
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Appendix 6: Oral SCC specimens stained with antibody to human Total MSF (7.1) and MSF-aa (TYN1.1) 
 
Comparison between HYB 7.1 Ab and TYN Ab (OSCC) 
  7.1 Ab TYN Ab 
No Expermintal 
code 
Path. 
Grade(PG) 
(1) 
% Area 
Stained 
(1) 
Final Score 
(1) 
 
KP 
(2) 
ITF 
(2) 
% Area Stained 
(consensence11/
02) 
F Score 
 
 
KP ITF 
1. 27401/83 2 60 60 1 1 0 0 0 0 
2. 5930-84 2 95 230 3 1 90 210 3 1 
3. 24643/84 3 100 180 2 1 70 140 2 0 
4. 7816/85 2 100 200 2 1 95 250 3 2 
5. 12602-85 3 30 60 3 1 30 60 3 1 
6. 17175-85 3 100 200 3 1 95 185 2 1 
7. 27314-85 2 95 215 3 2 95 185 3 2 
8. 29736-85 2 87.5 187.5 3 1 80 130 3 1 
9. 31829-85 2 90 180 3 1 90 180 2 0 
10. 38822/85 1 90 150 2 1 80 130 2 1 
11. 39489-85 2 100 220 3 1 90 180 2 0 
12. 42719/85 2 90 240 3 2 90 230 3 2 
13. 4546-86 2 100 220 3 1 90 200 3 2 
14. 5397/86 2 100 160 2 1 70 140 2 0 
15. 9353-86 2 95 190 2 2 80 190 3 2 
16. 13670-86 2 60 160 3 2 60 80 2 1 
17. 15107-86 2 50 90 3 1 30 70 3 2 
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18. 27948/86 2 90 210 3 1 50 110 3 1 
19. 29859-86 2 85 220 3 2 75 135 3 1 
20. 32839-86 2 50 150 3 0 40 80 2 2 
21. 33215-86 2 80 240 3 0 80 200 3 2 
22. 36923-86 1 100 260 3 2 100 250 3 2 
23. 37779-86 2 85 205 3 1 80 180 3 2 
24. 39777/86 2 90 240 3 2 90 240 3 2 
25. 45206-86 1 100 240 3 2 100 240 3 2 
26. 9617-87 2 95 260 3 2 90 220 3 2 
27. 17044/87 2 95 175 2 1 80 220 3 2 
28. 18587-87 1 95 250 3 2 95 215 3 2 
29. 35807-87 2 95 195 3 1 90 200 3 2 
30. 40296-87 2 70 140 2 0 60 100 3 1 
31. 49335-87 2 85 230 3 2 80 200 3 2 
32. 7765-88 2 100 160 3 1 50 100 2 0 
33. 10546-88 2 100 200 2 1 95 190 2 0 
34. 31345-88 2 80 200 3 2 80 180 3 2 
35. 31536-88 2 100 210 3 2 100 200 3 2 
36. 33866-88 2 95 215 3 1 90 205 3 2 
37. 39451-88 2 75 95 3 1 65 85 2 1 
38. 40448-88 2 100 200 2 2 100 220 3 2 
39. 40862-88 2 100 200 3 1 100 120 3 2 
40. 50706-88 2 100 220 3 1 90 130 2 1 
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41. 52796-88 2 50 70 3 1 40 60 2 1 
42. 16329-89 1 90 160 2 1 80 160 2 2 
43. 21484-89 2 90 190 3 1 85 185 3 2 
44. 42229-89 2 85 255 3 0 90 170 3 1 
45. 25524/91 3 100 200 2 1 90 210 3 2 
46. 28344-85 2 95 240 3 2 90 190 3 1 
47. 12203-87 2 95 215 3 2 95 145 3 1 
48. 16125-87 2 60 180 3 0 60 180 3 0 
49. 30713-88 2 100 240 3 2 100 220 3 1 
50. 45255-88 1 100 200 2 1 100 210 3 2 
 87.4±16.6 192.2±49.4   78.9±21.8 166.2±57.3   
 95 200   90 182.5   
Mean 
Median 
IQR  85-100 167.5-225   70-95 130-210   
 
Statistical Comparison of antibodies  
 
Appendix 7: Comparison between two antibodies regarding percentage of area stained and final score OSCC 
Abs criteria  P value (Munn  
Whitney  test) 
Wilcoxon signed rank 
test 
Paired test unPaired test 
% area stained 0.008 < 0.0001 <0.0001 0.030 7.1 v TYN  
No=50 Final Score 0.016 0.012 0.009 0.017 
% of area stained Abs 7.1 v TYN (Mann Whitney test n= 64-50) = 0.026 
Final score Abs 7.1 v TYN (Mann Whitney test n= 64-50) = 0.040
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Appendix 8: Kp (n=50) Distribution of MSF grade in OSCC specimens 
stained with Abs 7.1 and TYN.   
 
Table shows the number of specimens showing the indicated MSF grade. 
Grade with Ab 7.1  Grade 
with Ab 
TYN1.1 
0 1 2 3 All 
grades 
0  1   1 
1     0 
2   5 9 14 
3   7 28 35 
All 
grades 
 1 12 37 50 
 
Appendix 9: ITF (n=50).Distribution of MSF grade in OSCC specimens 
stained with Abs 7.1 and TYN. 
  
Table shows the number of specimens showing the indicated MSF grade. 
Grade with Ab 7.1  Grade 
with Ab 
TYN1.1 
0 1 2 3 All 
grades 
0 1 7   8 
1 2 9 5  16 
2 2 12 12  26 
3     0 
All 
grades 
5 28 17  50 
 
 
  
265 
Appendix 10:  Number (and %) of specimens showing MSF grades 0-3 (TYN & 7.1) 
 
Type of 
tumour 
Number (and %) of specimens showing MSF grades 
0-3  Ab 7.1 
 
Number (and %) of specimens showing MSF 
grades 0-3 TYN 
 
 No 0 1 2 3 No 0 1 2 3 
           
OSCC KP 0 2 
(3) 
23 
(36) 
39 
(61) 
1 
(2) 
0 
 
14 
(28) 
35 
(70) 
OSCC ITF 
64 
 
9 
(14) 
32 
(50) 
22 
(34) 
1 
(2) 
50 
 
 8 
(16) 
16 
(32) 
26 
(52) 
0 
OSCC KP 0 1 
2% 
12 
24% 
37 
74% 
     
OSCC ITF 
50 
5 
10% 
28 
56% 
17 
34% 
0      
31 28 
(90) 
1 
(3) 
2 
(7) 
0 26 
 
24 
(92) 
1 
(4) 
 
1 
(4) 
 
0 NSG(serous 
& mucous 
cell) 
26 24 
(92) 
1 
(4) 
 
1 
(4) 
 
0      
37 
 
1 
(3) 
16 
(43) 
15 
(41) 
5 
(13 ) 
31 
 
 
1 
(3) 
 
21 
(68) 
8 
(26) 
 
1 
(3) 
HP 
suprabasal 
31 1 
3 
12 
39 
13 
42 
5 
16 
     
HP basal 
 
 37 0 0 0  31 
(100) 
0 0 0 
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Appendix 11: Clinical details of OSCC patients   
 
Expermintal 
code 
Path. 
 Grade(PG) 
(1) 
Survival 
 
 
 
TF Surv. 
 
 
 
Gender Age Censor Path. T 
 
 
 
Path. N 
 
 
 
27401-83 2 93 93 1 55 0 2 0 
5930-84 2 103 103 1 62 1 2 0 
24643-84 3 11 8 1 49 1 1 0 
7816-85 2 99 99 1 58 0 2 0 
12602-85 3 60 60 1 66 0 1 1 
17175-85 3 120 120 1 50 0 2 1 
27314-85 2 10 8 1 45 1 2 1 
29736-85 2 74 74 1 63 0 2 0 
31829-85 2 106 106 1 48 0 2 0 
38822-85 1 86 72 1 43 1 4 1 
39489-85 2 118 118 1 36 0 2 1 
42719-85 2 9 7 1 79 1 2 0 
4546-86 2 63 63 1 64 0 3 1 
5397-86 2 112 27 2 48 1 3 0 
9353-86 2 42 27 1 47 1 4 2 
13670-86 2 105 105 1 55 0 1 2 
15107-86 2 18 12 1 52 1 4 1 
27948-86 2 81 72 1 35 1 2 0 
29859-86 2 9 8 1 62 1 2 1 
32839-86 2 59 54 1 50 1 2 0 
33215-86 2 69 65 1 59 1 2 0 
36923-86 1 17 9 2 54 1 2 2 
37779-86 2 10 8 1 41 1 4 0 
39777-86 2 71 56 1 38 1 2 0 
45206-86 1 102 102 1 45 0 4 0 
9617-87 2 7 5 1 48 1 4 2 
17044-87 2 67 26 1 54 1 2 0 
18587-87 1 48 48 1 74 0 2 1 
35807-87 2 20 16 1 63 1 2 1 
40296-87 2 6 5 1 65 1 2 1 
49335-87 2 9 5 1 33 1 2 1 
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7765-88 2 86 40 1 55 1 3 1 
10546-88 2 25 17 1 66 1 2 0 
31345-88 2 84 84 1 56 1 2 1 
31536-88 2 13 11 1 66 1 4 2 
33866-88 2 83 83 1 46 0 2 0 
39451-88 2 82 45 1 63 1 1 0 
40448-88 2 7 4 1 54 1 3 2 
40862-88 2 9 6 2 39 1 2 1 
50706-88 2 42 42 2 62 0 2 2 
52796-88 2 79 74 1 57 1 2 0 
16329-89 1 69 69 1 48 0 4 2 
21484-89 2 
 
60 
 
47 
 
2 51 1 1 
 
0 
 
42229-89 2 67 67 2 63 0 2 0 
25524-91 3 11 4 2 80 1 2 0 
 
Name Comment 
Pathol grade 
(WHO) 
1= well differentiated; 2= moderate; 3= poorly differentiated 
Gender Male=1, female =2  
Age Age at Diagnosis in years  
Censor Progress or death on Tumour (0 -dead, 1 -alive)  
Path. T Tumour size 
Path. N Lymphnode involvement 
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Appendix 12: Comparison of antibodies 7.1 v TYN1.1 MSF grade all 
samples. SGT Specimens stained with antibodies 7.1 and TYN 
 
MSF grade  
7.1 TYN 7.1 TYN 
Type of 
tumour 
 
Diagnosis 
 
 
code 0 1 2 3 0 1 2 3   
M ACC 41034/93 
Up jaw 
   √     3 nd 
M ACC 20720/97 
 
 √   √    1 0 
M ACC 17597/93 
 
   √   √  3 2 
M ACC 9121/95 
 
   √   √  3 2 
M ACC 31806/00 
 
 √   √    1 0 
M ACC 21162/94 
 
   √   √  3 2 
M ACC 43583/98  
 
  √    √  2 2 
M ACC 9788/01 
 
  √    √  2 2 
M ACC 24753/96 
Soft 
palate 
   √     3 nd 
M ACC 15597/98 
 
√    √    0 0 
M ACC 36031/98 
 
  √  √    2 0 
M ACC 35984/90 
 
 √    √   1 1 
M ACC 37628/98 
Up jaw 
   √     3 nd 
M ACC 43145/97 
 
  √   √   2 1 
M ACC 7753/96 
 
  √    √  2 2 
M ACC 11424/96 
 
  √    √  2 2 
M MC 34891/00 
 
   √    √ 3 3 
M MC 14005/93 
 
  √    √  2 2 
M MC 17596/93 
 
  √   √   2 1 
M MC 44602/95 
 
   √   √  3 2 
M MC 29206/00 
 
  √    √  2 2 
M MC 18091/00 
 
  √    √  2 2 
  
269 
M AC 42160/99   √    √  2 2 
M AC 
 
12633/97    √   √  3 2 
M BcAC  
 
33838/98    √   √  3 2 
M BcAC 
 
28237/00  √    √   1 1 
M SA 
 
10856/00    √    √ 3 3 
Total M 
N=24 
 1 4 11 8 4 4 14 2   ± 
specimen
s 
indicated 
Total M 
N=27 
 1 4 11 11 nd   
B PA 15974/99 
 
  √   √   2 1 
B PA 33048/96 
 
   √   √  3 2 
B PA 38262/97 
 
 √   √    1 0 
B PA 14668/96 
 
√    √    0 0 
B PA 35428/95 
 
√    √    0 0 
B PA 
 
5828/94 √    √    0 0 
B  Ang 44429/94 
 
 √    √   1 1 
Total B 
N=6 
 3 1 1 1 4 1 1 0   ± 
specimen 
indicated Total B 
N=7 
 3 2 1 1 4 2 1 0   
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Appendix 13: COMPARISON OF ANTIBODIES 7.1 v TYN1.1 MSF % area 
stained and final score. SGT Specimens stained with antibodies 7.1 and 
TYN 
MSF % area stained MSF final score Type of 
tumour 
Diagnosis code 
7.1 TYN 7.1 TYN 
M ACC 41034/93 
Up jaw 
90 nd 250.0 nd 
M ACC 20720/97 
 
30 10 30.0 10 
M ACC 17597/93 
 
80 80 220.0 160 
M ACC 9121/95 
 
100 100 280.0 200 
M ACC 31806/00 
 
30 10 30.0 10 
M ACC 21162/94 
 
40 40 280.0 80 
M ACC 43583/98  
 
75 60 135.0 120 
M ACC 9788/01 
 
30 60 30.0 60 
M ACC 24753/96 
Soft palate 
100 nd 300.0 nd 
M ACC 15597/98 
 
10 10 10.0 10 
M ACC 36031/98 
 
40 0 110.0 0 
M ACC 35984/90 
 
30 30 30.0 30 
M ACC 37628/98 
Up jaw 
75 nd 150.0 nd 
M ACC 43145/97 
 
50 50 90.0 50 
M ACC 7753/96 
 
50 40 90.0 80 
M ACC 11424/96 90 80 270 160 
 
M MC 34891/00 
 
100 100 300 300 
M MC 14005/93 
 
100 100 200 200 
M MC 17596/93 
 
75 60 130.0 60 
M MC 44602/95 
 
100 100 270.0 200 
M MC 29206/00 
 
90 90 180 180 
M MC 18091/00 
 
70 70 140 140 
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M AC 42160/99 75 75 150.0 150 
M AC 
 
12633/97 100 100 280.0 200 
M BcAC 
  
33838/98 90 85 270.0 170 
M BcAC 
 
28237/00 40 10 40.0 10 
M SA 
 
10856/00 95 90 270 270 
mean± SD 
 
65.8±28.9   59.5±35.2   155.8±96.2  
  
  120± 18.4  
median 72.5 65 140 130 
Total M 
N=24 
(IQR) 40-92 30-95 75-250 
 
40-190 
mean± SD 
 
 68.3 ± 28.3  164.4±96.2  
median 75 150 
 
± 
specimens 
indicated 
Total M 
N=27 
(IQR) 40-95 
nd 
90-270 
nd 
B PA 15974/99 
 
50 45 90 45 
B PA 33048/96 
 
90 90 250 180 
B PA 38262/97 
 
30 0 30 0 
B PA 14668/96 
 
10 10 10 10 
B PA 
 
35428/95 35 0 35 0 
B PA 
 
5828/94 10 0 10 0 
B  Ang 44429/94 
 
60 50 60 50 
mean± SD 
 
37.5±29.9 24.1±36.6   70.8± 92.5 39.1± 71.1 
median 32.5 5 32.5 5 
 
Total B 
N=6 
(IQR) 10-70 0-67.5 10-170 0-112.5 
mean± SD 
 
40.7±28.6  27.8±34.6   69.2± 84.5   40.7± 65  
median 35 10 35 
 
10 
± specimen 
indicated  
Total B 
N=7 
(IQR) 10-60 25 10-90 
 
0-50 
nd= not done 
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Statistical comparison between tissue groups 
 
Appendix 14: Comparison between Malignant & benign regarding 
percentage of area stained and final score for each antibody (7.1 & TYN) 
Abs B n M n criteria  P value (B v M) 
 Munn  Whitney  test 
% area stained 0.040 
 
7.1 7 27 
Final Score 0.003 
 
     
% area stained 0.042 
 
TYN 7 24 
Final Score 0.027 
 
 
Statistical Comparison of antibodies  
 
Appendix 15: Comparison between two antibodies (7.1 v TYN) regarding 
percentage and final score for benign and malignant salivary tumours 
P value (Munn  Whitney  test) 
 
Abs B n M n criteria  
(B v B) (M v M) 
% area stained 0.317 
 
0.664 7.1 v TYN  7 24 
Final Score 0.223 
 
0.243 
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Appendix 16: Indirect MSD ELISA summary of eluted recombinant alpha 
v beta 3 across three affinity chromatography columns    
 
 
- Recombinant αvβ3 (R&D Systems Cat. # 3050-AV-050) (Lot # 
OMM0409081) 100µg/ml. Standard curve at [50ng/ml, 10ng/ml, 2ng/ml, 
400pg/ml, 0].Two antibodies were used Anti- human integrin αVlCD 51 
antibody AF 1219 and Mouse Anti- human integrin beta 3 (CD61) antibody 
-  The unknown samples were compared with a standard curve for rh αvβ3 and 
the values estimated by Linear Regression test. 
-  
Sensitivity defined as the analyte concentration resulting in absorption 
significantly higher than of the mean plus three standard deviations of the dilution 
medium (SD of the blank x 3) 
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Standard curve Exp 1 
 
Standard curve Exp 2 Standard curve Exp 3 Standard curve Exp 4 
Detection Ab Dil/conc. OD (~ 620nm  ) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
OD (  ~ 620nm) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 80541.5±28.19 
 
285311±55.3 
 
14065±71.5 
 
88292± 80.3 
 
10ng/ml 12861.5±73.05 
 
40216±46.7 
 
8463±55.6 
 
11863.5± 30.4 
 
2ng/ml 2413±58.3 
 
6380.5±73.5 
 
1411±64.3 
 
4165.5± 10.6 
 
400pg/ml 512.5±50.9 
 
977.5±115.9 
 
644±21.2 
 
2567± 75.1 
 
 
Anti- human 
integrin 
αVlCD 51 
antibody AF 
1219 
0 
 
219.5 ±24.74 
 
136.5±3.53 
 
111 ± 2.8 
 
117 ± 5.6 
 
SD of blank x 3 74.22 
 
11 8.4 16.8 
Sample 1 (E-αvβ3) dialysed &  Freeze dried(FD) Sample 2 dialysed & FD Sample 3 dialysed & FD 
 
Sample 4 without FD 
Affinity column OD (~ 620nm  ) 
Blank 
substracted 
Estimated 
 Conc 
OD (  ~620nm) 
Blank  
substracted 
estimated 
Conc 
OD (~ 620nm  ) 
Blank 
substracted 
estimated  
Conc 
OD (~ 620nm ) 
Blank 
substracted 
Estimated 
 Conc 
E-[αvβ3]-MSF+aa 
6928.5± 38.8 
 
 
4.834ng/m
l 
 
 
7119.5±54.07 
 
 
2.163ng/m
l 
 
 
1953.5±10.6 
 
1.192ng/ml 
 
   
E-[αvβ3]-MSF-aa 
    
2067.5±6.3 
 
 
1.623ng/ml 
 
 
3381±26.2 
 
 
2.224ng/ml 
 
 
E-[αvβ3]-BSA 
    
86± 8.4 
 
-5.876 
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Standard curve Exp 1 Standard curve Exp 2 Standard curve Exp 3 
Detection Ab Dil/conc. OD (~ 620nm  ) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 12052.5± 60.8 13202± 34.05 14402± 2.8 
10ng/ml 2711.5± 87.6 7600± 55.7 8041± 72.2 
2ng/ml 1863.5± 24.04 548± 96.79 6584± 140.0 
400pg/ml 1152± 54.4 -219± 159.8 1139± 97.5 
Mouse Anti- 
human integrin 
beta 3 (CD61) 
antibody 
0 983.5 ± 6.36 
 
 
995 ± 95.4 
 
 
2428 ± 72.12 
SD of blank x 3 19.08 
 
286.2 216.36 
 
Affinity column OD (~ 620nm  ) 
Blank 
substracted 
estimated Conc OD (~ 620nm   ) 
Blank 
substracted 
estimated Conc OD (~ 620nm  ) 
Blank 
substracted 
estimated 
Conc 
E-[αvβ3]-MSF+aa  29512±735.3  
 
8.820ng/ml 
 
1667±41.01 
 
1.601ng/ml 
   
E-[αvβ3]-MSF-aa 1247±141 
 
1.039ng/ml 
 
1790±8.4 
 
2.088ng/ml 
 
4947±131.5 
 
1.443ng/ml  
 
E-[αvβ3]-BSA 
  
24± 2.8 
 
- 4.898  
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Appendix 17: Indirect MSD ELISA summary of eluted HSG cell membrane proteins across MSF +aa affinity 
chromatography columns   
Eluted membrane protein 
- 5 X106 of Human salivary gland tumour cells (HSG harvested by trypsin) had been isolated for membrane protein extraction procedure. 
10µl membrane protein extracts from HSG cell membrane ( hydrophobic fraction) diluted in 20mM Tris pH 7.4  had been  passed 
through  MSF+aa affinity column (agarose bead). Cell membrane material (hydrophobic fraction) that was bound to MSF and then eluted 
dialysed against distilled water and freeze-dried.. 
 
 
Standard curve Exp 1  Standard curve Exp 2  Standard curve Exp  
Detection Ab protein Dil/conc. OD (~ 620nm   ) 
Blank substracted 
OD (  ~ 620nm) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 80541.5± 28.1 
 
88292± 80.3 
 
75461.5± 72.4 
 
10ng/ml 12861.5± 73.05 11863.5± 30.4 10458.5± 91.03 
2ng/ml 2413± 58.3 4165.5± 10.6 1262.5± 65.05 
400pg/ml 512.5± 50.9 2567± 75.1 157± 3.5 
Anti- human 
integrin 
αVlCD 51 
antibody AF 
1219 
rhαvβ3 
 
0 219.5 ± 24.74 
 
117 ± 5.6 
 
106.5 ± 0.7 
 
SD of blank x 3 74.22 16.8 2.1 
Affinity column OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
OD (  ~ 620nm) 
Blank 
 substracted 
estimated 
Conc 
E-[HSG-Cm]-MSF+aa  
 
584.5 ±28 
 
919pg/ml  
 
2511.5± 127.9 
 
1.729ng/ml  
 
1113.5±7.07 
 
1.762 ng/ml 
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HSG: Mouse Anti- human integrin beta 3 (CD61) antibody. 
Standard curve Exp 1  Standard curve Exp  Standard curve Exp 3  
Detection Ab protein Dil/conc. OD (  ~ 620nm) 
Blank substracted 
OD (  ~ 620nm) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 13202± 34.05 14402± 2.8 19527.5± 62.13 
10ng/ml 7600± 55.7 8041± 72.2 15361± 46.6 
2ng/ml 548± 96.79 6584± 140.0 13365± 71.7 
400pg/ml -219± 159.8 1139± 97.5 --- 
Mouse Anti- 
human integrin 
beta 3 (CD61) 
antibody 
rhαvβ3 
 
0 995 ± 95.4 2428 ± 72.12 1508 ± 127.2 
SD of blank x 3 286.2 
 
216.36 
 
381.6 
Affinity column OD (~ 620nm   ) 
Blank 
 substracted 
estimated  
Conc 
OD (~ 620nm   ) 
Blank 
 substracted 
estimated  
Conc 
OD (  ~ 620nm) 
Blank 
 substracted 
estimated  
Conc 
E-[HSG-Cm]-MSF+aa  
 
1605± 29.6 
 
1.312ng/ml 
 
4140±24.9 
 
1.820ng/ml 
 
6001.5±51.8 
 
3.824ng/ml  
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Appendix 18: Indirect MSD ELISA summary of eluted TYS cell membrane proteins across MSF +aa (Agarose beads) and 
anti-αv (Magnetic beads) affinity chromatography columns   
 
Eluted membrane protein 
- 5 X106 of oral tumour cell line (TYS harvested mechanically) had been isolated for membrane protein extraction procedure. 10µl 
membrane protein extracts from TYS cell membrane ( hydrophobic fraction) diluted in 20mM Tris pH 7.4  had been  passed through  
MSF+aa affinity column (agarose bead). Cell membrane material (hydrophobic fraction) that was bound to MSF and then eluted one time 
without dialysis and freeze drying. 
Standard curve Exp 1  Standard curve Exp 2  
Detection Ab protein Dil/conc. OD (~ 620nm  ) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 88292± 80.3 
 
75461.5± 72.4 
 
10ng/ml 11863.5± 30.4 10458.5± 91.03 
2ng/ml 4165.5± 10.6 1262.5± 65.05 
400pg/ml 2567± 75.1 157± 3.5 
Anti- human 
integrin αVlCD 51 
antibody AF 1219 
rh αvβ3 
 
0 117 ± 5.6 
 
106.5 ± 0.7 
 
SD of blank x 3 16.8 2.1 
Affinity column OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
E-[TYS-Cm]-MSF+aa Ag 
 
5737 ± 79.4 
 
3.565ng/ml 
 
4947 ± 26.5 
 
4.271ng/ml 
 
E-[TYS-Cm]-Anti-αv Magnetic 
beads 
 
3115 ±26.8 
 
 
2.072ng/ml 
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TYS: Mouse Anti- human integrin beta 3 (CD61) antibody 
Standard curve Exp 1  Standard curve Exp 2  
Detection Ab protein Dil/conc. OD (  ~ 620nm) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 14402± 2.8 
 
19527.5± 62.13 
 
10ng/ml 8041± 72.2 15361± 46.6 
2ng/ml 6584± 140.0 13365± 71.7 
400pg/ml 1139± 97.5 --- 
Mouse Anti- 
human integrin 
beta 3 (CD61) 
antibody 
rh αvβ3 
 
0 2428 ± 72.12 1508 ± 127.2 
SD of blank x 3 216.36 
 
381.6 
Affinity column OD (~ 620nm   ) 
Blank 
 substracted 
estimated  
Conc 
OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
E-[TYS-Cm]-MSF+aa  
 
4399±21.2 
 
2.981ng/ml 
 
9436.5±30.9 
 
2.695ng/ml 
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Appendix 19: Indirect MSD ELISA summary of eluted Endo 742 cell membrane proteins across MSF +aa ( Agarose beads),  
Anti-αv (Magnetic beads) and BSA affinity chromatography columns.   
 
Eluted membrane protein 
 
- Exp 1: 5 X106 of Human Endothelial cells (Endo 742 harvested by trypsin) had been isolated for membrane protein extraction procedure. 10µl 
membrane protein extracts from Endo cell membrane ( hydrophobic fraction) diluted in 20mM Tris pH 7.4  had been  passed through  MSF+aa 
affinity column (agarose bead). Cell membrane material (hydrophobic fraction) that was bound to MSF and then eluted dialysed against distilled 
water and freeze-dried (FD).  
 
- Exp 2 & 3: 5 X106 of Human Endothelial cells (Endo 742 harvested mechanically) had been isolated for membrane protein extraction procedure. 10µl 
membrane protein extracts from Endo cell membrane ( hydrophobic fraction) diluted in 20mM Tris pH 7.4  had been  passed through  MSF+aa 
affinity column (agarose bead). Cell membrane material (hydrophobic fraction) that was bound to MSF and then eluted one time without dialysis and 
freeze drying. 
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Endo: Anti- human integrin αVlCD 51 antibody AF 1219 
 
Standard curve Exp 1  Standard curve Exp 2 Standard curve Exp 3  
Detection Ab protein Dil/conc. OD (~ 620nm  ) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
OD (  ~ 620nm) 
Blank substracted 
50ng/ml 285311±55.3 
 
14065±71.5 
 
88292± 80.3 
 
10ng/ml 40216±46.7 
 
8463±55.6 
 
11863.5± 30.4 
 
2ng/ml 6380.5±73.5 
 
1411±64.3 
 
4165.5± 10.6 
 
400pg/ml 977.5±115.9 
 
644±21.2 
 
2567± 75.1 
 
Anti- human 
integrin αVlCD 
51 antibody AF 
1219  
rh αvβ3 
 
0 136.5±3.53 
 
111 ± 2.8 
 
117 ± 5.6 
 
SD of blank x 3 11 8.4 
 
16.8 
 
Affinity column OD (~ 620nm   ) 
Blank 
 substracted 
estimated  
Conc 
OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
E-[Endo742-Cm]-MSF+aa  
 
694±9.1 
 
1.314ng/ml 
 
3953±2.1 
 
2.085ng/ml 
 
3319.5±6.3 
 
2.188ng/ml 
 
E-[Endo742-Cm]-BSA  
     
67±23 
 
0.33pg/ml 
 
E-[Endo742-Cm]-Anti-αv 
Magnetic beads 
     
3970±110.3 
 
 
2.559 ng/ml 
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Endo: Mouse Anti- human integrin beta 3 (CD61) antibody.  
Standard curve Exp 1  Standard curve Exp 2  
Detection Ab protein Dil/conc. OD (~ 620nm   ) 
Blank substracted 
OD (~ 620nm  ) 
Blank substracted 
50ng/ml 39105± 57.1 14402± 2.8 
10ng/ml 16097± 37.2 8041± 72.2 
2ng/ml 10282± 65.7 6584± 140.0 
400pg/ml 1790± 46.1 1139± 97.5 
Mouse Anti- 
human integrin 
beta 3 (CD61) 
antibody 
rh αvβ3 
 
0 132± 8.4 
 
2428 ± 72.12 
SD of blank x 3 25.2 
 
216.3 
Affinity column OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
OD (~ 620nm  ) 
Blank 
 substracted 
estimated  
Conc 
E-[Endo742-Cm]-MSF+aa  
 
11644±28.3 
 
9.893ng/ml 
 
13288±42.09 
 
42.815ng/ml 
 
E-[Endo742-Cm]-BSA  
   
-552±13 
 
-19.306 
 
 
 
 
 
 
 
 
  
